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Lymphomas are neoplasms derived from lymphoid cells at various stages of development and 
they are among the ten most frequent types of human cancer. Their incidence has 
dramatically increased in the past several decades. Although lymphomas are among the most 
curable tumors, the mortality rate of lymphoma is still very high. Thus, the development of 
novel treatment strategies and the identification of biological and genetic relevant targets are 
urgent. Genes involved in chromatin remodeling are very frequently altered in lymphomas, 
indicating the importance of aberrant epigenetic mechanisms, and providing a rationale to 
evaluate drugs targeting pathway deregulated in lymphomas.  
The aim of this work was to study the anti-lymphoma activity of novel epigenetic drugs, 
understanding their mechanism of action and identifying biologic and genetic features 
associated with responses. For this purpose, novel HDAC (ST7612AA1) and BET inhibitors 
(OTX015/MK-8628, BAY 1238097, BAY-7575 and BAY-5627) were studied in numerous 
lymphoma preclinical models.  
ST7612AA1 is a potent pan-histone deacetylase inhibitor, that targets and consequently 
inhibits different class I and class II HDACs. Here, in vitro and in vivo significant antitumor 
activity in lymphomas was demonstrated, which was linked with an ability to induce 
transcriptional changes of several genes involved in key biologic processes.  
OTX015/MK-8628 is a BET bromodomain inhibitor targeting BRD2-3-4 nuclear kinases and, 
here, it was tested as single agent and in combination with a series of conventional and 
targeted anti-lymphoma agents, in mature B-cell lymphomas. OTX015/MK-8628 targeted 
NFKB/TLR/JAK/STAT signaling pathways, MYC and E2F1-regulated genes, cell cycle 
regulation, and chromatin structure. OTX015/MK-8628 presented in vitro synergism with 
several anti-cancer agents, especially with mTOR and BTK inhibitors. Gene expression 
signatures associated with different degree of sensitivity to OTX015/MK-8628 were 
identified, and it was found that OTX015/MK-8628 induced apoptosis only in a genetically 
defined subgroup of cells, derived from activated B-cell like DLBCL, bearing WT TP53, 
mutations in MYD88 and CD79B or CARD11.  
Finally, a set of three novel BET bromodomain inhibitors (BAY-7575, BAY-5627 and 
remarkably BAY 1238097) showed a wide pre-clinical antitumor activity in lymphoma 
models. These inhibitors affected important biologic pathways, such as MYC, NFKB, TLR 
and JAK/STAT.  
Through this work, new therapeutic strategies to target the epigenome of the lymphoma cells 
to possibly increase the curability of lymphoma patients could be developed. 
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Les lymphomes sont des néoplasmes dérivés de cellules lymphoïdes à diffèrent stades de 
développement et ils sont entre les dix cancers, les plus fréquents et leur incidence a 
considérablement augmenté au cours des dernières décennies. Bien que les lymphomes 
sériant parmi les tumeurs les plus soignable, encore trop de patients succombent pour leur 
maladie. Ainsi, le développement de nouvelles stratégies de traitement et l'identification de 
cibles biologiques et génétiques pertinentes sont urgents. Les gènes impliqués dans le 
remodelage de la chromatine sont très fréquemment altérés dans le lymphomes, ce qui 
indique l'importance des mécanismes épigénétiques aberrants, et fournit une méthode 
rationnelle pour évaluer les médicaments ciblant la voie déréglementée dans le lymphomes. 
Le but de ma thèse était d'étudier l'activité anti-lymphome des nouveaux médicaments 
épigénétiques, de comprendre leur mécanisme d'action et d'identifier les caractéristiques 
biologiques et génétiques associées aux réponses. Dans ce but, j'ai étudié les nouveaux 
inhibiteurs HDAC (ST7612AA1) et BET (OTX015/MK-8628, BAY 1238097, BAY-7575 et 
BAY-5627) dans de nombreux modèles précliniques de lymphomes. 
ST7612AA1 est un puissant inhibiteur de pan-histone désacétylase (HDACi) qui cible et 
inhibe par conséquent différents HDAC de classe I et de classe II. Ici, j'ai montré in vitro et in 
vivo une activité antitumorale significative dans les lymphomes, qui a été apparié avec une 
capacité à induire des changements de transcription de plusieurs gènes impliqués dans les 
principaux processus biologiques. OTX015/MK-8628 est un inhibiteur de bromodomane BET 
ciblant BRD2-3-4 nucléaires kinases et, ici, il a été testé comme agent unique et en 
combinaison, dans les lymphomes à cellules B matures. OTX015/MK-8628 ciblé NFKB / 
TLR / JAK / STAT voies de signalisation, MYC et E2F1-gènes régulés, la régulation du cycle 
cellulaire et la structure de la chromatine. OTX015/MK-8628 a présenté une synergie in vitro 
avec plusieurs agents anticancéreux, et en particulier avec des inhibiteurs mTOR et BTK. Les 
signatures d'expression génétique associées à un degré différent de sensibilité à OTX015 ont 
été identifiées et OTX015/MK-8628 a induit l'apoptose uniquement dans un sous-groupe de 
cellules génétiquement défini, dérivé de lymphocytes B activés comme DLBCL, porteurs de 
wtTP53, de mutations dans MYD88 et CD79B ou CARD11.  
Enfin, un ensemble de trois nouveaux inhibiteurs du bromodomane BET (BAY 1238097, 
BAY-7575 et BAY-5627) et en particulier BAY 1238097 ont montré une large activité 
antitumorale préclinique dans les modèles de lymphomes et ils ont affecté des voies 
biologiques importantes, telles que MYC, NFKB , Les voies TLR et JAK / STAT.  
En conclusion, j'ai identifié de nouvelles stratégies thérapeutiques pour cibler l'épigénome des 
cellules de lymphome afin d'augmenter éventuellement la guérison des patients atteints de 
lymphome.
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1. Principles of genetics and biology of lymphomas   
Lymphomas are a heterogeneous group of neoplasms derived from lymphoid cells. They 
originate from either mature or immature B-cells, T-cells or natural killer cells.  Lymphomas 
represent the sixth most frequent common cancer [1]. The phenotypic and biologic features of 
lymphomas derived from B-cells largely mirror the normal development and maturation of B-
cells. An important key event in normal and neoplastic B-cells is the genetic rearrangement 
occurring at the VDJ locus, which can lead to chromosomal translocations and also to somatic 
mutations.  
The identification of lymphoma subtypes allows a better evaluation of the pathogenesis and a 
more accurate therapy. In fact the various types of B-cell lymphoma can have very different 
clinical behaviors, and therefore require diverse treatment strategies [2]. 
 
1.1 Malignant transformation during germinal center (GC) B-cell development  
During B-cell development in the bone marrow, recombination of V, D and J gene segments 
assembles immunoglobulin heavy-chain (IgH) and light-chain (IgL) genes. This process is 
characterized by the presence of two enzymes encoded by recombinase activating genes 
(RAG1 and RAG2) that cause breaks in double stranded DNA and the DNA repair processes 
(non homologous end-joining) that resolve and fix the breaks. However, such breaks can 
contribute to chromosomal translocations in lymphoma [3]. Naïve B-cells migrate to germinal 
center, undergo clonal expansion and differentiate into centroblasts in the dark zone. During 
this proliferation, the process of somatic hypermutation (SHM) introduces base pair changes 
into the VDJ regions and change the amino acid sequence. Centroblasts differentiate into 
centrocytes and move to the light zone where take place the selection through T-cells and 
follicular dendritic cells. Centrocytes that have negative selection, then reactive to self, 
undergo apoptosis. Antigen-selected centrocytes differentiate into memory B-cells or plasma 
cells.  
Most B-cell lymphomas originate from GC as indicated by the presence of somatically 
mutated IgV genes. Moreover, the genomes of these B-cell lymphomas subtypes present 
distinctive recurrent primary chromosomal translocations and aberrant SHM, due to 
malfunctions in the immunoglobulin gene remodeling mechanisms [4]. Some of these base 
pair mutation lead to a change in the amino acid sequence that contribute to the pathogenesis 
of follicular lymphoma (FL), Burkitt’s lymphoma (BL), germinal center diffuse large B-cell 
lymphoma (GCB-DLBCL), activated B-cell lymphoma (ABC-DLBCL) and Hodgkin’s 
lymphoma. 
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Figure 1. Different B-cell lymphomas arise from different stages in the normal life cycle of a 
lymphocyte (modified from Kuppers et al, Nat Rev Cancer 2005). Antigen activated B-cells 
differentiate into centroblasts in the dark zone, undergo clonal expansion and SHM process. 
Centroblasts differentiate into centrocytes and move to the light zone for selection. Centrocytes 
undergoes immunoglobulin class-switch recombination. Centrocytes differentiate into memory B-cells 
or plasma cells [5]. Most B-cell LYMPHOMASs originate from GCB-cells (as it is shown). 
 
1.2 Lymphoma subtypes 
Lymphomas comprise many subtypes and here the most common will be briefly presented [6, 
7].  
Diffuse large B-Cell Lymphoma (DLBCL) is the commonest lymphoma but it is likely to 
comprise different entities since it is a very heterogeneous disease in term of histological and 
clinic features. In 30-40% of cases in DLBCL there is a genetic alteration affecting the BCL6 
gene (chromosome 3q27) and in 20% of cases a translocation of the BCL2 gene with Ig locus 
[8]. At least two major subtypes have been identified: the germinal center B-cell like (GCB-
DLBCL) and activated B-cell like (ABC-DLBCL) subgroups. Genes that normally are highly 
expressed in GC B-cells are strongly expressed in GCB-DLBCL. So probably this subtype is 
derived from GCB-cell [9]. ABC-DLBCL subtype is characterized by a gene expression 
signature with features reminiscent of in vitro activated B-cells, pointing to a post GCB-cells 
as the cell of origin of these cases. ABC-DLBCL is characterized by the constitutive 
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activation of NF-κB pathway. Interestingly, the heterogeneity between the two DLBCL 
subtypes is also recognizable in terms of genomic aberrations [10, 11]. 
Primary mediastinal B-cell lymphoma (PMBL) is a relatively rare lymphoma subtype 
derived from thymic B-cells. Initially, it was classified as DLBCL subtype, but gene 
expression profiling (GEP) studies demonstrates a significant overlap between PMBL and 
nodular sclerosing Hodgkin lymphoma and mediastinal gray zone lymphomas [12]. The most 
common genetic alterations in PMBL are abnormalities on chromosome 9p (75%) and 2p 
(50%), these subtypes expresses several genes such as CD30, IL-13 and TARC and may arise 
from thymic B-cells [13, 14]. 
Follicular Lymphoma (FL) is the most common indolent B-cell lymphomas and accounts 
for about 30% of all adult Lymphomas and, generally, FL patients present an indolent clinical 
course. Over time, some FL patients may develop a disease progression or undergo 
histological transformation to an aggressive lymphoma [15]. FL typically shows the 
t(14;18)(q32;q21) translocation, detected in approximately 85% of the cases. This 
translocation juxtaposes the BCL2 gene on chromosome 18q21 to IgH enhancer on 
chromosome 14, leading to a constitutive expression of BCL2. 
Mantle Cell Lymphoma (MCL) is an aggressive B-cell lymphomas that comprises about 3-
10% of Lymphomas and presents a considerable clinical variability with a generally poor 
clinical outcome [16]. The cytogenetic peculiarity of MCL is the translocation 
t(11;14)(q13;q32) that leads to the over expression of cyclin D1 gene, due to the juxtaposition 
of the CCND1 gene on chromosome 11q13 to the IgH enhancer [17]. The translocation 
exhibits its pro-proliferative properties through inhibition of cell-cycle regulators RB1 and 
CDKN1B [18, 19]. 
Marginal Zone Lymphomas (MZLs) are divided into three subtypes: extranodal MZLs of 
mucosa-associated lymphoid tissue (MALT), nodal marginal zone lymphoma (NMZLs) and 
splenic marginal zone lymphoma (SMZLs) [20]. The incidence is about 12%, but it is 
difficult to distinguish subtypes because the subgroups share some similarities in histological 
features as well as some genetic lesions. Gains at 3q and 18q are common in all three 
subtypes; MALT frequently has specific translocations involving API2, MALT1, BCL10, and 
FOXP1. The commonest genomic aberrations in SMZLs are loss of 7q31 and somatic 
mutations affecting the NOTCH2 and KLF2 genes. Somatic mutations and deletions of 
PTPRD gene are found in NMZLs [21-23]. 
Burkitt’s Lymphoma (BL) is an aggressive B-cell lymphoma. It often presents in extranodal 
sites. Three clinical variants can be recognized: the endemic, the sporadic and the 
immunodeficiency-associated cases, each manifesting differences in clinical presentation, 
morphology and biology.  The cytogenetic peculiarity of all variants of BL is the 
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translocation involving MYC gene in chromosome 8q24 and the IGHV locus on chromosome 
14q32 in more than 80% of cases, or the light chain loci [24]. The consequence of this 
translocation is the deregulated expression of MYC, which is a master regulatory gene. MYC 
plays a central role in cellular processes such as proliferation, differentiation and apoptosis, 
and that we will see is affected by treatment with BET Bromodomain inhibitors.  
Chronic lymphocytic leukemia (CLL) is a generally indolent disease although some patients 
face a more aggressive clinical course. The most common genetic alterations include the loss 
of 13q14.3 (miR-15a, miR-16-1; 55% of cases), trisomy 12 (20%) and, less commonly, 
deletions of 11q22-23 (ATM), 17p13 (TP53) and 6q21 [25]. The distribution of these variable 
abnormalities based on the mutational status of IGHV gene is associated with different 
clinical outcomes. CLL had mutations on NOTCH1 (12.2%), MYD88 (2.9%), XPO (2.4%) 
and KLHL6 (1.8%) genes [26].  
The T-cell lymphomas are a heterogeneous group of often rare diseases that are divided into 
two main groups: those arising from precursor cells correspond to the single entity called 
"lymphoblastic lymphoma", while lymphomas derived from mature lymphocytes are referred 
to as "peripheral T-cell lymphomas" (PTCLs). The PTCLs represent <15% of all Lymphomas 
[27]. Their classification is largely based on the presentation of the lymphoma, i.e. 
disseminated, nodal or extranodal/cutaneous disease. 
While in B-cell lymphomas it is possible to identify the cell of origin, the cellular origin of 
PTCLs remains difficult to determine, although molecular profiling has recently allowed 
significant progress [28]. Some of the entities recognized by the WHO classification are very 
rare. 
Peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS) are a heterogeneous 
group of mature T-cell lymphomas, which do not correspond to any of the other specifically 
defined entities in the current WHO classification [29]. 
Angioimmunoblastic T-cell Lymphoma (AITL) is an aggressive and rare systemic disease, 
which represents about 1-2% of all Lymphomas. AITL characterized by consistent 
association with Epstein Barr virus (EBV), which suggests a pathogenic role for this virus, 
eliciting chronic antigen-driven T-cell-mediated response.  
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2. Epigenetic and cancer 
Epigenetics is the branch of medicine that study the heritable changes in gene expression that 
do not involve alterations of the DNA sequence [30]. Epigenetic modulation is a key 
biological process in cell regulation [31]. The gene regulation occurs in the nucleosome, a 
very well organized structure in which DNA is packaged with eight histone proteins. Amino 
acid residues of the aforementioned histones can undergo post-translational modifications 
such as acetylation, methylation, and phosphorylation [32]. These modifications change the 
secondary structure in the nucleosome by increasing the distance between DNA and histones 
and by facilitating the link of transcription factors to gene promoter regions [33]. Chromatin 
remodeling is a dynamic biological process regulated via several enzymes. The latter can be 
broadly divided in three classes based on their function: writers, erasers and readers [34]. 
Writers are epigenetic proteins that promote the addition of post-translational modifications 
on histone; this family of enzymes contains histone acetyltransferases (HAT), histone 
methyltransferases (HMT), and kinases. Enzymes that remove these marks (post-translational 
modifications) are known as erasers and comprise histone deacetylases (HDAC), 
demethylases, and phosphatases. Epigenetic readers bind these epigenetic marks; to this class 
of enzymes belonging proteins containing bromodomains, chromodomains and tudor 
domains. Readers are effector proteins since they can recognize specific marks on histones or 
nucleotides [35]. While somatic DNA mutations, leading to inactivation of tumor suppressor 
genes or activation of oncogenes, are irreversible, epigenetic modifications can be reversed 
[36]. Thus, the latter can be potential targets for antitumor treatment. Indeed, the deregulation 
of the epigenetic control is common in cancer [37], via aberrant changes in DNA methylation, 
histone modifications and noncoding RNA expression levels [34, 38]. Also, genes involved in 
chromatin remodeling (EZH2, MLL2, MEF2B, EP300, CREBBP) are very often altered in 
lymphoma. These features indicate the importance of aberrant epigenetic mechanisms, and 
providing a rational to evaluate drugs targeting the lymphoma epigenome. 
 I will now describe the proteins involved in epigenetics regulation and their role in cancer in 
more detail.  
 
Epigenetic writers are enzymes that catalyze the introduction of the post-translational 
modifications on target proteins. These dynamic modifications respond rapidly to 
environmental changes. Histone acetylases (HAT) and histone methyltransferases (HMT) are 
epigenetic writers that will be more extensively discussed in the following paragraphs. 
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2.1 Histone methyltransferases (HMTs) 
Histone methylation involves two possible amino acid residues: lysine and arginine. Lysines 
can be monomethylated, dimethylated or trimethylated on their ɛ-amine group by histone 
lysine methyltransferases (HKMTs). Arginines can be monomethylated, symmetrically 
dimethylated or asymmetrically dimethylated on their guanidinyl group by protein arginine 
methyltransferases (PRMTs) [39]. HMTs transfer a methyl group from the cofactor S-
adenosylmethionine (SAM) to the terminal amine of specific substrate lysine and/or arginine 
residues. The catalytic transfer of a methyl group from SAM by using a conserved SET 
domain, facilitate the SN2 transfer reaction generating S-adenosylhomocysteine (SAH) and 
the methylated histone side chain as products [40]. The transfer of an acetyl-group from the 
co-factor acetyl-CoA to lysine residues on histone tails neutralizes the positive charge of 
lysine, and it weakens the affinity of the histone tail for the DNA, reducing chromatin 
condensation. Methylation is associated with activated euchromatic genes (H3K4, H3K36 and 
H3K79) or with silenced heterochromatic genes (H3K9, H3K27 and H4K20) [41, 42]. 
Enhancer of zeste homolog 2 (EZH2) is the catalytic component of polycomb repression 
complex 2 (PCR2), which is responsible for tri-methylation of histone 3 lysine 27 
(H3K27me3) [43]. The human PRC2 includes five subunits: EZH2, EED, SUZ12, 
RbAp46/48 and AEBP2. An important function of PRC2 is to silence genes involved in cell 
differentiation [44]. The AEBP2 subunit acts as a cofactor that interacts with the other four 
subunits by binding to the center of the PRC2 complex and helps the stabilization of PRC2 
architecture. The AEBP2 subunit also facilitates the PRC2 complex targeting to specific DNA 
sites and enhances its methyltransferase activity [44]. In early B-cell development, EZH2 is 
required for VDJ recombination and is then subsequently down regulated in mature B-cells 
[45]. EZH2 regulates the expression of gene involved in differentiation and inhibitors of cell 
growth and proliferation such as CDKN1A, CDKN1B and CDKN2 [46]. Polycomb-group 
proteins have been implicated in several cellular processes, including cell-cycle control, 
cancer, and senescence [35, 47-50]. 
Aberrancy in HMTs, such as EZH2 and MLL, plays a role in pathogenesis of FL and DLBCL 
[46, 51]. Loss of function mutations in MLL are detected in 89% of FL and 32% of DLBCL 
[51], while mutations in EZH2 are seen in 7–12% of FL, 22% of GCB-DLBCL [52, 53], 7% 
of BL [54] and in myeloid malignancies [55]. Furthermore, several other Lymphomas, 
including MCL [56], ALCL [57] and adult T-cell leukemia/lymphoma [58] show strong 
expression of EZH2. Somatic activating mutations in the SET domain of EZH2 have been 
identified in FL, and DLBCL, leading to increased H3K27me3 [51, 59]. In DLBCL EZH2 
presents several missense mutations in the catalytic SET domain that change a single highly 
evolutionarily conserved tyrosine residue (Tyr641 or wild-type) to phenylalanine (Y641F), 
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asparagine (Y641N), histidine (Y641H) or serine (Y641S) [60]. The wild-type (WT) enzyme 
is more efficient as a mono-methyltransferase and decreases in catalytic efficiency for the 
second and especially the third methylation reaction. In contrast, all the mutant enzymes, 
observed in lymphoma cells, are effective in catalyzing the reaction of mono- and di-methyl 
are very efficient in catalyzing the reaction of di- tri-methyl [61]. In naive B-cells and in GC 
B-cells, EZH2 is normally downregulated, but upregulated in actively proliferating GC B-
cells [62, 63]. In DLBCL, EZH2 is important for G2/S transition and represses cell-cycle of 
tumor suppressor genes through tri-methylation of H3K27 [62]. Based on these data EZH2 
appeared as a good therapeutic target. 
 
 
Figure 2. The interaction and effect of EZH2 in regulation of transcriptional repression (adapted from 
Martinez-Garcia, 2010). PRC2 exerts methyltransferase activity to H3K27 via the SET domain of the 
EZH2 subunit [42]. 
 
 
2.1.1 HMT inhibitors 
HMT inhibitors are a new class of drugs that target epigenetic and in particular EZH2 [64]. 3-
deazaneplanocin A (DZNep) is the cyclopentanyl analog of 3-deazaadenosine, an inhibitor of 
SAH hydrolase. DZNep inhibits and induce the degradation of the PRC2 complex [61], with 
loss of H3K27me3. Also, it induces the F-box protein FBXO32, a component of the SCF 
ubiquitin protein E3 ligase complex, associated with apoptosis of cancer cells [65]. In MCL 
cell lines DZNep induces cell-cycle arrest and apoptosis [66]. Depletion of EZH2 by short 
interfering RNA (siRNA) also induces the levels of p16, p21, p27, and FBXO32, which 
indicate that DZNep-mediated depletion of EZH2 is responsible for modulating these protein 
levels and growth inhibition in MCL cells [66]. DZNep is not a specific inhibitor of EZH2, 
and it can affect the methylation status of chromatin marks other than H3K27 [67]. 
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Different EZH2 inhibitors are now under active preclinical and clinical investigation [68]. 
GSK126, used in the work presented in this thesis, is a specific EZH2 inhibitor [69]. GSK126 
significantly increases cell death in non-small cell lung cancer, prostate cancer [70], skin 
cancer [71], colorectal cancer [72] and lymphoma cell lines [73]. Importantly, GSK126 
inhibits both mutant Y641 EZH2 and WT GSK126 induces in DLBCL cell lines a 50% loss 
of H3K27me3 levels in both WT and mutant and induces transcriptional activation of EZH2 
target genes in sensitive cell lines [73]. 
 
2.1.2 Histone acetyltransferases (HATs) 
HATs use acetyl-CoA as a cofactor and catalyze the transfer of an acetyl-group to the ɛ-
amino group of lysine side chains on the histone protein. This process causes the 
neutralization of the positive charge of lysine and reduced the affinity of the histone tail that 
protrudes from the nucleosome core of DNA. As final result, chromatin relaxes and by 
modifying its structure allow the recruitment of proteins and initiation of transcription [40]. 
Type A HATs are nuclear proteins that acetylate chromatin-associated proteins and histones, 
comprise three families of enzymes GNATs, EP300/CREBBP and MYST. Type B HATs are 
located in the nucleus and the cytoplasm, where they acetylate newly synthesized cytoplasmic 
histones to promote their nuclear localization and deposition onto nascent DNA chains [74]. 
KAT1 is the only HAT in the type B group.  
Mutations affecting the chromatin have been detected in genes coding for HATs CREBBP 
and EP300 [75] and HAT-recruiting protein MEF2B [51]. CREBBP and EP300 proteins are 
co-activators of transcription factors and acetylate many proteins including P53, Hsp90, and 
NF-kB [67, 76, 77]. EP300 is a direct target of BCL6. In DLBCL, BCL6 inhibitors can 
stimulate EP300 protein function in vivo and in vitro, leading to activation of tumor-
suppressor activity [77]. Deletions and/or somatic mutations of CREBBP or EP300 are 
detected in approximately 39% of DLBCL, 41% of FL [78], 13% of GCB-DLBCL and 15% 
of FL displayed recurrent point mutations in the MADS box or MEF2 domains of the MEF2B 
gene [51, 79, 80]. Mutations affecting the HAT activity of CREBBP and EP300 promote the 
activation of BCL6 and Hsp90 while destabilizing P53 [77, 78]. The balance between HATs 
and HDACs can be pharmacologically manipulated using HDAC inhibitors and preclinical 
studies suggest that DLBCL with CREBBP and/or EP300 mutations may be resistant to this 
strategy [77]. 
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2.2 Epigenetic erasers in cancer 
The overexpression of several HDACs have been implicated as an important oncogenic 
mechanism in different types of cancers, including ovarian, gastric, lung, breast, pancreatic, 
colorectal, prostate cancer, myeloid leukaemia and lymphoma [4, 81-86]. 
HDACs 1 and 2 are critical for B-cell development and are required for proliferation induced 
by mitogens in mature B-cells [87]. In primary ABC- and GCB-DLBCL samples the 
expression of HDACs 1 and 2 has been found to be elevated relative to normal lymphoid 
tissue [88, 89]. In DLCBL and PTCL HDAC1, 2 and 6 were found to be highly expressed 
[88], while in cutaneous T-cell lymphoma (CTCL) HDAC2 have a prognostic significance 
[90]. HDACs inhibition induces cell differentiation, transcriptional control and arrest of cell 
growth or prevention of tumor development in animal models [91]. HDAC3 is implicated in 
STAT3-positive DLBCL, as a direct interaction partner of STAT3, important for STAT3 
phosphorylation and activity [92].  
 
2.2.1 HDAC inhibitors 
Epigenetic erasers remove epigenetic marks (post-translational modifications), and they 
comprise HDACs, lysine demethylases (KDMs) and phosphatases [41]. HATs acetylate ε-
amino lysine residues located in the NH2-terminal, creating a tail of core histones open 
chromatin conformation associated with transcriptional activation. Conversely, HDACs 
catalyze the deacetylation of α-acetyl lysine residues through creating a closed chromatin 
conformation that is associated with transcriptional repression [93-95]. HDACs remove 
acetyl-groups from the ε-amino group of lysine side chains of the histones H2A, H2B, H3, 
and H4, thus reconstituting the positive charge on the lysine. HDACs affect several 
substrates, including transcription factors, signal transcription mediators, DNA repair 
enzymes, chaperones and structural proteins [96]. HDACs can be classified into four classes:  
class I: are predominantly localized in the nucleus and comprise HDAC1, HDAC2, HDAC3 
and HDAC8;  
class II: are subdivided into class IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and class IIb 
(HDAC6 and HDAC10), shuttle between the nucleus and cytoplasm; 
class III: comprise the Sirtuins, mainly localized in the nucleus and mitochondrion. 
Differently from the zinc-dependent HDACs in the other three classes, Sirtuins require NAD+ 
as a co-factor to carry out deacetylase activity. Importantly, since they have a different 
catalytic mechanism, they do respond to classical HDAC inhibitors. 
Class IV contains HDAC11, a nuclear protein [3, 97, 98]. 
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Figure 3. The histone deacetylase family (modified from Dell’Aversana et al, 2012 and Shirakawa et 
al, 2013). Schematic representations of class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9 and 
10), class III (SIRT1) and class IV (HDAC11). Structure and Length of HDACs are shown. The total 
number of amino acid residues is depicted on the right, next to each HDAC.  
 
 
HDAC inhibitors bind to the catalytic pocket of HDACs, preventing substrate binding to the 
enzyme and accessibility of promoter regions to transcription factors [99, 100]. HDAC 
inhibitors kill cells through upregulation of death receptors, cell-cycle checkpoint disruption 
[101], upregulation of pro-apoptotic proteins, induction of oxidative injury [102], and 
interference with Hsp90 function. HDAC inhibitors are considered transcriptional activators 
[103]. Natural and synthetic HDAC inhibitors can be structurally divided into four classes: 
hydroxamic acids (Hb-HDACs), small molecular weight carboxylates, benzamides, cyclic 
peptides and short-chain fatty acids [32]. Hb-HDAC inhibitors typically contain a metal-
binding moiety represented by the hydroxamic acid group [19]. The catalytic pocket of the 
HDAC enzyme consists in the hydroxamic acid group able to chelate the Zn2+ metal ions, an 
aliphatic linker, and a capping group that interacts with the residues at the entrance of the 
active site. Each of structure differently interacts with the catalytic pocket [33]. By inserting 
in the HDAC catalytic pocket, Hb-HDAC inhibitors block the substrate access to the enzyme, 
Mitochondrion	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inhibiting its activity with the consequence of an accumulation of acetylated histone and non-
histone proteins [19, 104] 
 
Figure 4. Chemical structures of Hb-HDAC inhibitors (from Grassadonia, et al., 2013). Chemical 
structure of vorinostat, belinostat and panobinostat are shown. In the square is represented the 
hydroxamic acid group, that characterizes this class of HDAC inhibitors. It is responsible for the 
binding of these compounds to the Zn2+ located into the catalytic domain of the enzyme [19]. 
 
 
Several HDAC inhibitors are under clinical development in leukemia, lymphoma, and 
myelodysplastic syndrome [105, 106]. HDAC inhibitors, such as vorinostat for the treatment 
of CTCL [107], panobinostat (previously called LBH589) for the treatment of CTCL and 
multiple myeloma (MM) [108], romidepsin [109] for the treatment of CTCL and PTCL, and 
belinostat [110] for the treatment of PTCL have been approved by the FDA (Food and Drug 
Administration) [109, 111, 112]. HDAC1 mutations have been associated with a sensitization 
of cells to the HDAC inhibitor panobinostat [113] suggesting that HDAC mutations could be 
used as predictive biomarkers [114].  
Panobinostat is a non-selective HDAC inhibitors and it is a cinnamic hydroxamic acid 
analogue. It has shown antitumor activity in patients with Hodgkin’s lymphoma, MM and 
acute myeloid leukemia (AML) [115]. In vitro, panobinostat induces acetylation of histone 
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H3 and H4, increase p21 levels, affect the function of Hsp90, and induce cell-cycle G1-phase 
accumulation and apoptosis of acute leukemia cells [116]. 
Romidepsin is a cyclic peptide that has activity against class I-III HDACs [97, 117]. 
Romidepsin has been shown to induce cell differentiation, cell-cycle arrest, and apoptosis. 
This agent also inhibits hypoxia-induced angiogenesis and depletes several Hsp90-dependent 
oncoproteins [46]. 
Belinostat is a hydroxamic acid HDAC inhibitors, that has pro-apoptotic activity and growth-
inhibitory at low concentrations in several cancer types [60, 118]. It down regulates several 
kinase, like aurora kinase, vascular endothelial growth factor (VEGF), epidermal growth 
factor receptor (EGFR), and up regulates cyclin A [119]. Since HDAC inhibitors are 
generally well tolerated and show selectivity toward tumor cells, there is interest in 
combining them with other therapeutics to increase effectiveness against DLBCL [120-122]. 
 
2.2.2 Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone 
deacetylase (HDAC) inhibitor. 
ST7612AA1 (property of Sigma-Tau, Italy), a thioacetate-ω (γ-lactam amide) derivative, is a 
potent, second generation, oral pan HDAC inhibitors. Pan HDAC inhibitors inhibit HDACs 
from class I, II and IV, while class specific HDAC inhibitors only inhibit HDACs from either 
class I or class II. The hydroxamates are able to target and affect all classes of HDACs, thus 
exerting nonspecific HDAC inhibition activity [123-125]. ST7612AA1 is a prodrug of 
ST7464AA1, selected within lactam carboxamide inhibitors.  
 
Figure 5. Chemical structure of the prodrug ST7612AA1 and its drug ST7464AA1 (from Vesci et al., 
2015). 
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The active drug, ST7464AA1 revealed the maximum potency on HDAC3 and 6 (mean of 
IC50= 4 nM), and then on HDAC1, 10 and 11 (mean of IC50=13 nM) and HDAC2 (IC50=78 
nM). The minor potency was observed on HDAC8 (IC50=281 nM) [126]. 
 
2.3 Epigenetic readers in cancer 
Readers are a class of proteins scaffolds that recognize covalent modifications of histone 
proteins or DNA. The ε-N-acetylation of lysine residues on histone tails is associated with an 
open chromatin architecture and transcriptional activation [127]. The bromodomain and 
extra-terminal (BET) family (BRD2, BRD3, BRD4 and BRDT) shares a common domain 
architecture comprising two N-terminal bromodomains, which exhibit high levels of sequence 
conservation, and a more divergent C-terminal recruitment domain [72]. The name of these 
proteins arises from the presence of two bromodomains BD1 and BD2 and the extra-terminal 
region in the C-terminal moiety [128]. The bromodomain is a 110 amino acid motif 
comprised of four anti-parallel α-helices with two connecting loops that form a binding 
pocket for ε-acetyl-lysines of histones present in nucleosomal chromatin [129, 130]. Human 
genome encodes 61 bromodomains present in 46 different proteins [131]. The differences lie 
in the amino acid residues around the acetyl-lysine binding site.  BET proteins are found in 
the cell nucleus, where they bind via their two bromodomains to acetylated proteins, 
including histones H3 and H4 [131]. BET proteins are part of large nuclear complexes that 
have been implicated in transcriptional networks, such as replication, transcription processes 
and chromatin remodeling [132]. Accordingly, BET proteins also are involved in 
inflammation, adipogenesis, post-mitotic memory, virus episomal persistence, latency and 
memory [133-137]. BET family comprises four members: BRD2, BRD3, BRD4, and BRDT. 
Mammalian BET proteins have been implicated in proliferation and mitosis process [138-
140].  
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Figure 6. The evolutionarily conserved domains found in bromodomain containing protein 4 (BRD4) 
and the other BET family proteins include bromodomain 1 (BD1), bromodomain 2 (BD2), 
extraterminal (ET) (modified from Chiang, 2009). Numbers indicate the amino acid boundaries of each 
protein derived from human (h). The short form of human BRD4 (hBRD4) is also shown for 
comparison. Alignment of amino acid sequences and the accession number for each protein-coding 
gene are based on the information described by Wu and Chiang [128]. 
 
 
BRD2 is a nuclear transcriptional regulator, that mediate recruitment of histone 
acetyltransferase and E2 promoter binding factors (E2Fs) [141]. BRD2 expression drives 
cyclin A, cyclin D1, cyclin E transcription and cell-cycle progression [142]. BRD2 also is 
involved in the recruitment of HDACs, histone H4 specific acetyltransferase (HAT) and 
proteins involved in chromatin remodeling [98, 143]. 
BRD3 plays a role in the regulation of erythropoiesis, interact with acetylated GATA1 and 
promotes chromatin occupancy of this transcription factor at target genes [144, 145]. 
Interestingly, RNA polymerase II (Pol II) need BRD2 and BRD4 for its transcription [143].  
BRD4 is a super-enhancer protein that plays an important role in regulating gene expression 
by recruiting transcription modulators to specific genomic promoters. BRD4 regulates 
oncogenes such as MYC, BCL6, BCL-xL [146-148]. Its BD2 domain interacts with the 
acetylated region of cyclin T1 [149]. Cyclin T1 and CDK9 are included in the heterodimeric 
complex of the active form of the positive transcription elongation factor b (P-TEFb). The 
recruitment of active P-TEFb is important for the sustained presence of Pol II in active genes 
and for transcription initiation and elongation [150-152]. In fact it is crucial for the expression 
of cell-proliferation supporting genes, including MYC and its target genes [153]. 
The ET domain of BRD4 is able to recruit the arginine demethylase JMJD6 and the lysine 
methyltransferase NSD3 and CHD4, a catalytic component of the NuRD nucleosome 
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complex [154, 155]. Active P-TEFb phosphorylates Pol II during promoter clearance at the 
start of transcription elongation [156]. 
Finally, BRDT is expressed only in testis, where it plays a role in spermatogenesis by 
regulating several genes important during and after meiosis [157, 158]. BRDT is involved in 
the post-meiotic organization and remodeling of chromatin that takes place during 
spermiogenesis [159, 160]. 
Somatic mutations, amplifications and translocations in genes that encode for chromatin-
related proteins are frequent in cancer. The epigenetic proteins represent several targets for 
the discovery of new active drugs. BRDs are interesting targets for drug development for the 
large number of diseases that are caused by aberrant acetylation of lysine residues [161]. BET 
proteins have two amino-terminal bromodomains that facilitate binding to hyperacetylated 
promoter/enhancer regions [131, 162] and a distal carboxyl terminal binding site for the P-
TEFb [163]. BRD2 expression drives cyclin A, cyclin D1, cyclin E transcription and cell-cycle 
progression, [142] which promotes lymphoid malignancy [164]. Constitutive expression of 
BRD2 in the lymphoid lineage of mice transcriptionally co-activates cyclin A [103], thus 
eventually leading to B-cell malignancy [98, 164]. BRD3 down-regulates the RB-E2F 
pathway in most cancers and especially in nasopharyngeal carcinoma cells [98]. BRD4 is 
regulating gene expression by recruiting relevant transcription modulators to specific genomic 
loci. The recruitment of P-TEFb and Pol II by BRD4 regulates the expression of cell-
proliferation supporting genes, including MYC [153]. Functional studies suggested that BRD4 
regulates growth-associated genes by retaining P-TEFb at the promoters of key regulatory 
genes throughout mitosis [149, 165]. In cancer, BET bromodomains promote M to G1 cell-
cycle progression [149] and contribute to mitotic memory [140, 146]. Chimeric proteins of 
the N-terminal BRDs of BRD4 or BRD3 with the protein NUT (nuclear protein in testis) 
cause NUT midline carcinoma (NMC), an incurable subtype of squamous carcinoma [166]. 
 
2.3.1 Bromodomain inhibitors 
Bromodomain inhibitors mimic the binding mode of acetylated lysine by forming hydrogen 
bonds with the conserved asparagine residue. These inhibitors also competitively inhibit the 
binding of acetylated lysine containing peptides to bromodomains. Inhibitors that belong to 
this class include the thienodiazepines [167]. These inhibitors directly interact with the acetyl-
lysine-binding BD1 and BD2 pockets of all BET proteins. Bromodomain inhibitors displace 
the BET protein from chromatin, which alters the transcriptional activity of the target genes. 
The discovery that MYC regulates promoter proximal pause release of Pol II, also through the 
recruitment of P-TEFb [153], established a rationale for targeting BET bromodomains to 
inhibit MYC dependent transcription [90]. For this main reason BET inhibitors have been 
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proposed for therapeutic treatment in MM [90], BL [168], acute lymphoblastic lymphoma 
[59], DLBCL [169] and AML [170]. BET inhibitors block the assembly of a functional 
protein complex and disturb the interaction of the bromodomain with the acetylated residue. 
BET inhibitors (JQ1, I-BET151, I-BET762, OTX015/MK-8628, TEN-010, CPI-0610 and 
BAY 1238097) have been developed for the treatment of hematopoietic malignancies, solid 
tumor and the rare NMC disease [132, 150, 171]. Four BET inhibitors are currently in clinical 
trials for cancer patients: OTX015/MK-8628 is tested in patients with hematological and solid 
malignancies (NCT01949883, NCT02698189 NCT01587703, NCT01713582, 
NCT01987362, NCT02259114, NCT02698176); I-BET762 (GSK525762) is investigated in 
solid tumors and in refractory hematological malignancies (NCT02964507, NCT01943851); 
CPI-0610 is being evaluated in Phase I studies in patients with AML, MM and progressive 
lymphoma (NCT02158858, NCT02157636, NCT01949883) and TEN-010 is administered 
subcutaneously to patients with hematological or solid tumors (NCT02308761, 
NCT01987362). A clinical study for testing BAY 1238097 orally in patients with solid and 
hematological tumors has recently been terminated [172]. Inhibition of BRD4 by JQ1 or 
specific siRNA treatment resulted in the downregulation of BCL6 expression and impaired 
activation of NF-kB signaling pathway in primary activated B-cells and B-cell lymphoma 
[173]. Also it induces the suppression of MYC expression [59, 90, 168]. I-BET suppresses 
induction of a subset of TLR4-induced genes in mouse macrophages and suppresses 
inflammation in mouse models [174]. 
BRD4 is essential for maintenance of AML and JQ1 cause the same effects of RNA 
interference of BRD4 [170, 175]. JQ1 showed anti-proliferative effect in other hematological 
malignancies and solid organ tumors including glioblastoma, prostate cancer, and 
neuroblastoma [59, 176-179]. Another study shows that combination of JQ1 with rituximab 
desensitizes resistant DLBCL cell lines to this drug [180]. Finally, synergy with the HDAC 
inhibitor vorinostat was reported for RVX2135 in a MYC-dependent mouse lymphoma model 
[181]. 
PROTACs (Proteolysis Targeting Chimeras) are chimeric molecules with one small moiety 
binding a desired target protein that is connected by a flexible polyethylene glycol linker with 
a ligand for the E3 ubiquitin ligase. Thus, the PROTAC technology had the goal to induce the 
degradation of their target proteins through the ubiquitin proteasome system [182]. ARV-825 
contains OTX015/MK-8628 moiety to binding BRD4, and a ligand for the E3 ubiquitin ligase 
cereblon (pomalidomide). ARV-825 actively recruits BRD4 to cereblon, resulting in the rapid 
and efficient degradation of the former via the proteasome [183].  
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2.3.2 The BET Bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical 
B-cell tumor models and synergizes with targeted drugs.  
OTX015/MK-8628 (Merck, Germany) is a BET bromodomain inhibitor in early clinical 
development, has shown preclinical activity against a wide range of hematologic 
malignancies [184] as well as both pediatric and adult solid tumors. [29] 
 
 
Figure 7. Chemical structure of the OTX015/MK-8628. 
 
 
OTX015/MK-8628, like JQ1 and I-BET151, is able to induce growth inhibition, block of cell-
cycle G1-S transition and causes apoptosis in acute leukemia cell lines and patient-derived 
leukemic samples [132, 175]. OTX015/MK-8628 inhibits BRD proteins in several preclinical 
models and shows significant in vitro and in vivo antitumor activity with cell-cycle arrest and 
downregulation of MYC in a number of hematologic malignancy models [185], including 
leukaemia [168], lymphomas [186], anaplastic large T-cell lymphoma and MM [50]  as well 
as in solid tumor models like triple-negative breast cancer [187] and non-small cell lung 
carcinoma [188].  
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2.3.3 BAY 1238097, BAY-7575 and BAY-5627 are novel BET Bromodomain inhibitors with 
anti-lymphoma activity.   
BAY 1238097, BAY-7575 and BAY-5627 are a novel BET inhibitors developed by Bayer, 
Germany. Most BET inhibitors are derived from diazepine and azepine scaffolds and, 
recently, from quinazolinones and isoxazoles. BAY 1238097 is derived from a new scaffold 
identified by Bayer. In particular, BAY 1238097 is a potent inhibitor of BET binding to 
histones that showed selectivity for BRD4 and strong anti-proliferative activity in AML and 
MM models. This novel compound has shown strong BRD4-BrD1 bromodomain inhibitory 
activity in vitro. A strong reduction of MYC transcript and protein levels are observed in 
treated MOLM-13 (AML) and MOLP-8 (MM) cell lines. In vivo, BAY 1238097 shows 
strong efficacy in the AML models THP-1, MOLM-13 and KG-1 [189]. 
BAY 1238097 underwent clinical investigation in patients with Lymphomas and solid tumors 
(NCT02369029) to determine the safety, tolerability and maximum tolerated dose of 
BAY1238097. Unfortunately, the study was closed due to toxicity (severe and unexpected 
headaches, vomit and back pain) [172]. 
 
3 Aim of the study 
Aim of this thesis is to study new epigenetic drugs as novel anti-lymphoma agents, 
understand their mechanism of action and identify biological and genetic features associated 
with responses. 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
    RESULTS 
 
 
28 
 
In summary, I focused my PhD work on the study of modalities to target the epigenome of 
lymphomas. I had the opportunity to work with novel epigenetic drugs, such as HDAC and 
BET inhibitors studying their anti-proliferative and pro-apoptotic role in several lymphoma 
models and also the changes at RNA and protein levels induced by these compounds. In most 
cases, the studies were completed with in vivo proof of efficacy in lymphoma models. 
 
Article 1 
My first work was the study of a novel HDAC inhibitor, ST7612AA1 (SigmaTau, Italy). 
ST7612AA1 is a pan-HDAC inhibitor, targeting HDAC1-2-3-6-8-10-11, that was studied as 
follow. Established human cell lines derived from DLBCL (n=11), MCL (n=4), and SMZL 
(n=3) were exposed to increasing concentrations of ST7612AA1 and the MTT assay was 
performed after 72 hours to determine its effect on lymphoma proliferation. All cell lines 
were sensitive to ST7612AA1 without differences among histological subtypes. ST7612AA1 
induced moderate apoptosis in 3/8 lymphoma cell lines. ST7612AA1 presented both nuclear 
and cytoplasmic anti-deacetylase activity as demonstrated by Western blotting analysis 
showing increased levels of both acetylated histone H3 and acetyl-α-tubulin. To obtain a 
global view of the transcriptional changes after ST7612AA1 treatment, GEP was done with 
the Illumina HumanHT-12 Expression BeadChips on two sensitive cell lines (TMD8 and 
DOHH-2) treated with ST7612AA1 or DMSO for 8h. Differential expression analysis was 
performed with LIMMA, GSEA and Metacore. The most down-regulated genes are 
oncogenes or involved in lymphoma pathogenesis such as IRAK1, MYD88, MYC, MYB, 
CCND2, BLK, CDK4, IKZF1 or TNFRSF17 (BCMA). The up-regulated ones comprised 
tumor suppressor genes (CDKN2C, CDKN1A, CDKN2D) or genes involved in immune 
response (HLA, CD69). Validation of GEP results was obtained by real-time PCR analysis, 
confirming the upregulation of CDKN1A and downregulation of MYC, IRAK4, MYD88, 
STAT3, and, in the ABC-DLBCL cell line, also of IRAK1. DOHH-2 cells were injected s.c. in 
NOD-SCID mice, then mice were treated with ST7612AA1 (40mg/Kg, p.o.) or its vehicle 
control. ST7612AA1 determined a significant delay in tumor progression (p = 0.0449). 
 
Article 2 
The second work was on the study of the first-in-class clinical BET inhibitor, OTX015/MK-
8628  (Merck, Germany). OTX015/MK-8628 targets BRD2-3-4 and it was mainly tested in 
DLBCL and in MCL. 33 lymphomas cell lines were exposed to increasing concentrations of 
OTX015/MK-8628  and the MTT assay was performed after 72 hours. The median IC50 
value for the whole series was 240 nmol/L (range, 70 nmol/L–15 µmol/L). OTX015/MK-
8628 showed cytostatic activity in 29/33, induced cell-cycle arrest with G1 accumulation and 
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decreased S-phase and apoptosis in 3/22. GEP was done on two sensitive cell lines (SU-DHL-
6 and SU-DHL-2) treated with DMSO or with OTX015/MK-8628  for 1, 2, 4, 8, and 12 
hours. Most up-regulated genes were histones. MYC target genes were highly significantly 
enriched among all OTX015/MK-8628 regulated transcripts and MYC was the most 
frequently down-regulated gene. OTX015/MK-8628 also down-regulated MYD88, IRAK1, 
TLR6, IL6, STAT3, and TNFRSF17, members of the NFKB, TLR and JAK/STAT pathways. 
Real-time PCR showed that there was a significant downregulation of MYC, IL6, TLR6, 
TNFSRF17 and, although not reaching the statistical significance, of IRAK1, IRF4, and 
STAT3. Immunoblotting and immunohistochemistry showed a reduction of transcriptionally 
active pSTAT3 in 2 ABC-DLBCL cell lines, and a reduction in nuclear localization of p50 
(NFKB1), indicating an inhibitory effect of OTX015/MK-8628 on the canonical NFKB 
pathway. GEP suggested combination study using a series of conventional and targeted anti-
lymphoma agents in a panel of five DLBCL cell lines. Strong synergism was observed with 
everolimus (CI=0.11) and ibrutinib (CI=0.04); moderate synergism with  idelalisib (CI=0.5), 
vorinostat (CI=0.5), rituximab (CI=0.5), decitabine (CI=0.6), lenalidomide (CI=0.7). Additive 
effect with romidepsin (CI=1.08), bendamustine (CI=0.63) and doxorubicin (CI=0.83). 
Baseline GEP were obtained in 14 cell lines with an IC50 lower than 500 nmol/L and eight 
with a higher IC50. Transcripts positively associated with OTX015/MK-8628 sensitivity were 
significantly enriched of genes involved in IFN, IL6 and IL10 signaling genes, TLR and 
JAK/STAT signaling, STAT3 targets, genes involved in glucose metabolism, and hypoxia-
regulated genes. Transcripts associated with lower sensitivity to OTX015/MK-8628 were 
significantly enriched of E2F target genes, genes involved in cell-cycle regulation, DNA 
repair, P53 signa<ling, chromatin structure, and apoptosis. NOD-SCID mice were treated 
with OTX015/MK-8628  (25 mg/kg, p.o) or its vehicle control. OTX015/MK-8628 induced a 
reduced growth of the lymphoma xenografts, the median tumor volumes for the control and 
for the experimental arm were 600 mm3 (95% CI, 550–684) and 239 mm3 (95% CI, 0–582), 
respectively (p = 0.001). 
I performed the combination study of OTX015/MK-8628 with a series of conventional and 
targeted anti-lymphoma agents (Figure 5), I prepared samples for GEP analysis and I 
validated several genes by real-time PCR (Figure 3A and Figure 4A). 
 
Article 3 
The third work was aimed to the study and evaluation of three novel BET inhibitors, BAY 
1238097, BAY-7575 and BAY-5627 (Bayer, Germany), BAY 1238097 mainly targeting 
BRD4. BAY 1238097, BAY-7575 and BAY-5627 resulted very active in vitro models of 
Lymphomas and BAY 1238097 resulted active also in vivo. BAY 1238097, BAY-7575 and 
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BAY-5627 showed anti-proliferative activity in 51 lymphomas cell lines treated, the median 
IC50 values of 208 nM (157-260), 100 nM (75-120) and 70 nM (54-90 nM) respectively, 
with a very similar pattern of activity. The antitumor activity was mainly cytostatic. Cell lines 
presented LC50 values more similar to their IC50 exposed to the compounds for 72h or 96h 
underwent apoptosis. Baseline GEP showed that sensitive cell lines had high expression 
levels of genes involved in the JAK/STAT, IFN and BCR signaling. Sensitive cell lines had 
high incidence of mutation in EZH2 and MYD88. Chromatin Immunoprecipitation assay 
shown that treatment with BAY 1238097 reduced BRD4 binding to the EZH2 upstream 
regulatory region, indicating a direct effect of BAY 1238097 on the regulation of the EZH2 
mRNA. GEP suggested combination study using EZH2, BTK and mTOR inhibitors. BAY 
1238097 was combined with two different EZH2 inhibitors, DZNep and GSK126. Synergistic 
effects were seen in 3/5 cell lines harbouring EZH2 mutation, while additive effects or not 
benefits were detected in 3/3 WT EZH2 cell lines. We assessed changes at protein levels of 
EZH2, total histone H3 and H3K27me3 after exposure to BAY 1238097 single agent and in 
combination with the GSK126 or DZNep. BAY 1238097 determined a downregulation of 
EZH2, Histone 3 and H3K27me3, which apparently led to a stronger downregulation of 
H3K27me3 levels after the BAY 1238097/GSK126 combination. BAY 1238097 was 
combined with the BTK inhibitor ibrutinib for 72 h. Synergism was observed in 2/2 ABC-
DLBCL cell lines harboring L265P-MYD88 mutation (OCI-LY-10, TMD8). No benefit was 
observed in 2/2 ABC-DLBCL with WT MYD88 (SU-DHL-2, U-2932). BAY 1238097 was 
combined with the mTOR inhibitor everolimus, leading to synergism in 2/2 ABC-DLBCL 
(U-2932, TMD8) and in 5/6 GCB-DLBCL (KARPAS-422, SU-DHL-6, DOHH-2, SU-DHL-
8, Toledo) and additive in the remaining WSU-DLCL2.  The treatment of two DLBCL cell 
lines with single BAY 1238097 induced a downregulation of pAKT protein levels, 
maintained in the cell lines exposed to both compounds. BAY 1238097 affected the growth of 
both GCB-DLBCL (SU-DHL-8) and ABC-DLBCL (OCI-LY-3) xenografts: treated tumors 
resulted 6-8 fold smaller in volume respect to controls. 
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Lymphomas are a heterogeneous group of neoplasms derived from lymphoid cells at various 
stages of development and they are among the ten most frequent human cancers. Treatment of 
lymphomas patients that are resistant/refractory to standard chemotherapy is in need for new 
drugs therapeutic and approaches.  
Epigenetic modulation is a dynamic and reversible process. Somatic mutations, amplifications 
and translocations in genes that encode for chromatin-related proteins are frequent in cancer, 
providing interesting targets for epigenetic drugs [190, 191]. Different classes of protein are 
involved, mainly divided in epigenetic writers, epigenetic erasers and epigenetic readers [34, 
114, 192].  
Histone deacetylation induces transcriptional repression in closed-chromatin configuration. 
On the converse, histone acetylation induces transcriptional activation and relaxing chromatin 
[193, 194]. The acetylation status of the histone is a dynamic process and depends on the 
balance between these two conditions. Thus, compounds targeting the histone deacetylation - 
HDAC inhibitors - are generally considered to be transcriptional activators. Several HDAC 
inhibitors are under clinical development in various malignancies, many of them of 
hematological origin, such as multiple myeloma, leukemia, lymphoma and myelodysplastic 
syndrome [105, 106]. Recently, a systematic study of medicinal chemistry aimed at 
identifying a new generation of HDAC inhibitors identified a new class of thiol-based potent 
pan-HDAC inhibitors [126]. ST7612AA1 (property of Sigma-Tau, Italy) is a thioacetate-ω (γ-
lactam amide) derivative, first synthetic thiol-derivative, potent oral pan-HDAC inhibitor. 
This is a prodrug of ST7464AA1, which has exquisite potency toward class I and class IIb 
HDACs. In agreement with the powerful inhibition of class I HDACs, here, we show that 
ST7612AA1 had a broad spectrum anti-proliferative activity on cell lines derived from 
lymphoma. We evaluated the activity of ST7612AA1 on a panel of 17 lymphoma cell lines. 
The median IC50 was 375 nM (range, 46-2664) for all the cell lines without significant 
differences among histological subtypes or between GCB- and ABC-DLBCL. ST7612AA1 
presented both nuclear and cytoplasmic anti-deacetylase activity as demonstrated by Western 
blotting analysis showing increased protein levels of both acetylated histone H3 and acetyl-α 
tubulin. GEP was performed on two sensitive cell lines (DOHH-2 and TMD8) treated with 
ST7612AA1, important oncogenes and tumor suppressor genes were affected. The most 
down-regulated genes were related to TLR and NF-κB pathways, such as TNFRSF17 
(BCMA), MYC, IRAK1, MYD88, BLK, CDK4, IKZF1, BID, while the up-regulated transcripts 
comprised cell-cycle genes (CDKN2C (p18), CDKN1A (p21), CDKN2D (p19), genes coding 
histones, MHC-I, MHC-II and metallothioneins). Our validations by real-time PCR 
confirmed the upregulation of CDKN1A and downregulation of MYC, IRAK4, MYD88, 
STAT3. ST7612AA1 by affecting NF-κB pathway and cell-cycle. All these genes are relevant 
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not only in cancer therapy but also in the inflammatory diseases [195]. Since ST7612AA1 can 
down-regulate MYC target genes and NF-κB pathway, it is also of interest for DLBCL. 
Indeed, the in vivo activity of ST7612AA1 was observed against a DLBCL cell line 
characterized by both MYC and BCL2 gene translocations with a significant delay tumor 
progression was observed. 
In one study, we reported that this novel HDAC inhibitor inhibited cell growth/proliferation 
in not only in lymphoma cell lines but also in tumor cell lines from solid tumors.  
 
Epigenetic readers facilitate transcriptional activation by recognizing specific histone 
acetylated lysine residues and recruiting specific transcription factors (BET bromodomain 
proteins) [150]. Inhibition of epigenetic readers looks an interesting option for the treatment 
of human cancer. In several pre-clinical lymphoma models BET bromodomain inhibitors 
have shown antitumor activity [180, 181, 186, 196] and, interestingly, efficacy have been 
observed in phase I studies  [197-199]. We evaluated the activity of OTX015/MK-8628, a 
new oral BET bromodomain inhibitor in pre-clinical lymphoma models and showed its 
proliferative activity on 33 cell lines derived from mature B-cell lymphoid tumors. DLBCL 
cells treated with OTX015/MK-8628 underwent cell-cycle arrest with G1 accumulation and 
decreased S-phase. OTX015/MK-8628 appeared to induce a senescence-like phenotype, 
compatible with described “senescence with incomplete growth arrest” [200], also observed 
after treatment of DLBCL cells with demethylating agents [201]. Baseline GEP showed that 
sensitivity to the OTX015/MK-8628 were significantly enriched of genes involved in 
interferon, interleukin signaling genes, TLR and JAK/STAT signaling, STAT3 targets, genes 
involved in glucose metabolism, and hypoxia-regulated genes. Transcripts associated with 
lower sensitivity to OTX015/MK-8628 were significantly enriched of E2F target genes, genes 
involved in cell-cycle regulation, DNA repair, P53 signaling, chromatin structure, and 
apoptosis. MYC, E2F1 targets and genes involved in NFKB/TLR/JAK/STAT pathways were 
down-regulated by OTX015/MK-8628 and other BRD-inhibitors [59, 90, 168, 176, 196].  
MYC plays an important role in the pathogenesis and in the progression of most of the 
lymphoma subtypes. In particular, some DLBCL cases carry chromosomal translocations of 
both MYC and BCL2 genes (“double hit lymphomas”) and others express, albeit in the 
absence of chromosomal translocations, express both MYC and BCL2 proteins (“double 
expressors”), and both groups of patients present inferior outcome when compared with the 
remaining DLBCL cases [202]. Thus, compounds that can target MYC appear very 
interesting for their potential clinical implication [202-204].  
We performed combination study by using OTX015/MK-8628 with a series of conventional 
and targeted anti-lymphoma agents. Strong synergistic effects were observed with the mTOR 
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inhibitor everolimus and with the BTK inhibitor ibrutinib. The mTOR is central to a signaling 
cascade leading to cell growth and proliferation, and mTOR inhibitors are approved for 
treatment of relapsed MCL [205]. Ibrutinib is more active in ABC-DLBCL cases with 
CD79B/CD79A, CARD11 and MYD88 mutated genes [206, 207]. Moderate synergism were 
observed with PI3K-delta inhibitor idelalisib that is clinically active in B-cell lymphomas 
[208], with anti-CD20 monoclonal antibody rituximab and with the immunomodulant 
lenalidomide, as also recently reported for another BET bromodomain inhibitor in MCL 
[209]. OTX015/MK-8628 presented synergism with the demethylating agent decitabine and 
the HDAC inhibitor vorinostat at concentrations pharmacologically achievable in clinical use 
[210], in accordance with the similarities here observed at the level of gene expression 
signatures, and also with published data obtained with other BET bromodomain inhibitors 
[181]. Additive effects were observed for combinations with class I HDAC inhibitor 
romidepsin, chemotherapy agent bendamustine and chemotherapy agent doxorubicin. 
HDACs of both classes I and II were associated with a lower sensitivity to OTX015/MK-
8628 as single agent and indeed the synergism appeared stronger with the class I and IIa/b 
HDAC inhibitor vorinostat than that seen with the class I HDAC inhibitor romidepsin 
suggesting that the synergism might be class dependent.  
Further pre-clinical studies with OTX015/MK-8628 will help to understand the mechanism of 
action of the molecule and to optimize its use as an anti-lymphoma agent. 
An article “in preparation” will report new in vitro and in vivo data on OTX015/MK-8628 in 
MCL (Bernasconi, Gaudio et al., in preparation). GEP was performed on MCL cell lines after 
treatment with OTX015/MK-8628 and genetic features associated with sensitivity and 
resistance. We report also the pre-clinical activity of OTX015/MK-8628 combinations that 
might overcome adaptive resistance mechanisms. 
 
OTX015/MK-8628 is in clinical trials, including patients with hematologic malignancies 
such as lymphoma, MM, AML, myelodysplastic syndrome and show clinical activity [197, 
199, 211, 212]. A recent study shows that OTX015/MK-8628 induces a rapid tumor 
regression in two patients affected by NMC [198] and OTX015/MK-8628 has been initiated 
in patients with selected solid tumors and glioblastoma multiforme. The trials suggest the use 
of OTX015/MK-8628 combated with other compounds and can help to identify therapeutic 
target.  
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Finally, we have evaluated the activity of three new novel BET bromodomain inhibitors 
(BAY 1238097, BAY-7575 and BAY-5627) in pre-clinical models of mature B-cell lymphoid 
tumors, correlating the sensitivity to genetic and biologic features.  
These BET bromodomain inhibitors showed anti-proliferative activity in most of the 
lymphoma cell lines tested, with no differences in sensitivity among the histologic subtypes. 
The antitumor activity of BAY 1238097 was also conformed in two DLBCL xenograft 
models. Strong efficacy was demonstrated when giving the compound orally using either a 
daily or a twice weekly schedule. BAY 1238097 induced a block in cell-cycle with G1 
accumulation and decreased S-phase as observed with other BET bromodomain inhibitors 
[213, 214] Few cell lines derived from ABC-DLBCL, GCB-DLBCL and MCL underwent 
apoptosis after 72h of drug exposure, how observed in OTX015/MK-8628 activity.  
Baseline GEP is a strategy to identify mutations and features associated with response to a 
compound and to suggest possible combinatorial schemes.  
Transcripts associated with highest sensitivity to BAY 1238097 were significantly enriched 
of genes involved in the JAK/STAT, IFN and BCR signaling. The less sensitive GCB-
DLBCL had higher expression of genes involved in cell cycle, chromatin structure, and E2F1 
targets. Baseline GEP signature of BAY 1238097 were overlap with that of OTX015/MK-
8628. In fact transcripts positively associated with OTX015/MK-8628 sensitivity were 
significantly enriched of genes involved in interferon, IL6 and IL10 signaling genes, TLR and 
JAK/STAT signaling, STAT3 targets, genes involved in glucose metabolism, and hypoxia-
regulated genes. While transcripts associated with lower sensitivity to OTX015/MK-8628 
were significantly enriched of E2F target genes, genes involved in cell cycle regulation, DNA 
repair, P53 signaling, chromatin structure, and apoptosis.  
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Figure 8. Representative GSEA plots illustrating: (A) the enrichment of genes involved in JAK/STAT, 
IFN and BCR signaling among the transcripts associated with a higher BAY 1238097 sensitivity; (B) 
the enrichment of genes involved in cell cycle, chromatin structure, and E2F1 targets among the 
transcripts associated with a lower sensitivity to BAY 1238097; (C) the enrichment of genes involved 
in interferon and IL6 signaling, in glucose metabolism, and in hypoxia among the transcripts associated 
with a higher OTX015/MK-8628 sensitivity; (D) the enrichment of genes involved in cell cycle 
regulation and chromatin structure and of E2F targets among the transcripts associated with a lower 
sensitivity to OTX015/MK-8628. FDR, false discovery rate; NES, normalized enrichment score.  
 
 
Mutations of EZH2 occur frequently in DLBCL and in FL and EZH2 signature from FL 
patients with or without mutated EZH2 [215] was associated with higher sensitivity in GCB-
DLBCL cell lines. Treatment with BAY 1238097 reduced BRD4 binding to the EZH2 
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upstream regulatory region, indicating a direct effect of BET bromodomain inhibitors on the 
regulation of the EZH2 mRNA. Based on this data and our previous data with the BET 
inhibitor OTX015/MK-8628 [186], we perform combination study using EZH2, BTK and 
mTOR inhibitors. DZNep induce a synergistic or additive effect in GCB-DLBCL with 
mutated EZH2, while it did not present any benefit in cell lines with WT EZH2 tested.  
To obtain a global view of the transcriptional changes after BAY 1238097 treatment, GEP 
study was done on the cell line DOHH-2 exposed to DMSO or BAY 1238097 for 8, 12 or 24 
hours. The up-regulated transcripts were mainly represented by histones. The up-regulated 
genes included CCL5, CDKN2C, CD69, JUN, and MKNK2.  
BAY 1238097 decreased target genes of MYC, NOTCH and E2F, members of 
NFKB/MYD88 and mTOR/AKT signaling. BTK, CCDC86, CCND2, CCRL1, CD19, CD27, 
FAIM, FAIM3, IL7R, IRAK1, MAPK13, MLKL, MYB, MYC, PDE4B, PTPN22, PVRIG, 
TNFRSF13B, TNFRSF17, VPREB3 were among the top down-regulated genes.  
BAY 1238097 gene expression signature overlapped with HDAC, highly overlapped with the 
signatures obtained with other BET inhibitors JQ1, with OTX015/MK-8628 [179, 186, 196, 
216, 217]. In fact, GEP was done on two sensitive cell lines (TMD8 and DOHH-2) treated 
with the HDAC inhibitor ST7612AA1 or DMSO for 8h. The up-regulated genes comprised 
tumor suppressor genes or genes involved in immune response. The most down-regulated 
genes were genes known as oncogenes or involved in lymphoma pathogenesis such as IRAK1, 
MYD88, MYC, MYB, CCND2, BLK, CDK4, IKZF1 or TNFRSF17 (BCMA). Furthermore GEP 
was done on two sensitive cell lines (SU-DHL-6 and SU-DHL-2) treated with DMSO or with 
BET Bromodomain inhibitor OTX015/MK-8628 for 1, 2, 4, 8, and 12 hours. Most up-
regulated genes were histones. Most down-regulated genes were MYD88, IRAK1, TLR6, IL6, 
STAT3, and TNFRSF17, members of the NFKB, TLR and JAK/STAT pathways.  
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Figure 9. Representative GSEA plots illustrating the gene-set enrichment in genes up-regulated (A) 
and down-regulated (B) in DOHH-2 cell line after BAY 1238097 exposure; GEP shows transcripts 
with higher expression (C) and lower expression (D) in two sensitive cell lines (TMD8 and DOHH-2) 
treated with ST7612AA1; up-regulated gene-set (E) and down-regulated gene-set (F) in two sensitive 
cell lines (SU-DHL-6 and SU-DHL-2) after OTX015/MK-8628 exposure. FDR, false discovery rate; 
NES, normalized enrichment score.  
 
BAY 1238097 in combination with ibrutinib was synergistic in ABC-DLBCL cell lines 
harboring L265P-MYD88 and of no benefit in ABC-DLBCL with WT MYD88. Similarly to 
what seen with OTX015/MK-8628 [213], the combination of BAY 1238097 with everolimus 
was very beneficial, both in ABC- and in GCB-DLBCL cells. Immunoblotting data suggested 
that the synergism could be due to decreased levels of pAKT after BET inhibitor, which 
might attenuate the negative feedback observed after mTOR inhibitors alone [218]. 
BAY 1238097 underwent clinical investigation in patients with solid tumors 
(NCT02369029), but unfortunately, the study was closed due to toxicity (severe and 
unexpected headaches, vomit and back pain) [172].  
 
In conclusion, the epigenetic compounds studied in this PhD work represents promising new 
anti-lymphoma agents with anti-proliferative activity in the clear majority of the examined 
pre-clinical models. They are able to modulate important signaling pathways that are 
commonly deregulated in lymphomas. It will be important to properly move these drugs to 
the clinics as single agents and in combination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 
  
    REFERENCES 
 
 
41 
 
 
1. Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2016. CA Cancer J Clin, 
2016. 66(1): p. 7-30. 
2. Lenz, G., et al., Stromal gene signatures in large-B-cell lymphomas. N Engl J Med, 
2008. 359(22): p. 2313-23. 
3. Jung, D., et al., Mechanism and control of V(D)J recombination at the 
immunoglobulin heavy chain locus. Annu Rev Immunol, 2006. 24: p. 541-70. 
4. Saji, S., et al., Significance of HDAC6 regulation via estrogen signaling for cell 
motility and prognosis in estrogen receptor-positive breast cancer. Oncogene, 2005. 
24(28): p. 4531-9. 
5. Kuppers, R., Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer, 2005. 
5(4): p. 251-62. 
6. Swerdlow, S.H., et al., The 2016 revision of the World Health Organization 
classification of lymphoid neoplasms. Blood, 2016. 127(20): p. 2375-90. 
7. Swerdlow, S.H., et al., eds. WHO Classification of Tumours of Haematopoietic and 
Lymphoid Tissues. 2008, IARC Press: Lyon, France. 439. 
8. Lossos, I.S., Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol, 
2005. 23(26): p. 6351-7. 
9. Lenz, G., et al., Molecular subtypes of diffuse large B-cell lymphoma arise by distinct 
genetic pathways. Proc Natl Acad Sci U S A, 2008. 105(36): p. 13520-5. 
10. Tilly, H., et al., Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice 
Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: p. 
vii78-82. 
11. Testoni, M., et al., Genetic lesions in diffuse large B-cell lymphomas. Ann Oncol, 
2015. 26(6): p. 1069-80. 
12. Grant, C., et al., Primary mediastinal large B-cell lymphoma, classic Hodgkin 
lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: 
what is the oncologist to do? Curr Hematol Malig Rep, 2011. 6(3): p. 157-63. 
13. Raia, V., et al., Dynamic mathematical modeling of IL13-induced signaling in 
Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic 
targets. Cancer Res, 2011. 71(3): p. 693-704. 
14. Dunleavy, K. and W.H. Wilson, Primary mediastinal B-cell lymphoma and 
mediastinal gray zone lymphoma: do they require a unique therapeutic approach? 
Blood, 2015. 125(1): p. 33-9. 
15. Horning, S.J., Follicular lymphoma: have we made any progress? Ann Oncol, 2000. 
11 Suppl 1: p. 23-7. 
16. Swerdlow, S.H. and M.E. Williams, From centrocytic to mantle cell lymphoma: a 
clinicopathologic and molecular review of 3 decades. Hum Pathol, 2002. 33(1): p. 7-
20. 
17. Li, J.Y., et al., Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma 
by fluorescence in situ hybridization. Am J Pathol, 1999. 154(5): p. 1449-52. 
18. Kelly, W.K., et al., Phase I study of an oral histone deacetylase inhibitor, 
suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol, 
2005. 23(17): p. 3923-31. 
19. Grassadonia, A., et al., Role of Hydroxamate-Based Histone Deacetylase Inhibitors 
(Hb-HDACIs) in the Treatment of Solid Malignancies. Cancers (Basel), 2013. 5(3): p. 
919-42. 
20. Rinaldi, A., et al., Genome-wide DNA profiling of marginal zone lymphomas 
identifies subtype-specific lesions with an impact on the clinical outcome. Blood, 
2011. 117(5): p. 1595-604. 
21. Thieblemont, C., T. Molina, and F. Davi, Optimizing therapy for nodal marginal zone 
lymphoma. Blood, 2016. 127(17): p. 2064-71. 
22. Arcaini, L., D. Rossi, and M. Paulli, Splenic marginal zone lymphoma: from genetics 
to management. Blood, 2016. 127(17): p. 2072-81. 
    REFERENCES 
 
 
42 
 
23. Spina, V., et al., The genetics of nodal marginal zone lymphoma. Blood, 2016. 
128(10): p. 1362-73. 
24. Hummel, M., et al., A biologic definition of Burkitt's lymphoma from transcriptional 
and genomic profiling. N Engl J Med, 2006. 354(23): p. 2419-30. 
25. Dohner, H., et al., Genomic aberrations and survival in chronic lymphocytic 
leukemia. N Engl J Med, 2000. 343(26): p. 1910-6. 
26. Bergsagel, P.L. and W.M. Kuehl, Comprehensive identification of somatic mutations 
in chronic lymphocytic leukemia. Cancer Cell, 2011. 20(1): p. 5-7. 
27. O'Leary, H.M. and K.J. Savage, Update on the World Health Organization 
classification of peripheral T-cell lymphomas. Curr Hematol Malig Rep, 2009. 4(4): 
p. 227-35. 
28. de Leval, L., et al., The gene expression profile of nodal peripheral T-cell lymphoma 
demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) 
and follicular helper T (TFH) cells. Blood, 2007. 109(11): p. 4952-63. 
29. Henssen, A., et al., Targeting MYCN-Driven Transcription By BET-Bromodomain 
Inhibition. Clin Cancer Res, 2016. 22(10): p. 2470-81. 
30. Kelly, T.K., D.D. De Carvalho, and P.A. Jones, Epigenetic modifications as 
therapeutic targets. Nat Biotechnol, 2010. 28(10): p. 1069-78. 
31. Jones, R.S., Epigenetics: reversing the 'irreversible'. Nature, 2007. 450(7168): p. 
357-9. 
32. Drummond, D.C., et al., Clinical development of histone deacetylase inhibitors as 
anticancer agents. Annu Rev Pharmacol Toxicol, 2005. 45: p. 495-528. 
33. Chen, P.C., et al., Synthesis and structure-activity relationship of histone deacetylase 
(HDAC) inhibitors with triazole-linked cap group. Bioorg Med Chem, 2008. 16(9): p. 
4839-53. 
34. Dawson, M.A., T. Kouzarides, and B.J. Huntly, Targeting epigenetic readers in 
cancer. N Engl J Med, 2012. 367(7): p. 647-57. 
35. Lalonde, M.E., X. Cheng, and J. Cote, Histone target selection within chromatin: an 
exemplary case of teamwork. Genes Dev, 2014. 28(10): p. 1029-41. 
36. Simo-Riudalbas, L. and M. Esteller, Targeting the histone orthography of cancer: 
drugs for writers, erasers and readers. Br J Pharmacol, 2015. 172(11): p. 2716-32. 
37. Baylin, S.B. and P.A. Jones, A decade of exploring the cancer epigenome - biological 
and translational implications. Nat Rev Cancer, 2011. 11(10): p. 726-34. 
38. Jiang, Y., K. Hatzi, and R. Shaknovich, Mechanisms of epigenetic deregulation in 
lymphoid neoplasms. Blood, 2013. 121(21): p. 4271-9. 
39. Li, K.K., et al., Chemical and biochemical approaches in the study of histone 
methylation and demethylation. Med Res Rev, 2012. 32(4): p. 815-67. 
40. Arrowsmith, C.H., et al., Epigenetic protein families: a new frontier for drug 
discovery. Nat Rev Drug Discov, 2012. 11(5): p. 384-400. 
41. Falkenberg, K.J. and R.W. Johnstone, Histone deacetylases and their inhibitors in 
cancer, neurological diseases and immune disorders. Nat Rev Drug Discov, 2014. 
13(9): p. 673-91. 
42. Martinez-Garcia, E. and J.D. Licht, Deregulation of H3K27 methylation in cancer. 
Nat Genet, 2010. 42(2): p. 100-1. 
43. Stimson, L. and N.B. La Thangue, Biomarkers for predicting clinical responses to 
HDAC inhibitors. Cancer Lett, 2009. 280(2): p. 177-83. 
44. Tan, J.Z., et al., EZH2: biology, disease, and structure-based drug discovery. Acta 
Pharmacol Sin, 2014. 35(2): p. 161-74. 
45. Kapoor, S., Inhibition of HDAC6-dependent carcinogenesis: emerging, new 
therapeutic options besides belinostat. Int J Cancer, 2009. 124(2): p. 509. 
46. Campas-Moya, C., Romidepsin for the treatment of cutaneous T-cell lymphoma. 
Drugs Today (Barc), 2009. 45(11): p. 787-95. 
47. Lessard, J. and G. Sauvageau, Bmi-1 determines the proliferative capacity of normal 
and leukaemic stem cells. Nature, 2003. 423(6937): p. 255-60. 
    REFERENCES 
 
 
43 
 
48. Sparmann, A. and M. van Lohuizen, Polycomb silencers control cell fate, 
development and cancer. Nat Rev Cancer, 2006. 6(11): p. 846-56. 
49. Bracken, A.P., et al., The Polycomb group proteins bind throughout the INK4A-ARF 
locus and are disassociated in senescent cells. Genes Dev, 2007. 21(5): p. 525-30. 
50. Boi, M., et al., Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 
in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome 
resistant phenotypes. Oncotarget, 2016. 
51. Morin, R.D., et al., Frequent mutation of histone-modifying genes in non-Hodgkin 
lymphoma. Nature, 2011. 476(7360): p. 298-303. 
52. Morin, R.D., et al., Somatic mutations altering EZH2 (Tyr641) in follicular and 
diffuse large B-cell lymphomas of germinal-center origin. Nat Genet, 2010. 42(2): p. 
181-5. 
53. Bodor, C., et al., EZH2 Y641 mutations in follicular lymphoma. Leukemia, 2011. 
25(4): p. 726-9. 
54. Love, C., et al., The genetic landscape of mutations in Burkitt lymphoma. Nat Genet, 
2012. 44(12): p. 1321-5. 
55. Nikoloski, G., et al., Somatic mutations of the histone methyltransferase gene EZH2 
in myelodysplastic syndromes. Nat Genet, 2010. 42(8): p. 665-7. 
56. Visser, H.P., et al., The Polycomb group protein EZH2 is upregulated in 
proliferating, cultured human mantle cell lymphoma. Br J Haematol, 2001. 112(4): p. 
950-8. 
57. Eckerle, S., et al., Gene expression profiling of isolated tumour cells from anaplastic 
large cell lymphomas: insights into its cellular origin, pathogenesis and relation to 
Hodgkin lymphoma. Leukemia, 2009. 23(11): p. 2129-38. 
58. Sasaki, D., et al., Overexpression of Enhancer of zeste homolog 2 with trimethylation 
of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for 
epigenetic therapy. Haematologica, 2011. 96(5): p. 712-9. 
59. Ott, C.J., et al., BET bromodomain inhibition targets both c-Myc and IL7R in high-
risk acute lymphoblastic leukemia. Blood, 2012. 120(14): p. 2843-52. 
60. Gimsing, P., Belinostat: a new broad acting antineoplastic histone deacetylase 
inhibitor. Expert Opin Investig Drugs, 2009. 18(4): p. 501-8. 
61. Knutson, S.K., et al., A selective inhibitor of EZH2 blocks H3K27 methylation and 
kills mutant lymphoma cells. Nat Chem Biol, 2012. 8(11): p. 890-6. 
62. Velichutina, I., et al., EZH2-mediated epigenetic silencing in germinal center B cells 
contributes to proliferation and lymphomagenesis. Blood, 2010. 116(24): p. 5247-55. 
63. van Galen, J.C., et al., Distinct expression patterns of polycomb oncoproteins and 
their binding partners during the germinal center reaction. Eur J Immunol, 2004. 
34(7): p. 1870-81. 
64. Hassler, M.R., A.I. Schiefer, and G. Egger, Combating the epigenome: epigenetic 
drugs against non-Hodgkin's lymphoma. Epigenomics, 2013. 5(4): p. 397-415. 
65. Tan, J., et al., Pharmacologic disruption of Polycomb-repressive complex 2-mediated 
gene repression selectively induces apoptosis in cancer cells. Genes Dev, 2007. 
21(9): p. 1050-63. 
66. Fiskus, W., et al., Superior efficacy of a combined epigenetic therapy against human 
mantle cell lymphoma cells. Clin Cancer Res, 2012. 18(22): p. 6227-38. 
67. Miranda, T.B., et al., DZNep is a global histone methylation inhibitor that reactivates 
developmental genes not silenced by DNA methylation. Mol Cancer Ther, 2009. 8(6): 
p. 1579-88. 
68. Kim, K.H. and C.W. Roberts, Targeting EZH2 in cancer. Nat Med, 2016. 22(2): p. 
128-34. 
69. Takeshima, H., et al., Identification of coexistence of DNA methylation and 
H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. 
Carcinogenesis, 2015. 36(2): p. 192-201. 
    REFERENCES 
 
 
44 
 
70. Kirk, J.S., et al., Top2a identifies and provides epigenetic rationale for novel 
combination therapeutic strategies for aggressive prostate cancer. Oncotarget, 2015. 
6(5): p. 3136-46. 
71. Adhikary, G., et al., Survival of skin cancer stem cells requires the Ezh2 polycomb 
group protein. Carcinogenesis, 2015. 36(7): p. 800-10. 
72. Maryan, N., et al., Regulation of the expression of claudin 23 by the enhancer of zeste 
2 polycomb group protein in colorectal cancer. Mol Med Rep, 2015. 12(1): p. 728-
36. 
73. McCabe, M.T., et al., EZH2 inhibition as a therapeutic strategy for lymphoma with 
EZH2-activating mutations. Nature, 2012. 492(7427): p. 108-12. 
74. Ruiz-Carrillo, A., L.J. Wangh, and V.G. Allfrey, Processing of newly synthesized 
histone molecules. Science, 1975. 190(4210): p. 117-28. 
75. Yuan, Z.L., et al., Stat3 dimerization regulated by reversible acetylation of a single 
lysine residue. Science, 2005. 307(5707): p. 269-73. 
76. Rothgiesser, K.M., M. Fey, and M.O. Hottiger, Acetylation of p65 at lysine 314 is 
important for late NF-kappaB-dependent gene expression. BMC Genomics, 2010. 11: 
p. 22. 
77. Cerchietti, L.C., et al., BCL6 repression of EP300 in human diffuse large B cell 
lymphoma cells provides a basis for rational combinatorial therapy. J Clin Invest, 
2010. 120(12): p. 4569-82. 
78. Pasqualucci, L., et al., Inactivating mutations of acetyltransferase genes in B-cell 
lymphoma. Nature, 2011. 471(7337): p. 189-95. 
79. Lohr, J.G., et al., Discovery and prioritization of somatic mutations in diffuse large 
B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A, 
2012. 109(10): p. 3879-84. 
80. Ying, C.Y., et al., MEF2B mutations lead to deregulated expression of the oncogene 
BCL6 in diffuse large B cell lymphoma. Nat Immunol, 2013. 14(10): p. 1084-92. 
81. Khabele, D., et al., Drug-induced inactivation or gene silencing of class I histone 
deacetylases suppresses ovarian cancer cell growth: implications for therapy. Cancer 
Biol Ther, 2007. 6(5): p. 795-801. 
82. Song, J., et al., Increased expression of histone deacetylase 2 is found in human 
gastric cancer. APMIS, 2005. 113(4): p. 264-8. 
83. Bartling, B., et al., Comparative application of antibody and gene array for 
expression profiling in human squamous cell lung carcinoma. Lung Cancer, 2005. 
49(2): p. 145-54. 
84. Mariadason, J.M., HDACs and HDAC inhibitors in colon cancer. Epigenetics, 2008. 
3(1): p. 28-37. 
85. Abbas, A. and S. Gupta, The role of histone deacetylases in prostate cancer. 
Epigenetics, 2008. 3(6): p. 300-9. 
86. Melnick, A. and J.D. Licht, Histone deacetylases as therapeutic targets in 
hematologic malignancies. Curr Opin Hematol, 2002. 9(4): p. 322-32. 
87. Yamaguchi, T., et al., Histone deacetylases 1 and 2 act in concert to promote the G1-
to-S progression. Genes Dev, 2010. 24(5): p. 455-69. 
88. Marquard, L., et al., Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and 
T-cell lymphomas. Histopathology, 2009. 54(6): p. 688-98. 
89. Gloghini, A., et al., Expression of histone deacetylases in lymphoma: implication for 
the development of selective inhibitors. Br J Haematol, 2009. 147(4): p. 515-25. 
90. Delmore, J.E., et al., BET bromodomain inhibition as a therapeutic strategy to target 
c-Myc. Cell, 2011. 146(6): p. 904-17. 
91. Richon, V.M., et al., Histone deacetylase inhibitor selectively induces p21WAF1 
expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A, 2000. 
97(18): p. 10014-9. 
92. Gupta, M., et al., Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell 
lymphoma: implications for therapy. Leukemia, 2012. 26(6): p. 1356-64. 
    REFERENCES 
 
 
45 
 
93. Dokmanovic, M., C. Clarke, and P.A. Marks, Histone deacetylase inhibitors: 
overview and perspectives. Mol Cancer Res, 2007. 5(10): p. 981-9. 
94. Yang, X.J. and E. Seto, HATs and HDACs: from structure, function and regulation to 
novel strategies for therapy and prevention. Oncogene, 2007. 26(37): p. 5310-8. 
95. Glozak, M.A. and E. Seto, Histone deacetylases and cancer. Oncogene, 2007. 
26(37): p. 5420-32. 
96. Peng, L. and E. Seto, Deacetylation of nonhistone proteins by HDACs and the 
implications in cancer. Handb Exp Pharmacol, 2011. 206: p. 39-56. 
97. Lue, J.K., J.E. Amengual, and O.A. O'Connor, Epigenetics and Lymphoma: Can We 
Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs? Curr 
Oncol Rep, 2015. 17(9): p. 40. 
98. Belkina, A.C. and G.V. Denis, BET domain co-regulators in obesity, inflammation 
and cancer. Nat Rev Cancer, 2012. 12(7): p. 465-77. 
99. Sasakawa, Y., et al., Effects of FK228, a novel histone deacetylase inhibitor, on 
tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett, 2003. 
195(2): p. 161-8. 
100. Lin, H.Y., et al., Targeting histone deacetylase in cancer therapy. Med Res Rev, 
2006. 26(4): p. 397-413. 
101. Burgess, A., et al., Histone deacetylase inhibitors specifically kill nonproliferating 
tumour cells. Oncogene, 2004. 23(40): p. 6693-701. 
102. Ruefli, A.A., et al., The histone deacetylase inhibitor and chemotherapeutic agent 
suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized 
by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U 
S A, 2001. 98(19): p. 10833-8. 
103. Peng, J., et al., Brd2 is a TBP-associated protein and recruits TBP into E2F-1 
transcriptional complex in response to serum stimulation. Mol Cell Biochem, 2007. 
294(1-2): p. 45-54. 
104. Witter, D.J., et al., Benzo[b]thiophene-based histone deacetylase inhibitors. Bioorg 
Med Chem Lett, 2007. 17(16): p. 4562-7. 
105. Lane, A.A. and B.A. Chabner, Histone deacetylase inhibitors in cancer therapy. J 
Clin Oncol, 2009. 27(32): p. 5459-68. 
106. Prince, H.M., M.J. Bishton, and S.J. Harrison, Clinical studies of histone deacetylase 
inhibitors. Clin Cancer Res, 2009. 15(12): p. 3958-69. 
107. West, A.C. and R.W. Johnstone, New and emerging HDAC inhibitors for cancer 
treatment. J Clin Invest, 2014. 124(1): p. 30-9. 
108. Giles, F., et al., A phase I study of intravenous LBH589, a novel cinnamic hydroxamic 
acid analogue histone deacetylase inhibitor, in patients with refractory hematologic 
malignancies. Clin Cancer Res, 2006. 12(15): p. 4628-35. 
109. Piekarz, R.L., et al., Phase II multi-institutional trial of the histone deacetylase 
inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J 
Clin Oncol, 2009. 27(32): p. 5410-7. 
110. McDermott, J. and A. Jimeno, Belinostat for the treatment of peripheral T-cell 
lymphomas. Drugs Today (Barc), 2014. 50(5): p. 337-45. 
111. Whittaker, S.J., et al., Final results from a multicenter, international, pivotal study of 
romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol, 2010. 28(29): p. 
4485-91. 
112. Coiffier, B., et al., Results from a pivotal, open-label, phase II study of romidepsin in 
relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J 
Clin Oncol, 2012. 30(6): p. 631-6. 
113. Masica, D.L. and R. Karchin, Collections of simultaneously altered genes as 
biomarkers of cancer cell drug response. Cancer Res, 2013. 73(6): p. 1699-708. 
114. Ryan, R.J. and B.E. Bernstein, Molecular biology. Genetic events that shape the 
cancer epigenome. Science, 2012. 336(6088): p. 1513-4. 
    REFERENCES 
 
 
46 
 
115. Prince, H.M., M.J. Bishton, and R.W. Johnstone, Panobinostat (LBH589): a potent 
pan-deacetylase inhibitor with promising activity against hematologic and solid 
tumors. Future Oncol, 2009. 5(5): p. 601-12. 
116. George, P., et al., Combination of the histone deacetylase inhibitor LBH589 and the 
hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells 
with activating mutation of FLT-3. Blood, 2005. 105(4): p. 1768-76. 
117. Sandor, V., et al., Phase I trial of the histone deacetylase inhibitor, depsipeptide 
(FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res, 
2002. 8(3): p. 718-28. 
118. Plumb, J.A., et al., Pharmacodynamic response and inhibition of growth of human 
tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer 
Ther, 2003. 2(8): p. 721-8. 
119. Martinet, N. and P. Bertrand, Interpreting clinical assays for histone deacetylase 
inhibitors. Cancer Manag Res, 2011. 3: p. 117-41. 
120. Dasmahapatra, G., et al., The pan-HDAC inhibitor vorinostat potentiates the activity 
of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. 
Blood, 2010. 115(22): p. 4478-87. 
121. Kalac, M., et al., HDAC inhibitors and decitabine are highly synergistic and 
associated with unique gene-expression and epigenetic profiles in models of DLBCL. 
Blood, 2011. 118(20): p. 5506-16. 
122. Bots, M. and R.W. Johnstone, Rational combinations using HDAC inhibitors. Clin 
Cancer Res, 2009. 15(12): p. 3970-7. 
123. Marks, P.A., The clinical development of histone deacetylase inhibitors as targeted 
anticancer drugs. Expert Opin Investig Drugs, 2010. 19(9): p. 1049-66. 
124. Schneider-Stock, R. and M. Ocker, Epigenetic therapy in cancer: molecular 
background and clinical development of histone deacetylase and DNA 
methyltransferase inhibitors. IDrugs, 2007. 10(8): p. 557-61. 
125. Vesci, L., et al., Preclinical antitumor activity of ST7612AA1: a new oral thiol-based 
histone deacetylase (HDAC) inhibitor. Oncotarget, 2015. 6(8): p. 5735-48. 
126. Giannini, G., et al., ST7612AA1, a thioacetate-omega(gamma-lactam carboxamide) 
derivative selected from a novel generation of oral HDAC inhibitors. J Med Chem, 
2014. 57(20): p. 8358-77. 
127. Marushige, K., Activation of chromatin by acetylation of histone side chains. Proc 
Natl Acad Sci U S A, 1976. 73(11): p. 3937-41. 
128. Wu, S.Y. and C.M. Chiang, The double bromodomain-containing chromatin adaptor 
Brd4 and transcriptional regulation. J Biol Chem, 2007. 282(18): p. 13141-5. 
129. Dhalluin, C., et al., Structure and ligand of a histone acetyltransferase bromodomain. 
Nature, 1999. 399(6735): p. 491-6. 
130. Owen, D.J., et al., The structural basis for the recognition of acetylated histone H4 by 
the bromodomain of histone acetyltransferase gcn5p. EMBO J, 2000. 19(22): p. 
6141-9. 
131. Filippakopoulos, P., et al., Histone recognition and large-scale structural analysis of 
the human bromodomain family. Cell, 2012. 149(1): p. 214-31. 
132. Dawson, M.A., et al., Inhibition of BET recruitment to chromatin as an effective 
treatment for MLL-fusion leukaemia. Nature, 2011. 478(7370): p. 529-33. 
133. Xiao, Y., et al., Bromodomain and extra-terminal domain bromodomain inhibition 
prevents synovial inflammation via blocking IkappaB kinase-dependent NF-kappaB 
activation in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford), 2016. 
55(1): p. 173-84. 
134. Goupille, O., et al., Inhibition of the acetyl lysine-binding pocket of bromodomain 
and extraterminal domain proteins interferes with adipogenesis. Biochem Biophys 
Res Commun, 2016. 472(4): p. 624-30. 
135. Voigt, P. and D. Reinberg, BRD4 jump-starts transcription after mitotic silencing. 
Genome Biol, 2011. 12(11): p. 133. 
    REFERENCES 
 
 
47 
 
136. You, J., et al., Kaposi's sarcoma-associated herpesvirus latency-associated nuclear 
antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. J 
Virol, 2006. 80(18): p. 8909-19. 
137. Korb, E., et al., BET protein Brd4 activates transcription in neurons and BET 
inhibitor Jq1 blocks memory in mice. Nat Neurosci, 2015. 18(10): p. 1464-73. 
138. Dey, A., et al., A bromodomain protein, MCAP, associates with mitotic chromosomes 
and affects G(2)-to-M transition. Mol Cell Biol, 2000. 20(17): p. 6537-49. 
139. Maruyama, T., et al., A Mammalian bromodomain protein, brd4, interacts with 
replication factor C and inhibits progression to S phase. Mol Cell Biol, 2002. 22(18): 
p. 6509-20. 
140. Dey, A., et al., The double bromodomain protein Brd4 binds to acetylated chromatin 
during interphase and mitosis. Proc Natl Acad Sci U S A, 2003. 100(15): p. 8758-63. 
141. Denis, G.V., B.S. Nikolajczyk, and G.R. Schnitzler, An emerging role for 
bromodomain-containing proteins in chromatin regulation and transcriptional 
control of adipogenesis. FEBS Lett, 2010. 584(15): p. 3260-8. 
142. Sinha, A., D.V. Faller, and G.V. Denis, Bromodomain analysis of Brd2-dependent 
transcriptional activation of cyclin A. Biochem J, 2005. 387(Pt 1): p. 257-69. 
143. LeRoy, G., B. Rickards, and S.J. Flint, The double bromodomain proteins Brd2 and 
Brd3 couple histone acetylation to transcription. Mol Cell, 2008. 30(1): p. 51-60. 
144. Lamonica, J.M., et al., Bromodomain protein Brd3 associates with acetylated GATA1 
to promote its chromatin occupancy at erythroid target genes. Proc Natl Acad Sci U 
S A, 2011. 108(22): p. E159-68. 
145. Gamsjaeger, R., et al., Structural basis and specificity of acetylated transcription 
factor GATA1 recognition by BET family bromodomain protein Brd3. Mol Cell Biol, 
2011. 31(13): p. 2632-40. 
146. Zhao, R., et al., Gene bookmarking accelerates the kinetics of post-mitotic 
transcriptional re-activation. Nat Cell Biol, 2011. 13(11): p. 1295-304. 
147. Ceribelli, M., et al., Blockade of oncogenic IkappaB kinase activity in diffuse large B-
cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc 
Natl Acad Sci U S A, 2014. 111(31): p. 11365-70. 
148. Klein, U. and R. Dalla-Favera, Germinal centres: role in B-cell physiology and 
malignancy. Nat Rev Immunol, 2008. 8(1): p. 22-33. 
149. Yang, Z., N. He, and Q. Zhou, Brd4 recruits P-TEFb to chromosomes at late mitosis 
to promote G1 gene expression and cell cycle progression. Mol Cell Biol, 2008. 
28(3): p. 967-76. 
150. Filippakopoulos, P. and S. Knapp, Targeting bromodomains: epigenetic readers of 
lysine acetylation. Nat Rev Drug Discov, 2014. 13(5): p. 337-56. 
151. Chen, R., et al., Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer. 
Biomed Res Int, 2014. 2014: p. 232870. 
152. Itzen, F., et al., Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation. 
Nucleic Acids Res, 2014. 42(12): p. 7577-90. 
153. Rahl, P.B., et al., c-Myc regulates transcriptional pause release. Cell, 2010. 141(3): 
p. 432-45. 
154. Liu, W., et al., Brd4 and JMJD6-associated anti-pause enhancers in regulation of 
transcriptional pause release. Cell, 2013. 155(7): p. 1581-95. 
155. Rahman, S., et al., The Brd4 extraterminal domain confers transcription activation 
independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell 
Biol, 2011. 31(13): p. 2641-52. 
156. Bres, V., S.M. Yoh, and K.A. Jones, The multi-tasking P-TEFb complex. Curr Opin 
Cell Biol, 2008. 20(3): p. 334-40. 
157. Shang, E., et al., The first bromodomain of Brdt, a testis-specific member of the BET 
sub-family of double-bromodomain-containing proteins, is essential for male germ 
cell differentiation. Development, 2007. 134(19): p. 3507-15. 
    REFERENCES 
 
 
48 
 
158. Matzuk, M.M., et al., Small-molecule inhibition of BRDT for male contraception. 
Cell, 2012. 150(4): p. 673-84. 
159. Pivot-Pajot, C., et al., Acetylation-dependent chromatin reorganization by BRDT, a 
testis-specific bromodomain-containing protein. Mol Cell Biol, 2003. 23(15): p. 
5354-65. 
160. Dhar, S., A. Thota, and M.R. Rao, Insights into role of bromodomain, testis-specific 
(Brdt) in acetylated histone H4-dependent chromatin remodeling in mammalian 
spermiogenesis. J Biol Chem, 2012. 287(9): p. 6387-405. 
161. Muller, S., P. Filippakopoulos, and S. Knapp, Bromodomains as therapeutic targets. 
Expert Rev Mol Med, 2011. 13: p. e29. 
162. Zhang, W., et al., Bromodomain-containing protein 4 (BRD4) regulates RNA 
polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem, 2012. 
287(51): p. 43137-55. 
163. Bisgrove, D.A., et al., Conserved P-TEFb-interacting domain of BRD4 inhibits HIV 
transcription. Proc Natl Acad Sci U S A, 2007. 104(34): p. 13690-5. 
164. Greenwald, R.J., et al., E mu-BRD2 transgenic mice develop B-cell lymphoma and 
leukemia. Blood, 2004. 103(4): p. 1475-84. 
165. Dey, A., et al., Brd4 marks select genes on mitotic chromatin and directs postmitotic 
transcription. Mol Biol Cell, 2009. 20(23): p. 4899-909. 
166. French, C.A., Pathogenesis of NUT midline carcinoma. Annu Rev Pathol, 2012. 7: p. 
247-65. 
167. Filippakopoulos, P., et al., Selective inhibition of BET bromodomains. Nature, 2010. 
468(7327): p. 1067-73. 
168. Mertz, J.A., et al., Targeting MYC dependence in cancer by inhibiting BET 
bromodomains. Proc Natl Acad Sci U S A, 2011. 108(40): p. 16669-74. 
169. Trabucco, S.E., et al., Inhibition of bromodomain proteins for the treatment of human 
diffuse large B-cell lymphoma. Clin Cancer Res, 2015. 21(1): p. 113-22. 
170. Zuber, J., et al., RNAi screen identifies Brd4 as a therapeutic target in acute myeloid 
leukaemia. Nature, 2011. 478(7370): p. 524-8. 
171. French, C.A., NUT midline carcinoma. Cancer Genet Cytogenet, 2010. 203(1): p. 16-
20. 
172. Postel-Vinay, S., et al., First-in-human phase I dose escalation study of the 
Bromodomain and Extra-Terminal motif (BET) inhibitor BAY 1238097 in subjects 
with advanced malignancies. European Journal of Cancer. 69: p. S7-S8. 
173. Gao, F., et al., BRAD4 plays a critical role in germinal center response by regulating 
Bcl-6 and NF-kappaB activation. Cell Immunol, 2015. 294(1): p. 1-8. 
174. Nicodeme, E., et al., Suppression of inflammation by a synthetic histone mimic. 
Nature, 2010. 468(7327): p. 1119-23. 
175. Herrmann, H., et al., Small-molecule inhibition of BRD4 as a new potent approach to 
eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. 
Oncotarget, 2012. 3(12): p. 1588-99. 
176. Zhao, X., et al., Disruption of the MYC-miRNA-EZH2 loop to suppress aggressive B-
cell lymphoma survival and clonogenicity. Leukemia, 2013. 27(12): p. 2341-50. 
177. Tolani, B., et al., Targeting Myc in KSHV-associated primary effusion lymphoma 
with BET bromodomain inhibitors. Oncogene, 2014. 33(22): p. 2928-37. 
178. Gao, L., et al., Androgen receptor promotes ligand-independent prostate cancer 
progression through c-Myc upregulation. PLoS One, 2013. 8(5): p. e63563. 
179. Cheng, Z., et al., Inhibition of BET bromodomain targets genetically diverse 
glioblastoma. Clin Cancer Res, 2013. 19(7): p. 1748-59. 
180. Emadali, A., et al., Identification of a novel BET bromodomain inhibitor-sensitive, 
gene regulatory circuit that controls Rituximab response and tumour growth in 
aggressive lymphoid cancers. EMBO Mol Med, 2013. 5(8): p. 1180-95. 
    REFERENCES 
 
 
49 
 
181. Bhadury, J., et al., BET and HDAC inhibitors induce similar genes and biological 
effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci U 
S A, 2014. 111(26): p. E2721-30. 
182. Sakamoto, K.M., et al., Protacs: chimeric molecules that target proteins to the Skp1-
Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci U S A, 
2001. 98(15): p. 8554-9. 
183. Lu, J., et al., Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. 
Chem Biol, 2015. 22(6): p. 755-63. 
184. Coude, M.M., et al., BET inhibitor OTX015 targets BRD2 and BRD4 and decreases 
c-MYC in acute leukemia cells. Oncotarget, 2015. 6(19): p. 17698-712. 
185. Noel, J.K., et al., Development of the BET bromodomain inhibitor OTX015. 
Proceeding of the 2013 AACR- NCI-EORTC Molecular Targets and Cancer 
Therapeutics Conference, 2013: p. 414-414. 
186. Boi, M., et al., The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic 
Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. 
Clin Cancer Res, 2015. 21(7): p. 1628-38. 
187. Vazquez, R., et al., The bromodomain inhibitor OTX015 (MK-8628) exerts anti-
tumor activity in triple-negative breast cancer models as single agent and in 
combination with everolimus. Oncotarget, 2016. 
188. Riveiro, M.E., et al., OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor 
activity in non-small cell and small cell lung cancer models harboring different 
oncogenic mutations. Oncotarget, 2016. 
189. Lejeune, P., et al., Abstract 3524: BAY 1238097, a novel BET inhibitor with strong 
efficacy in hematological tumor models. Cancer Research, 2015. 75(15 Supplement): 
p. 3524. 
190. Marks, P.A. and R. Breslow, Dimethyl sulfoxide to vorinostat: development of this 
histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol, 2007. 25(1): p. 
84-90. 
191. Cerchietti, L. and J.P. Leonard, Targeting the epigenome and other new strategies in 
diffuse large B-cell lymphoma: beyond R-CHOP. Hematology Am Soc Hematol Educ 
Program, 2013. 2013: p. 591-5. 
192. Shih, A.H., et al., The role of mutations in epigenetic regulators in myeloid 
malignancies. Nat Rev Cancer, 2012. 12(9): p. 599-612. 
193. de Ruijter, A.J., et al., Histone deacetylases (HDACs): characterization of the 
classical HDAC family. Biochem J, 2003. 370(Pt 3): p. 737-49. 
194. Bolden, J.E., M.J. Peart, and R.W. Johnstone, Anticancer activities of histone 
deacetylase inhibitors. Nat Rev Drug Discov, 2006. 5(9): p. 769-84. 
195. Dekker, F.J., T. van den Bosch, and N.I. Martin, Small molecule inhibitors of histone 
acetyltransferases and deacetylases are potential drugs for inflammatory diseases. 
Drug Discov Today, 2014. 19(5): p. 654-60. 
196. Chapuy, B., et al., Discovery and characterization of super-enhancer-associated 
dependencies in diffuse large B cell lymphoma. Cancer Cell, 2013. 24(6): p. 777-90. 
197. Berthon, C., et al., Bromodomain inhibitor OTX015 in patients with acute leukaemia: 
a dose-escalation, phase 1 study. Lancet Haematol, 2016. 3(4): p. e186-95. 
198. Stathis, A., et al., Clinical Response of Carcinomas Harboring the BRD4-NUT 
Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. Cancer 
Discov, 2016. 6(5): p. 492-500. 
199. Amorim, S., et al., Bromodomain inhibitor OTX015 in patients with lymphoma or 
multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. 
Lancet Haematol, 2016. 3(4): p. e196-204. 
200. Sherman, M.Y., et al., Oncogenes induce senescence with incomplete growth arrest 
and suppress the DNA damage response in immortalized cells. Aging Cell, 2011. 
10(6): p. 949-61. 
    REFERENCES 
 
 
50 
 
201. Clozel, T., et al., Mechanism-Based Epigenetic Chemosensitization Therapy of 
Diffuse Large B-Cell Lymphoma. Cancer Discov, 2013. 3(9): p. 1002-1019. 
202. Thieblemont, C. and J. Briere, MYC, BCL2, BCL6 in DLBCL: impact for clinics in 
the future? Blood, 2013. 121(12): p. 2165-6. 
203. Aukema, S.M., et al., Double-hit B-cell lymphomas. Blood, 2011. 117(8): p. 2319-31. 
204. Ott, G., A. Rosenwald, and E. Campo, Understanding MYC-driven aggressive B-cell 
lymphomas: pathogenesis and classification. Blood, 2013. 122(24): p. 3884-91. 
205. Reeder, C.B. and S.M. Ansell, Novel therapeutic agents for B-cell lymphoma: 
developing rational combinations. Blood, 2011. 117(5): p. 1453-62. 
206. Staudt, L.M., II. Therapy of DLBCL based on genomics. Hematol Oncol, 2013. 31 
Suppl 1: p. 26-8. 
207. Honigberg, L.A., et al., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell 
activation and is efficacious in models of autoimmune disease and B-cell malignancy. 
Proc Natl Acad Sci U S A, 2010. 107(29): p. 13075-80. 
208. Gopal, A.K., et al., PI3Kdelta inhibition by idelalisib in patients with relapsed 
indolent lymphoma. N Engl J Med, 2014. 370(11): p. 1008-18. 
209. Moros, A., et al., Synergistic antitumor activity of lenalidomide with the BET 
bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. 
Leukemia, 2014. 28(10): p. 2049-59. 
210. Smith, M.A. and P. Houghton, A proposal regarding reporting of in vitro testing 
results. Clin Cancer Res, 2013. 19(11): p. 2828-33. 
211. Mottamal, M., et al., Histone deacetylase inhibitors in clinical studies as templates 
for new anticancer agents. Molecules, 2015. 20(3): p. 3898-941. 
212. Odore, E., et al., Phase I Population Pharmacokinetic Assessment of the Oral 
Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies. Clin 
Pharmacokinet, 2016. 55(3): p. 397-405. 
213. Boi, M., et al., The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic 
Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. 
Clinical Cancer Research, 2015. 21(7): p. 1628-38. 
214. Ezell, S.A., et al., Synergistic induction of apoptosis by combination of BTK and dual 
mTORC1/2 inhibitors in diffuse large B cell lymphoma. Oncotarget, 2014. 5(13): p. 
4990-5001. 
215. Guo, S., et al., EZH2 mutations in follicular lymphoma from different ethnic groups 
and associated gene expression alterations. Clin Cancer Res, 2014. 20(12): p. 3078-
86. 
216. Gupta, S.S., et al., Bromo- and extraterminal domain chromatin regulators serve as 
cofactors for murine leukemia virus integration. J Virol, 2013. 87(23): p. 12721-36. 
217. Picaud, S., et al., PFI-1, a highly selective protein interaction inhibitor, targeting 
BET Bromodomains. Cancer Res, 2013. 73(11): p. 3336-46. 
218. Gupta, M., et al., Inhibition of histone deacetylase overcomes rapamycin-mediated 
resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through 
mTORC2. Blood, 2009. 114(14): p. 2926-35. 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARTICLES 
 
 
  
     
 
 
 
 
   
 
 
 
 
 
 
 
 ARTICLE 1
  ARTICLE 1 
 
 
 
  
53 
 
 
 
 
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
Preclinical antitumor activity of ST7612AA1: a new oral thiol-
based histone deacetylase (HDAC) inhibitor 
Loredana Vesci1,*, Elena Bernasconi2,*, Ferdinando Maria Milazzo1, Rita De Santis1, 
Eugenio Gaudio2, Ivo Kwee2,3, Andrea Rinaldi2, Silvia Pace1, Valeria Carollo4, 
Giuseppe Giannini1 and Francesco Bertoni2,5
1 Research & Development, Sigma-Tau, Pomezia, Italy
2 Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland
3 Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland
4 Hysto-Cyto Service srl, Rome, Italy
5 Lymphoma Unit, IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
* These two Authors equally contributed to this work
Correspondence to: Loredana Vesci, email: loredana.vesci@sigma-tau.it 
Correspondence to: Francesco Bertoni, email: frbertoni@mac.com 
Keywords: histone deacetylase inhibitor, anti-tumor, oral, preclinical, tumor models
Received: November 12, 2014 Accepted: December 24, 2014 Published: December 25, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
ST7612AA1 (property of Sigma-Tau), a thioacetate-ω (γ-lactam amide) derivative, 
is a potent, second generation, oral pan-histone deacetylase inhibitor (HDACi). Aim 
of the study was to assess the efficacy of ST7612AA1 in solid and haematological 
tumors, and to characterize its mechanism of action. In vitro, ST7612AA1 potently 
inhibited different class I and class II HDACs, leading to restore the balance of both 
histone and non-histone protein acetylation. In vivo, it induced significant anti-tumor 
effects in xenograft models of lung, colon, breast and ovarian carcinomas, leukemia 
and lymphoma. This was likely due to the modulation of different HDAC substrates 
and induction of transcriptional changes with respect to several genes involved in key 
processes, such as cell cycle regulation, DNA damage checkpoints, immune response, 
cell adhesion and epithelial-to-mesenchymal transition. PK analysis confirmed the pro-
drug nature of ST7612AA1, which is rapidly absorbed and converted to ST7464AA1 
after a single oral dose in mice. ST7612AA1 was selected from a novel generation 
of oral HDAC inhibitors. Its high efficacy correlated with its potent and selective 
inhibitory activity of HDAC and was combined with a favorable pharmacodynamics 
profile. These aspects support a clinical development of ST7612AA1 towards a broad 
spectrum of human solid and haematologic malignancies. 
INTRODUCTION
Epigenetic mechanisms result in changes in gene 
expression without altering the DNA sequence per se. 
These changes involve DNA methylation and histone 
modifications (such as acetylation), which are potentially 
reversible. Due to this property, modulation of epigenetic 
gene suppression has become a very attractive model to 
treat cancer [1]. The expression of histone deacetylases 
(HDAC) is frequently altered in several malignancies 
[2], thus histone deacetylase inhibitors (HDACis) able to 
bind with high affinity to HDACs and to severely affect 
their enzymatic activity, have emerged as a promising 
new class of multifunctional anticancer drugs [3, 4]. In 
fact, HDACis have been previously shown to reduce 
multiple epigenetic pathways exerting pro-tumorigenic 
activity. In addition to regulate gene expression and 
transcription through chromatin remodelling, HDACis 
can also modulate a variety of cellular functions including 
growth, differentiation, and survival [5, 6], by enhancing 
acetylation of a wide variety of proteins, including 
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transcription factors, modular chaperones, and structural 
components [3, 7]. Specifically, HDACis have been 
shown to induce several down-stream effects in tumor cell 
lines, including: cell cycle arrest, induction of apoptosis, 
inhibition of angiogenesis, activation or inactivation of 
tumor suppressor genes or oncogenes, and decrease of 
invasion and metastasis [3, 4, 8]. Interestingly, tumor cells 
appear much more sensitive to the induction of apoptosis 
by HDAC inhibitors than normal cells, probably linked 
to the disturbed chromatin structure in cancer cells [9] 
and to the induction of double-strand DNA breaks [10]. 
The classical HDAC inhibitors inhibit the function of 
one or more of the 11 known zinc-containing HDAC 
enzymes. The zinc-containing HDAC enzymes can be 
classified into several Classes: Class I HDAC (HDAC1, 
2, 3, 8), Class IIA (HDAC4, 5, 7, 9), Class IIB (HDAC6, 
10) and Class IV (HDAC11) [11]. Class III HDACs or 
Sirtuins, have a different catalytic mechanism and are 
not a target for the classical HDAC inhibitors. Generally, 
pan-HDAC inhibitors inhibit HDACs from Class I, II and 
IV, while Class specific-HDAC inhibitors only inhibit 
HDACs from either Class I or Class II. At the present, 
three HDACis – vorinostat (suberoylanilide hydroxamic 
acid, Zolinza) orally delivered, depsipeptide (romidepsin, 
Istodax) and belinostat (Beleodaq) intravenously 
delivered– have received approval from the US Food and 
Drug Administration (FDA) for treatment of refractory 
cutaneous T-cell lymphoma (CTCL), and more recently, 
depsipeptide has gained FDA approval for peripheral 
T-cell lymphoma (PTCL) [12-14]. Several HDAC 
inhibitors are under clinical development in various 
malignancies, many of them of haematological origin, 
such as leukemia, lymphoma, and myelodysplastic 
syndrome [2, 15]. Broadly, HDACis can be classified into 
different structural groups: the hydroxamic acids, cyclic 
peptides, benzimides and short-chain fatty acids. Although 
HDAC inhibitors preferentially targeting a single HDAC 
have been recently developed [16], it is noteworthy that 
the hydroxamates are able to target and affect all classes 
of HDACs, thus exerting nonspecific HDAC-inhibition 
activity [17, 18]. 
We previously identified a highly potent HDAC 
inhibitor, named ST7612AA1 as prodrug of ST7464AA1 
(Figure 1A), showing oral antitumor activity in human 
tumor-bearing mice. This thioacetyl derivative, selected 
within a lactam carboxamide inhibitors screening project, 
showed a high cytotoxic activity on NCI-H460 (NSCLC) 
and HCT116 (colon carcinoma) cell lines and associated 
to strong induction of tubulin and histone H4 acetylation 
in cellular assays [19]. The active drug, ST7464AA1 
revealed the maximum potency on HDAC3 and 6 (mean 
of IC50= 4 nM), and then on HDAC1, 10 and 11 (mean 
of IC50=13 nM) and HDAC2 (IC50=78 nM). The minor 
potency was observed on HDAC8 (IC50=281 nM) [19].
In this study, the ability of ST7612AA1 in different 
pre-clinical cancer models characterized by specific 
protein-overexpression or mutation was determined 
to better define the pharmacological profile of the 
drug. Here we report that this novel HDAC inhibitor 
potently inhibited cell growth/proliferation in human 
tumor cell lines from both solid and hematologic origin, 
and significantly suppressed tumor growth in several 
xenograft models after oral daily delivery, thus suggesting 
a putative application against some tumor subsets in 
patients. Furthermore, the drug-dependent modulation 
of some transcripts involved in immune response and 
in key pathogenetic pathways, such NF-κB pathway 
and epithelial-mesenchymal transition, would suggest a 
relevant implication not only in cancer therapy but also in 
the inflammatory diseases. 
RESULTS
ST7612AA1 reduces HDACs activity
We have previously shown that ST7464AA1 (the 
active drug of ST7612AA1) is a very potent HDAC 
inhibitor, displaying activity against different HDAC 
isoforms in the low nanomolar range [19]. Here, we 
assessed the ability of ST7612AA1 to affect in vitro 
acetylation of tubulin and histone H4 substrates, which 
is mainly dependent on HDAC6 and class I HDACs 
respectively, through Western Blot analysis on NCI-H460 
NSCLC cells. As shown in Figure 1B, ST7612AA1 
was 40-fold more potent in increasing the acetylation of 
histone H4 (IC50 = 4.8 nM) than of tubulin (IC50 = 200 
nM). Results and details of the densitometry analysis are 
shown in Supplementary Figure 1. ST7612AA1 was very 
effective at increasing histone acetylation at concentrations 
lower than those determining cytotoxicity on the same cell 
line, thus confirming the ability of its drug (once released 
within the cell) to bind with a very high affinity to the 
catalytic site of different HDAC isoforms. 
ST7612AA1 affects proliferation and induces 
apoptosis in human tumor cell lines
ST7612AA1 showed a high potency in terms of 
antiproliferative effects in a first broad panel of human 
tumor cell lines from both solid and hematologic origin. As 
indicated in Table 1, ST7612AA1 inhibited proliferation 
in cell lines derived from epithelial cancers (lung, breast, 
colon, ovarian) and from leukemias and lymphomas, with 
IC50 values ranging from 43 to 500 nmol/L. ST7612AA1 
also inhibited the proliferation with comparable potency 
of different mature B cell lymphomas with a median 
IC50 of 375 nM (range, 46-2664 nM). There were no 
significant differences among histological subtypes 
or between germinal center B cell like (GCB) and the 
activated B cell like (ABC) type –DLBCL: ABC-DLBCL 
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257 nM (101-805 nM); GCB-DLBCL 597 nM (46-2664 
nM); mantle cell lymphoma (MCL) 433 nM (248-553 
nM); splenic marginal zone lymphoma (SMZL) 119 nM 
(102-257 nM). As shown in Supplementary Figure 2, the 
ST7612AA1 anti-proliferative activity was both time and 
dose-dependent. Exposure to ST7612AA1 (250 nM) for 
72 hrs induced moderate apoptosis in three out of eight 
lymphoma cell lines (Figure 1C). Differently from what 
observed regarding on the anti-proliferative activity, the 
apoptosis was apparently restricted to cell lines bearing a 
wild type TP53. 
ST7612AA1 affects key molecular pathways in 
DLBCL in vitro models 
To obtain a global view of the transcriptional 
changes after ST7612AA1 treatment, we performed 
GEP (Gene Expression Profiling) on two sensitive cell 
lines, one derived from GCB-DLBCL (DOHH2) and 
one from ABC-DLBCL (TMD8). We first confirmed the 
anti-deacetylase activity of ST7612AA1 in the two cell 
lines (Figure 2A). Then, the tumor cells were exposed 
to DMSO or to ST7612AA1 (300 nM) for 8 hours. 
(Figure 2B). ST7612AA1 importantly affected the gene 
Table 1: Antiproliferative activity of ST7612AA1 on different human tumor cell lines. 
Tumor cell line IC50 (µM)
Ovarian cancer
A2780
SKOV-3
0.043±0.01
0.38±0.003
Breast cancer
MDA-MB436
MDA-MB231
MCF-7
0.18±0.01
0.23±0.009
0.19±0.02
NSCLC
NCI-H460
NCI-H1975
0.066±0.01
0.50±0.05
Colon cancer
HCT116 0.075±0.01
Acute myeloid leukemia
MV4;11
U937
0.19±0.02
0.049±0.005
T-cell lymphoma
HUT78 0.48±0.02
Chronic myeloid leukemia
K562 0.19±0.02
Diffuse large B-cell lymphoma of the germinal center 
B-cell type
DOHH2
OCI-Ly8
OCI-Ly7
SUDHL-6
SUDHL-4
VAL
Karpas422
0.046±0.01
0.24±0.01
0.56±0.02
0.63±0.02
0.98±0.01
2.36±0.1
2.66±0.2
Diffuse large B-cell lymphoma of the activated B-cell like 
type
TMD8
OCI-Ly10
U2932
0.10±0.03
0.26±0.01
0.80±0.02
Splenic marginal zone lymphoma
K1718
VL51
SSK41
0.10±0.01
0.12±0.09
0.26±0.05
Mantle cell lymphoma
Jeko-1
MAVER1
Granta-519
REC-1
0.25±0.01
0.39±0.02
0.47±0.05
0.55±0.02
Tumor cells were treated for 72 h at different concentrations to evaluate IC50 values. IC50 values were determined using 
ALLFIT program, a sigmoidal dose response model. Results are the means ± S.E.M. of three independent experiments. 
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expression profile of the two DLBCL cell lines: applying 
stringent criteria (genes showing fold change > 1.5, 
with an adjusted p-value < 0.005, were considered as 
differentially expressed) 674 genes were up-regulated and 
563 down-regulated (Supplementary Table 4). Among 
the most down-regulated genes there were genes known 
as oncogenes or involved in lymphoma pathogenesis 
such as IRAK1, MYD88, MYC, MYB, CCND2, BLK, 
CDK4, IKZF1 or TNFRSF17 (BCMA). Conversely, the 
up-regulated ones comprised tumor suppressor genes 
(CDKN2C, CDKN1A, CDKN2D) or genes involved in 
immune response (HLA, CD69). Validation of GEP results 
was obtained by real-time PCR analysis, confirming the 
up-regulation of CDKN1A and down-regulation of MYC, 
IRAK4, MYD88, STAT3, and, in the ABC-DLBCL cell line, 
also of IRAK1 (Supplementary Figure 3). Further insights 
on the pathways affected by exposure to the HDACi were 
provided by applying the GSEA algorithm (Supplementary 
Table 5). Functional analysis highlighted that the down-
regulated genes were significantly enriched of MYC 
targets, E2F targets, transcripts coding proteins involved in 
cell cycle, RNA processing, G1/S transition, DNA damage 
checkpoint, genes down-regulated in hypoxia, by other 
HDACis, or by mTOR inhibitor rapamycin. Up-regulated 
genes were significantly enriched of genes involved in 
packaging of telomeres, in meiosis, in RNA polymerase I 
promoter opening, in autophagy regulation, genes coding 
components of lysosome, cell adhesion molecules, genes 
up-regulated by other HDACi, genes of the DLBCL 
prognostically favorable stromal signature. Figure 2C 
shows some of the gene sets significantly enriched among 
down- and up-regulated genes. 
ST7612AA1 causes growth inhibition of different 
tumor xenografts 
Following the observed potent in vitro inhibition of 
tumor cell proliferation by ST7612AA1, we subsequently 
investigated whether these properties translated into 
tumor growth inhibition in preclinical in vivo models. 
Oral ST7612AA1 (60 mg/10 mL/kg, qdx5/w, for 2-4 
weeks), strongly inhibited the growth of different pre-
established tumor xenografts. In particular, as shown in 
Table 2, ST7612AA1 inhibited tumor volume by 77% 
(P<0.01 vs vehicle treated group) in the colon carcinoma 
model HCT116, consistently with the antiproliferative 
effect achieved in vitro against the same tumor cell line. 
Analogously, a potent and significant antitumor activity 
of ST7612AA1 was also shown against other solid tumor 
xenografts, such as the NSCLC model NCI-H1975 
(TVI=65%, P<0.001), the ovarian carcinoma model 
SKOV-3 (TVI=59%, P<0.01) and the breast cancer model 
Figure 1: ST7612AA1 reduces HDAC activity and induces apoptosis of human cancer cells. A) Chemical structure of the 
prodrug ST7612AA1 and its drug ST7464AA1. B) Assessment of a dose-dependent effect of ST7612AA1 on acetylation of alpha-tubulin 
and histone H4 in NCI-H460 NSCLC cells after 3 h exposure. SAHA 5 µM was used as internal positive reference. To control for equal 
loading, blots were stripped and reprobed with antibodies against tubulin and histone H4. C) Assessment of ST7612AA1-induced apoptosis 
in lymphoma cell lines. Y-axis, percentage of Annexin V positive cells after exposure to ST7612AA1 (250 nM) for 72 hrs. The TP53 gene 
status of each cell line was shown below the X-axis.
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MDA-MB436 orthotopically implanted in mammary 
fat pad (TVI=35%, P<0.05). Finally, in vivo antitumor 
efficacy of ST7612AA1 was also observed against 
hematological tumor models, as shown by the potent 
antitumor activity (TVI=70%, P<0.01) in the AML model 
MV4;11 (Table 2) and in the GCB-DLBCL model DOHH2 
bearing both MYC and BCL2 chromosomal rearrangement 
in which a significant delay in tumor progression (P<0.05) 
was observed (Supplementary Figure 4).
ST7612AA1 affects key molecular pathways in 
colon cancer in vivo model 
Western Blot analysis of the HCT116 tumor 
xenografts collected 24 h after the last oral administration 
of ST7612AA1 revealed a strong induction of pan 
H3 acetylation (Figure 3A). Besides restoring histone 
acetylation through inhibition of class I HDACs, 
ST7612AA1 was also effective in targeting HDAC6, as 
shown by the increased levels of acetylated α-tubulin and 
by the dramatic decrease of HSP90 protein levels (this 
effect likely due to hyperacetylation of the chaperone), 
paralleled by a significant increase of HSP70 levels. 
Moreover, treatment of HCT116 tumor-bearing mice 
with ST7612AA1 resulted in up-regulation of P21 and 
ATF3 proteins, also confirmed at the transcriptional level 
in Figure 3B, thus suggesting that molecular pathways, 
activated by DNA damage events (TP53-mediated or not), 
or associated to a putative ER-stress response, might be 
involved. This evidence is further supported by qPCR 
data, showing increased mRNA levels of several genes 
associated to DNA-damage (gadd45α), TP53-mediated 
pro-apoptotic events (Noxa, P53AIP1, stratifin) and 
ER-stress response (gadd153/CHOP). Treatment with 
ST7612AA1 also resulted in down-modulation of NF-
κB gene (Figure 3B), whereas no effect was observed 
on the expression of genes involved in DNA replication, 
such as TYMS and AURK-A, although the last one was 
moderately down-modulated at the protein level (Figure 
3A). Finally, because HDACis have been shown to 
counteract the EMT process in different tumor models 
[20, 21], we next assessed the effects of ST7612AA1 
on epithelial/mesenchymal markers in HCT116 tumor 
xenografts. As shown in Figure 3B, ST7612AA1 induced 
a significant overexpression of several genes (e-cadherin, 
keratins 4/18, TJP1, PDE4D, claudin 1) coding typical 
epithelial markers and a concomitant down-modulation 
of genes associated to mesenchymal phenotype, such 
as ACTA2, syndecan-1 and vimentin (the last one being 
dramatically down-regulated also at the protein level, as 
depicted in Figure 3A). Overall, biochemical data suggest 
that reversion of the EMT process might contribute to the 
in vivo antitumor activity of the drug.
ST7612AA1 is in vivo rapidly converted to 
ST7464AA1
The PK profile of ST7612AA1 (pro-drug) and 
ST7464AA1 (drug) in healthy mice was determined after 
a single dose of 120 mg/kg of compound administered by 
oral route. As expected, ST7612AA1 was not detected in 
plasma after oral administration in mice, confirming its 
pro-drug properties. Conversely, ST7464AA1 rapidly 
appeared in plasma being quantifiable at the first blood 
sampling time (0.25 h). ST7464AA1 reached the Cmax of 
1577 ± 478 ng/mL (as mean ± SEM) 0.5 h post dosing; 
then its plasma concentration declined according to a 
bi-exponential profile (Figure 4) being still quantifiable 
Table 2: Antitumor activity of ST7612AA1 against different human tumor cell xenografts in nude mice.
Tumor cells DT Treatment schedule TVI% BWL%max Lethal toxicity
Colon cancer
HCT-116 5.9
Qdx5/wx3w
(3-7, 10-14, 17-21)
**77 1 0/8
NSCLC
NCI-H1975 3.5
Qdx5/wx2w
(5-9, 12-16)
***65 4 0/8
Ovarian cancer
SKOV-3 7.9
Qdx5/wx4w
(3-7, 10-14, 17-21, 24-28)
**59 1 0/8
Breast cancer
MDA-MB436 9.5
Qdx5/wx4w
(6-10, 13-17, 20-24, 27-31)
*35 4 0/8
Acute myeloid 
leukemia
MV4;11
6.6 Qdx5/wx3w(11-15, 18-22, 25-29)
**70 4 0/8
Mice bearing subcutaneously implanted tumor cells were orally administered with ST7612AA1 (60 mg/10 mL/kg) every day 
according to a schedule Qdx5/w. TVI was calculated 8-10 days after the end of treatment. n=8 mice/group. 
DT, Doubling Time. TVI, tumor volume inhibition. BWL%, maximum body weight loss during the experimental period.
Lethal toxicity: Number of mice dead from toxicity/total number of mice. The statistic comparison was performed between 
the mean of tumor lesions of drug-treated group and the mean of tumors of vehicle-treated group. 
*P<0.05 vs vehicle (Mann-Whitney test). **P<0.01 vs vehicle (Mann-Whitney test). ***P<0.001 vs vehicle (Mann-Whitney 
test).
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Figure 2: ST7612AA1 affects key molecular pathways in DLBCL. A) ST7612AA1 determines acetylation of alpha-tubulin 
and histone H3 in DOHH2 and TMD8 DLBCL after 4 h exposure. To control for equal loading, blots were probed with antibodies against 
tubulin. B) Heat map of the top 50 up- top 50 down-regulated rank ordered genes according to GSEA in DOHH2 and TMD8 DLBCL 
cells exposed to ST7612AA1 (300 nM) for 8 hrs. Expression values are represented as colors, where the range of colors (red, pink, light 
blue, dark blue) shows the range of expression values (high, moderate, low, lowest). C) GSEA plot illustrating the enrichment of different 
biologically relevant gene-sets in DOHH2 and TMD8 DLBCL cells exposed to ST7612AA1 as above. FDR, false discovery rate; NES, 
normalized enrichment score. 
Table 3: Pharmacokinetic parameters for ST7464AA1 in CD1 mice receiving a single oral dose of 120 mg/kg of 
ST7612AA1 derived from the plasma concentration vs time data according to a model independent approach for 
sparse data sampling. 
Tmax(h)
Cmax*(ng/mL)
Tlast(h)
Clast(ng/mL)
AUClast*(h* ng/mL)
AUCINF(h*ng/mL)
CL/F
(mL/h/kg)
Vz/F
(mL/kg)
T1/2(h)
0.5 1577±478 6.0 303 3747±299 5506 21795 119340 3.8
Cmax: maximum plasma concentration; Tmax: time of Cmax;  Clast: last quantifiable concentration; Tlast: time of Clast; AUClast: (area under the concentration vs time curve from 0 to Tlast; AUCINF: area under the concentration vs time curve from 0 to infinity; 
T1/2: terminal half-life; CL/F: apparent systemic clearance; Vz/F: apparent terminal volume of distribution; *: mean ± SEM.
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at the last blood sampling time (6 h). ST7464AA1 was 
cleared from plasma with a T1/2 of 3.8 h. ST7464AA1 
pharmacokinetics parameters are summarized in Table 
3. The drug showed a high CL/F; furthermore, its large 
Vz/F indicated a good propensity to distribute outside the 
systemic circulation.
DISCUSSION
Recently, a systematic study of medicinal chemistry 
aimed at identifying a new generation of HDAC inhibitors 
led us to select a new class of thiol-based potent pan-
HDACis [19]. In vivo pharmacodynamic analysis of 
several preselected analogues resulted in the identification 
of ST7612AA1, (property of Sigma-Tau), a thioacetate-ω 
(γ-lactam amide) derivative, first synthetic thiol derivative, 
as potent oral pan-histone deacetylase inhibitor (HDACi), 
in preclinical phase. This a prodrug of ST7464AA1, which 
has exquisite potency toward all class I HDACs (IC50 
values of 12.7 and 77.7 nM for HDAC1 and HDAC2, 
respectively) and toward HDAC isoforms encompassed 
within the class IIb HDACs (IC50 value of 3.18 nM for 
HDAC6). In agreement with the powerful inhibition of 
class I HDACs, here, we show that ST7612AA1 had a 
broad spectrum antiproliferative activity on cell lines 
derived from ovarian cancer, breast cancer, NSCLC, 
colon cancer and haematological tumors, including acute 
monocytic leukaemia, chronic myeloid leukaemia and 
lymphoma, at concentrations that are significantly below 
those achieved in plasma of mice (Cmax, 1577 ± 478 ng/
mL, dosing ST7612AA1 po at 120 mg/kg). Importantly, 
the oral treatment with ST7612AA1, once daily, for 2 
Figure 3: Effect of ST7612AA1 on key molecular targets in colon cancer. A) Western Blot analysis for assessing the degree 
of acetylation of histone H3 and tubulin, and for evaluating the expression levels of various target proteins in HCT-116 tumor xenografts 
collected 24 hours after the last treatment with 80 mg/10 mL/kg ST7612AA1 (lanes 4-6) once daily, according to the schedule qdx5/wx3w, 
with respect to vehicle-treated animals (lanes 1-3). Actin is shown as a control for protein loading. Representative blots of tumor samples 
from 3 animals/group are shown. B) Real-time qPCR analysis of ST7612-induced gene changes in HCT-116 tumor xenografts collected as 
above described. Data are normalized to cyclophilin A and presented as fold change (average ± s.d.) over the vehicle-treated control mice 
(n=3 animals/group). Sybr Green-based q-PCR analysis was performed using the primer set shown in Suppl. Table 3. 
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or 3 weeks, strongly inhibited tumor growth in several 
preclinical in vivo models derived from both solid tumors 
and haematological cancers. In particular, ST7612AA1 
was able to significantly inhibit tumor growth of the 
Ras-mutant HCT116 colon carcinoma xenografts, thus 
suggesting a putative therapeutic approach towards this 
subset of strongly proliferating dedifferentiated colorectal 
carcinoma, characterized by overexpression of class I 
HDAC family members and associated with reduced 
patient survival [22].
In addition, our data indicate that ST7612AA1 can 
significantly inhibit in vitro the proliferation of NSCLC 
cell lines bearing wild type EGFR (and mutant KRAS), 
such as NCI-H460, as well as a secondary (T790M) EGFR 
mutation, which is known to confer resistance to tyrosine 
kinase inhibitors [23], such as NCI-H1975. Interestingly, 
ST7612AA1 showed also a significant in vivo antitumor 
effect against the latter tumor xenograft model.
Since class I HDAC isoforms are expressed at 
significantly higher levels in ovarian cancer compared 
to normal ovarian tissue [24], and various HDAC 
inhibitors can prevent both in vitro and in vivo growth of 
ovarian cancer cells [25, 26], we investigated the in vivo 
efficacy of ST7612AA1 also in two ovarian carcinoma 
models. Our data clearly showed a strong antitumor 
effect of ST7612AA1 against both the SKOV-3 model, 
characterized by low levels of PTEN and overexpression 
of EGFR and ErbB2 [27], and even more the A2780 
xenograft, characterized by the absence of PTEN [19].
Triple-negative breast cancer (TNBC) represents 
a heterogeneous subset of neoplasms defined by the 
absence of estrogen receptor (ER), progesterone receptor 
(PR) and Her2/neu, which accounts for approximately 
15% of globally diagnosed breast cancers and which 
does not respond to hormonal therapy (such as tamoxifen 
or aromatase inhibitors) or therapies that target HER2 
receptors [28-31]. Anyhow, recent papers have suggested 
a putative therapeutic approach also with HDAC inhibitors 
[32, 33]. ST7612AA1 evidenced a strong antiproliferative 
activity in vitro against two TNBC cell lines (MDA-
MB231 and MDA-MB436). Moreover, when tested in 
vivo against the BRCA1-defective MDA-MB436 tumor 
xenograft ortotopically implanted in mammary fat pad, 
ST7612AA1 caused a significant reduction of tumor 
growth associated to minimal animal toxicity, thus 
providing promising preclinical data that would suggest a 
putative therapeutic approach against this subset of breast 
cancer. 
The ST7612AA1 treatment resulted also in a 
significant tumor growth inhibition of the AML model 
MV4;11, subcutaneously implanted in athymic nude 
mice. MV4;11 tumor is known to be driven by the tyrosine 
kinase receptor Flt3-ITD mutation. The activating internal 
tandem duplications (ITD) in the juxtamembrane domain 
of FLT3 have been identified in 35% AML patients [34]. 
MV4;11 has been shown to be dependent on FLT3-ITD 
by its sensitivity to selective FLT3 kinase inhibitors 
[35]. The best approach to the treatment of FLT3-ITD 
AML is currently undefined, and multiple clinical 
trials are investigating FLT3 kinase inhibitors [36] but, 
unfortunately, their action is very often transient, possibly 
due to inadequate dosing or insufficient selectivity of these 
Figure 4: Plasma concentration-time profile of ST7464AA1 following oral (PO) administration of ST7612AA1 to mice. 
The pharmacokinetic parameters of ST7464AA1 are shown in Table 3. Mean (± SEM) plasma concentration versus time of ST7464AA1 
after a single oral dose of 120 mg/kg of ST7612AA1 in CD1 male mice (lin-log scale) (n=5). 
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drugs. For these reasons, treatment with our HDACi might 
represent a promising therapeutic option also for patients 
with this kind of tumor.
Deregulation of proteins involved in chromatin 
remodelling is very frequent in lymphomas, which 
represent an interesting target for HDACi [12, 13, 
37]. Here, ST7612AA1 presented a wide in vitro anti-
proliferative activity on various models of lymphomas, 
induced apoptosis in TP53 wild type lymphoma cells, 
affected relevant pathogenetic pathways in DLBCL cell 
lines, and also reduced the growth of DLBCL xenografts. 
In particular, ST7612AA1 affected the NF-κB signaling, 
and this is of particular interest for the important role 
played by this pathway in the pathogenesis of certain 
lymphoma subtypes, such as the ABC-DLBCL, MCL 
and marginal zone lymphomas [38, 39]. Moreover, the 
compound was also able to down-regulate MYC target 
genes, and this might be clinically relevant for DLBCL, 
in which MYC confers a very poor clinical outcome 
when co-expressed with the BCL2 protein or when co-
translocated with the BCL2 gene [39, 40]. Importantly, 
the in vivo antitumor activity of ST7612AA1 was indeed 
observed against a cell line characterized by both MYC 
and BCL2 gene translocations. Thus, the compound 
appears worth of further investigation in the lymphoma 
context. Furthermore, present molecular and biochemical 
data suggest that, once hydrolyzed, ST7612AA1 acts 
both in nucleus and cytoplasm of the target tumor cell, 
through HDAC6 inhibition, as observed for other HDACi 
of the hydroxamate class [41]. In fact, beside restoring 
the balance of the histone acetylation that, in turn, results 
in a more relaxed chromatin structure, with areas of 
loosely compacted, and hencemore transcriptionally 
active chromatin that is more prone to DNA double strand 
breaks [42], ST7612AA1 is also able to target non-histone 
HDAC substrates involved, for example in the regulation 
of multiple cellular functions, such as P53, alpha-tubulin 
or the heat shock protein 90 (HSP90), through inhibition 
of HDAC6, which has been implicated in DNA damage 
signaling, transcription factor binding, and DNA repair 
processes [43]. Interestingly, at least when tested in vivo 
against colon carcinoma xenografts, ST7612AA1 induced 
increased transcription of e-cadherin, keratins and other 
typical epithelial markers and, concomitantly, induced 
down-regulation of vimentin and other genes associated 
to the mesenchymal phenotype, thus suggesting that 
treatment with ST7612AA1 might also cause a “cadherin 
switch” and reversion of the EMT process. Other HDAC 
inhibitors such as SAHA, TSA and panobinostat were 
shown to induce EMT phenotype, which was associated 
with increased expression of mesenchymal markers such 
as vimentin, N-cadherin and fibronectin [44, 45]. The 
ability of cells to transdifferentiate and dedifferentiate 
plays a key role in invasion and metastasis by the process 
of epithelial-mesenchymal-transition (EMT) [46], and 
differentiation patterning may be used as an additional 
prognostic and predictive indicator for therapeutic 
effectiveness. 
Histone deacetylase inhibitors (HDACi) 
were primarily developed as anti-tumor agents for 
cancer, but many are now being explored for treating 
neurodegenerative, immunologic, metabolic, inflammatory 
and cardiovascular disorders [47].
ST7612AA1 was able to determine expression 
changes of transcripts involved in immune response and 
in key pathogenetic pathways, such as the NF-κB pathway 
and cell cycle alteration, thus suggesting a relevant 
putative involvement not only in cancer therapy but also in 
the inflammatory diseases [48]. Lysine acetylation is a key 
regulator of the NF-κB pathway, which works in concert 
with other PTMs via complex crosstalk mechanisms 
to determine the signaling output. Importantly, small 
molecule modulators of its writers (HATs) or erasers 
(HDACs) have been demonstrated to regulate NF-κB 
signaling, suggesting that these are potential drugs for 
inflammatory diseases. 
These data combined with the excellent in vivo 
tolerability and the oral delivery may represent a 
therapeutic advantage for this novel HDAC inhibitor. 
In conclusion, based upon the obtained data, 
ST7612AA1 appears as a candidate for clinical 
development to evaluate its therapeutic activity towards 
a broad spectrum of human solid and haematologic 
malignancies. 
MATERIALS AND METHODS
Ethics Statement
All animal experiments were conducted according 
to relevant national and international guidelines. 
Experimental protocols were approved by the Ethic 
Committee for Animal Experimentation of Sigma 
Tau according to the United Kingdom Coordinating 
Committee on Cancer Research Guidelines. When tumor 
volume exceeded 2 cm3, mice were euthanized by cervical 
dislocation.
Drugs
For in vitro experiments, stock solutions of 
ST7612AA1 (property of Sigma-Tau) were prepared in 
100% dimethyl sulfoxide at 10 mM and stored at -20°C. 
For oral administration, ST7612AA1 was dissolved in 
solutol HS15 + water (1:20) and delivered in a volume of 
10 mL/kg.
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Cell lines and cell culture
Supplementary Table 1 lists all the cell lines used 
with their growth conditions and their origin. All cells 
were maintained in a humidified atmosphere with 5% 
CO2 at 37°C. All experiments were always performed 
starting from frozen cell stocks of each cell line. Upon 
thawing, such cells were characterized in house, by 
assessing cell morphology, cell growth kinetics curve and 
absence of mycoplasma. The human cell lines purchased 
from accredited biological resource centers (i.e. ATCC, 
ECACC, DSMZ) have been originally authenticated and 
characterized directly by the providers (STR profiling). 
Lymphoma cell lines were validated by the Authors 
using DNA profiling within the last six months from the 
beginning of the study. All the experiments have been then 
performed using cells within 6-8 passages since thawing 
from an internal cell bank. 
In vitro proliferation assay
Anti-proliferative activity was first assessed on 
a panel of cell lines derived from solid tumors and 
hematological cancers and then on a large panel of cell 
lines derived from mature B-cell lymphomas. In the 
first panel, cells were seeded in 96-wells tissue culture 
plates in complete medium and, 24 h after seeding, were 
exposed to increasing concentrations of ST7612AA1 for 
72 h; the inhibition of proliferation was assessed by the 
sulphorodamine B assay. Lymphoma cells were seeded 
in 96-wells tissue culture plates in complete medium 
and were exposed to increasing concentrations of 
ST7612AA1 for 48 or 72 h; the anti-proliferative activity 
was assessed using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). The drug potency 
was evaluated by means of the “ALLFIT” computer 
program and defined as IC50 (drug concentration required 
for 50% inhibition of cell survival). 
Detection of apoptotic cells
Apoptosis was assessed, on cells treated with DMSO 
or different doses of ST7612AA1, by Annexin V-FITC 
apoptosis detection kit (BD Biosciences), according to 
the manufacturer’s recommendations, on a FACScan flow 
cytometer (BD Biosciences).
Western Blotting Analysis
For assessing the in vitro effect of ST7612AA1 on 
acetylation of α-tubulin and histones, NSCLC cells were 
treated with the test compound at various concentrations 
(dose-response curve). SAHA 5 µM was used as 
reference inhibitor. Protein extraction, separation and 
immunoblotting were performed as previously described 
[19]. Immunoreactive bands were finally subjected to 
densitometry analysis by a phosphoimaging system 
(STORM, Molecular Dynamics), and then the IC50 values 
were calculated by the “ALLFIT” computer program. The 
antibodies used are listed in Supplementary Table 2.
In vivo xenograft models
Experiments on solid tumor and acute leukemia in 
vivo models were carried out at Sigma-Tau (Rome, Italy) 
using female athymic nude mice, 5-6 weeks-old (Harlan 
Laboratories, Udine, IT). Mice were maintained in laminar 
flow rooms with constant temperature and humidity in 
according to the NIH guidelines. The following human 
tumor xenograft models were used for antitumor activity 
studies: HCT116 derived from colon carcinoma), MV4;11 
from acute myeloid leukaemia (AML), SKOV-3 from 
ovarian carcinoma, and NCI-H1975 from non-small cell 
lung cancer (NSCLC). Exponentially growing tumor cells 
were s.c. inoculated (5x106/mouse) in the right flank of 
nude mice. Groups of eight mice/group were employed to 
assess antitumor activity. MDA-MB436 breast carcinoma 
(3x106 cells/0.1 mL of M199/Matrigel GFR 50:50, vol/
vol solution) was inoculated in mammary fat pad (mfp). 
Drug treatments were started from 3 to 11 days after 
tumor injection, depending on the tumor growth of the 
xenografted cancer model. ST7612AA1 was given daily 
for five days per week (qdx5/w). Tumor growth was 
followed by measurements of tumor diameters with a 
Vernier caliper. Tumor volume (TV) was calculated 
using the formula: TV (mm3) = [d2 x D]/2, where d and 
D are the shortest and the longest diameter, respectively. 
The efficacy of the drug treatment was assessed as: TV 
inhibition percentage (TVI%) in treated versus control 
mice, calculated as: TVI%=100-(mean TV treated/mean 
TV control x100). When tumors reached a volume of 500-
1000 mm3, mice were sacrificed by cervical dislocation. 
To examine the possible toxicity of treatment, body 
weight was recorded throughout the study. BWL% (body 
weight loss) was calculated as 100 – (mean BWdayx/mean 
BWday1x100), where day 1 is the first day of treatment and 
day x is any day after (maximum BWL%). DT as doubling 
time of control tumors was also evaluated.
In order to assess the in vivo effect of ST7612AA1 
on the acetylation degree of α-tubulin and histones, and 
on the expression of other key proteins, HCT116 tumor 
xenografts (3 samples/group) were excised at different 
times after the last treatment, and then total protein 
lysates were prepared through the homogenization of 
tumor samples in lysis buffer containing 0.5% NP-
40, supplemented with 10 µg/mL of protease inhibitor 
cocktail (Sigma Chemical Co., St. Louis, MO, USA). 
Determination of the protein concentration and Western 
Blotting analysis were finally performed as above 
described for the in vitro experiments. The antibodies used 
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are listed in Supplementary Table 2.
The in vivo experiment with lymphoma model 
was performed in the IOR laboratory according to study 
protocols approved by the local Cantonal Veterinary 
Authority (No. 5/2011). At day 1, tumors were established 
by injecting DOHH2 lymphoma cells (200 µL of PBS, 
8x106 cells/mouse) into the left flanks of 5-weeks old 
female NOD-SCID mice (Harlan Laboratories). Tumor 
size was measured on regular basis and until tumors 
reached around 0.5 mm in diameter (day 12). Then, 
treatments were conducted at day 12, 13, 15, 16, 18, 19. 
Tumors were measured at 12, 14, 17, 21, 25 days. Tumor 
volumes were calculated as described above. Mice were 
sacrificed when physical conditions became critical 
or when tumors reached a weight of about 0.5 gr. For 
comparison between a control and a treatment group, an 
unpaired Mann-Whitney’s test was used. A P-value <0.05 
was considered significant. 
Quantitative Real-Time RT-PCR
Total RNA was extracted from tumour xenografts 
and then retrotranscribed using the Trizol reagent and the 
ThermoScript RT-PCR System (Invitrogen, Paisley, UK), 
respectively, according to the manufacturer’s instructions. 
SYBR Green-based qPCR analyses were performed in 
96-well plates by using the 7900HT Sequence Detection 
System instrument and software (Applied Biosystems). 
Amplification mixes (20 µL) contained 1x QuantiTect 
SYBR PCR kit (QIAGEN, Hilden, Germany), and 0.2-
0.3 µM of each specific primer. In addition, the mRNA 
levels of cyclophilin A were quantitatively measured in 
each sample to control for sample-to-sample differences 
in RNA concentration. The cycling conditions comprised 
a 600 s denaturation step at at 95°C, followed by 40 
cycles of denaturation at 95°C for 15 s, annealing at 
60°C for 20 s, and extension at 72°C for 10 s. The 
oligonucleotides used as specific primers for each target 
gene were designed, using the manufacturer’s software 
and the sequences available in GenBank, to overlap a 
splice junction thereby avoiding a potential amplification 
of contaminating genomic DNA, and are described in 
Supplementary Table 3. A six-point serial standard curve 
was generated for each target gene. All expression levels 
were finally normalized to cyclophilin A in each well. 
PK sampling and analysis
CD1 nude mice were used. Male mice were treated 
with a single dose of ST7612AA1 at 120 mg/10 mL/
kg p.o., using 5% Solutol HS 15 in water for injection 
as vehicle. Blood samples were collected at 0.25, 0.5, 
1, 2, 4 and 6 h post treatment from 5 animals per time 
point. Levels of ST7612AA1 and ST7464AA1 were 
determined in plasma by quantitative LC-MS/MS having 
a limit of quantification of 25 ng/mL. The PK parameters 
Cmax (maximum plasma concentration), Tmax (time of 
maximum plasma concentration), Clast (last quantifiable 
concentration), Tlast (time of last quantifiable plasma 
concentration), AUClast (area under the concentration 
vs time curve from 0 to Tlast), AUCINF (area under the 
concentration vs time curve from 0 to infinity), T1/2 
(terminal half-life), CL/F (apparent systemic clearance) 
and Vz/F (apparent terminal volume of distribution) were 
derived from the analyte plasma concentration vs time data 
according to a model independent approach for sparse data 
sampling by using Phoenix WinNonlin® ver. 6.3 software 
(Pharsight, Cetara).
Gene expression profiling 
Gene Expression Profiling (GEP) was done using 
the HumanHT-12 v4 Expression BeadChip (Illumina, 
San Diego, CA, USA), as previously described [49]. 
Three replicates were done for each condition. Data were 
quantile normalized and differential expression analysis 
was performed using LIMMA [50]. Quantitative Real-time 
Polymerase chain reaction (qRT-PCR) was performed as 
previously described [49] (primer sequences available 
upon request). Gene-sets differentially affected by 
exposure to ST7612AA1 were identified with the Gene 
Set Enrichment Analysis (GSEA) tool using the GSEA C2, 
C3.tft, C6 collections [51] and the Signature DB collection 
[52]. Raw data are available at the National Center for 
Biotechnology Information (NCBI) Gene Expression 
Omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo) 
database (series record: GSE62460). 
Statistical analysis
Data are expressed as the mean ± S.E.M. Statistical 
analysis was performed using Mann-Whitney’s test. A 
P-value of <0.05 was considered statistically significant. 
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Michela Boi1, Eugenio Gaudio1, Paola Bonetti1, Ivo Kwee1,2,3, Elena Bernasconi1,
Chiara Tarantelli1, Andrea Rinaldi1, Monica Testoni1, LucianoCascione1,4, Maurilio Ponzoni5,
Afua Adjeiwaa Mensah1, Anastasios Stathis4, Georg Stussi4, María Eugenia Riveiro6,
Patrice Herait7, Giorgio Inghirami8,9,10, Esteban Cvitkovic6,7, Emanuele Zucca4, and
Francesco Bertoni1,4
Abstract
Purpose: In cancer cells, the epigenome is often deregulated,
and inhibition of the bromodomain and extra-terminal (BET)
family of bromodomain-containing proteins is a novel epigenetic
therapeutic approach. Preliminary results of an ongoing phase I
trial have reported promising activity and tolerability with the
new BET bromodomain inhibitor OTX015.
Experimental Design: We assessed the preclinical activity of
OTX015 as single agent and in combination in mature B-cell
lymphomamodels and performed in vitro and in vivo experiments
to identify the mechanism of action and the genetic features
associated with sensitivity to the compound.
Results: OTX015 showed antiproliferative activity in a large
panel of cell lines derived from mature B-cell lymphoid tumors
with median IC50 of 240 nmol/L, without signiﬁcant differences
among the different histotypes. In vitro and in vivo experiments
showed that OTX015 targeted NFKB/TLR/JAK/STAT signaling
pathways, MYC- and E2F1-regulated genes, cell-cycle regulation,
and chromatin structure. OTX015 presented in vitro synergism
with several anticancer agents, especially with mTOR and BTK
inhibitors. Gene expression signatures associated with different
degrees of sensitivity to OTX015 were identiﬁed. Although
OTX015 was mostly cytostatic, the compound induced apoptosis
in a genetically deﬁned subgroup of cells, derived from activated
B-cell–like diffuse large B-cell lymphoma, bearing wtTP53, muta-
tions in MYD88, and CD79B or CARD11.
Conclusions: Together with the data coming from the ongoing
phase I study, the in vitro and in vivo data presented here provide
the basis for further clinical investigation of OTX015 as single
agent and in combination therapies. Clin Cancer Res; 21(7); 1–11.
!2015 AACR.
Introduction
The epigenome is in a highly dynamic condition due to
precise temporal and spatial chromatin modiﬁcations, and
proper chromatin regulation is fundamental in controlling
gene expression and critical for fundamental cellular processes,
including self-renewal, differentiation, and proliferation (1, 2).
In cancer cells, the epigenome is very often deregulated due to
aberrant changes in histone modiﬁcations, DNA methylation,
and noncoding RNA expression levels (1). The contribution to
the assembly and the positioning of the transcriptional machin-
ery represents one of the most important functions of chro-
matin remodeling that is largely mediated by a variety of
histone-modifying enzymes that write and read the "histone
code" (1, 2). Epigenetic writers are enzymes that chemically
modify DNA or histones, erasers remove such chemical mod-
iﬁcations, and, ﬁnally, readers recognize speciﬁc histone acet-
ylated lysine residues and facilitate transcriptional activation by
recruiting transcription factors and other elements of the tran-
scription machinery. Importantly, chromatin modiﬁcations can
be manipulated and reversed (3), providing the rational to
pharmacologically target the epigenome. In the lymphoma
ﬁeld, the epigenetic erasers histone deacetylases (HDAC) rep-
resent the currently most explored therapeutic targets (3), with
HDAC inhibitors (HDACI), vorinostat and romidepsin,
approved by the FDA for cutaneous T-cell lymphomas.
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Inhibition of the bromodomain and extra-terminal (BET) fam-
ily of bromodomain-containing proteins (BRD2, BRD3, BRD4,
and the testis-speciﬁc BRDT) is a novel and promising epige-
netic therapeutic approach (4, 5). The BET bromodomain
proteins mainly act as epigenetic readers (2, 6), and their
important role in transcription regulation is demonstrated by
their enrichment in superenhancers, clusters of enhancers
incorporating high amounts of transcription factors and coac-
tivators that modulate the expression of key genes controlling
cell identity in normal cells and of oncogenes (6, 7). Different
evidence supports the direct involvement of BET bromodomain
proteins in cancer (2), including the observation that Em-BRD2
transgenic mice, overexpressing BRD2 in the B-cell compart-
ment, develop aggressive B-cell leukemias, and lymphomas
resembling diffuse large B-cell lymphomas (DLBCL; ref. 8).
Furthermore, BET bromodomain inhibitors have shown anti-
tumor activity in different preclinical models derived from
hematologic or solid tumors (4, 5, 9–20). The compounds
induce cell-cycle arrest in G1 and, depending on the type of
tumor model, apoptosis or cell differentiation (4, 5, 9, 11, 21).
BET bromodomain inhibitors highly downregulate the tran-
scription of genes regulated by superenhancers, such as MYC
and other genes fundamental for neoplastic cells (4–
6, 10, 14, 15). At least four BET bromodomain inhibitors are
in ongoing oncology/hematology phase I clinical studies (CPI-
0610, NCT01949883; GSK525762, NCT01587703; OTX015,
NCT01713582; TEN-010, NCT01987362). The ﬁrst results
from the phase I with the orally available BET bromodomain
inhibitor OTX015 (17) have been reported with clinical
responses in both leukemia and lymphoma patients in the
absence of major toxicities (22). Here, we show the preclinical
activity of OTX015, as a single agent and in combination, in
mature B-cell lymphomas, and we report data on the possible
mechanism of action and on genetic features associated with
sensitivity to the compound.
Materials and Methods
Cell lines and molecules
Established human cell lines derived from DLBCL, mantle cell
lymphomas (MCL), multiple myeloma (MM), splenic marginal
zone lymphoma (splenic MZL), and prolymphocytic leukemia
(PLL) were cultured in the culture media listed in Supplementary
Table S1. The cell lines were not authenticated independently.
OTX015 was provided by Oncoethix SA. Other compounds used
were everolimus, doxorubicin, ibrutinib, lenalidomide, benda-
mustine, decitabine, idelalisib, vorinostat, romidepsin (Selleck-
chem), and rituximab (Roche).
Cell proliferation, cell death, cell cycle
The effect on cell proliferation, cell growth, apoptosis, and cell
cycle were assessed as previously described (23, 24).
Senescence
Cells were treated with DMSO or different doses of OTX015
and stained using a b-Galactosidase Staining Kit (Calbiochem).
Cells wereﬁxedwith 4% formalin and the nuclei stainedwith fast-
red dye. Images were acquired using a Zeiss light microscope.
Senescence-associated b-galactosidase (SA-bgal) activity was also
assessed by a ﬂuorescence-based assay using ﬂow cytometry. Cells
were seeded and treated with OTX015 or the equivalent amount
ofDMSOand, after the treatment,were incubatedwith 100nmol/
L Baﬁlomycin A1 (Sigma-Aldrich) for 1 hour to alkalize the
lysosomes. Cells were then incubated for 2 hours with 33 mL of
2mmol/L 5-dodecanoylaminoﬂuorescein-di-b-D-galactopyrano-
side (C12FDG; Invitrogen), washed thoroughly and analyzed
with a FACSCan ﬂow cytometer (Becton Dickinson AG). Data
were analyzed with FlowJo 7.6.3 software (Tree Star).
Western blotting analysis
Protein extraction, separation, and immunoblotting were per-
formed as previously described (23). The following antibodies
were used: anti-BRD2 (ab37633), anti-BRD3 (ab56342), anti-
BRD4 (ab75898, AbCam), anti-MYC (9E10, Becton Dickinson
AG or Cell Signaling Technology), anti-a-GAPDH (MAB374,
Millipore), anti-STAT3 (9139), anti-phospho-STAT3 (Ser727;
9134), and anti-phospho-STAT3 (Tyr705; 9131; Cell Signaling
Technology).
Immunohistochemistry
Monoclonal antibodies against phospho-STAT, p50 (Cell Sig-
naling Technology) were applied. In all instances, antigen retriev-
al was performed with Tris-EDTA at pH 9, 30 minutes at 98!C.
Reactions were developed with Ultravision Quanto Detection
System (TL-125-QHL; Thermo Scientiﬁc).
Real-time PCR
RNAwas extractedusing theRNeasyKit (QiagenAG).Real-time
PCR was performed as previously described (ref. 23; sequences
available upon request).
Gene expression proﬁling
Gene expressionproﬁling (GEP)was doneusing theHumanHT-
12-v4 Expression BeadChip (Illumina). Data processing and sta-
tistical analysis was performed using R/Bioconductor (25). Tran-
script mapping was based on HG19 using manufacturer supplied
annotation. Data were quantile normalized and subsequently
batch corrected using ComBat (26). Differential expression anal-
ysis was performed using LIMMA (27). Functional annotation was
performed using the Gene set enrichment analysis (28) and Meta-
core (Thomson Reuters) tools. The top signiﬁcantly differentially
expressed genes between treated and untreated cells were analyzed
inMetaCore by building a network consisting of the shortest paths
(that is, having the smallest possible number of directed one-step
interactions) between pairs of the transcripts in each direction,
using standard Dijkstra shortest paths algorithm, maximum path
Translational Relevance
In cancer cells, the epigenome is often deregulated, and
inhibition of the bromodomain and extra-terminal (BET)
family of bromodomain-containing proteins is a novel epi-
genetic therapeutic approach. OTX015, a new oral BET bro-
modomain inhibitor that is now in its early clinical develop-
ment, shows a wide preclinical activity in lymphoma models
and it affects important biologic pathways, such as MYC,
NFKB, TLR, and JAK/STAT pathways. The observed synergism
with different compounds provides the basis for the future
clinical development of OTX015 in combination.
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length of two, and ﬁltering by limiting the interactions type to
transcription regulation, inﬂuence on expression, and miRNA
binding. Raw data will be available at the National Center for
Biotechnology Information Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo) database.
Evaluation of interleukins production
Cells treated with OTX015 or DMSO were harvested, washed,
and resuspended in ﬁx-perm buffer (Becton Dickinson AG) and
left for 30 minutes at 4!C. After a wash with perm buffer (Becton
Dickinson AG), cells were resuspended in perm buffer and the
antibodies anti-IL4-PE and anti-IL10-PE (eBioscience). Samples
were left for 30minutes in thedark. After the incubation, cellswere
washed in PBS, resuspended in PBS, analyzed using the FACScan
ﬂow cytometer. Data were analyzed with FlowJo 7.6.3 software.
Chromatin immunoprecipitation followedbyhigh-throughput
DNA sequencing
We analyzed the publicly available chromatin immunoprecip-
itation followed by high-throughput DNA sequencing (ChIP-
Seq) dataset from the Short Read Archive under accession number
SRP043524 (20). The 36-bp sequence reads were aligned to
human reference genome build GRCh37 (hg19) using Bowtie
(29). Redundant reads were removed and reads uniquely map-
ping to reference genome were used for further analysis. A max-
imum of one mismatch was allowed for each read. The detection
of genomic regions enriched by chromatin immunoprecipitation
(ChIP) versus the negative control immunoprecipitation (IP)
experiment donewith an anti-Flag antibody was carried out using
HOMER v2.6 (30). Speciﬁc peaks were deﬁned as having at least a
4-fold difference in enrichment within a 200-bp region between
the two SRP043524 experimental conditions (DMSO vs. JQ1)
and applying the HOMER default thresholds for statistical sig-
niﬁcance (FDR ¼ 0.001 and Poisson P cutoff ¼ 1e#04). All
discovered putative peaks were ranked by their normalized tag
counts (number of tags found at the peak, normalized to 10
million total mapped tags) and annotated with annotatePeaks.pl
using the GCRh37 (hg19) dataset.
Chromatin immunoprecipitation
Cells were cross-linked with 1% formaldehyde. Cross-linking
was quenched with 125 mmol/L glycine. Cells were washed with
ice-cold PBS containing 1$ HALT protease inhibitor (Thermo
Scientiﬁc) and resuspended in SDS lysis buffer (ChIP Assay Kit,
Millipore) before sonication. For each immunoprecipitation reac-
tion, 1$ 106 chromatin cell equivalents were incubated overnight
with 5 mg anti-BRD4 antibody (catalog no. A301-985A; Bethyl
Laboratories) or 3 mg of the negative control antibody, anti-IgG
(Millipore). Immune complexes were collected by incubation
with 20 mL magnetic protein G beads (4!C, 1.5 hours). Protein
G-bound complexes were sequentially washed with low salt wash
buffer, high salt wash buffer, LiCl wash buffer, and twice with TE
Buffer (ChIP Assay Kit; Millipore). Elution of protein/DNA com-
plexes was performed using 1% SDS and 0.1 mol/L NaHCO3.
Following reversal of cross-links (65!C for 4 hours), samples were
treated with RNAse A and then Proteinase K. DNA samples
puriﬁcation was performed with QIAquick PCR Puriﬁcation Kit
(Qiagen). Chromatin samples to which no antibody had been
added were processed in parallel as input references. Quantitative
real-time PCR of ChIP-DNAwas performed using primers speciﬁc
for a locus of BRD4 binding in the upstream regulatory region of
MYD88 (chr3:38179682-38179840) as determined by analyzing
theChIP-Seq dataset SRP043524 (20); primers speciﬁc for human
alpha-satellite were used as a negative control (sequences avail-
able upon request).
In vivo experiments
At day 1, tumors were established by injecting SU-DHL-2
lymphoma cells (200 mL of PBS, 15 $ 106 cells/mouse) into the
leftﬂanks of femaleNOD-SCIDmice (approximately 20 g of body
weight; The Harlan Laboratory, S. Pietro al Natisone, Udine,
Italy). Tumor size was measured on regular basis. Treatments
were conducted daily, twice a day. Mice maintenance and animal
experiments were performed with study protocols approved by
the local Cantonal Veterinary Authority (No. 5/2011).Differences
in tumor volumes were calculated using the Wilcoxon rank-sum
test (Stata/SE 12.1 for Mac, Stata Corporation). The P value for
signiﬁcance was <0.05.
Drug combinations and evaluation of synergism
Cells were seeded in 96-well plates at 104 cells per well.
Molecules were serially diluted in tissue culture media and added
to cells (in ﬁve replicates) and incubated for 72 hours at 37!C, 5%
CO2. MTT assay was then performed as described (31). The
combinations were evaluated using the Chou–Talalay Combina-
tion Index (CI), calculated with the Synergy R package (32). The
effect of the combinations was deﬁned synergistic (CI < 0.9),
additive (CI, 0–9–1.1) or antagonist (CI > 1.1).
Results
OTX015 has antiproliferative activity in in vitromodels of B-cell
lymphomas
We ﬁrst evaluated the antiproliferative activity of the BET
bromodomain inhibitor OTX015 in a panel of 33 cell lines
derived frommature B-cell lymphoid tumors. As assessed byMTT
assays performed after 72 hours of drug exposure, OTX015 was
active in a dose-dependentmanner in almost all the cell lines (Fig.
1A), at concentrations achievable in the clinical setting (33). The
median IC50 value for the whole series was 240 nmol/L (range, 70
nmol/L–15 mmol/L). The median values for the individual lym-
phoma entities were 195 nmol/L (70 nmol/L–1.5 mmol/L) in
DLBCL, 470 nmol/L (340 nmol/L–15 mmol/L) in MCL, 170
nmol/L (105–240 nmol/L) in splenic MZL, 450 nmol/L (60–
700 nmol/L) in MM, and 90 nmol/L in the PLL cell line. The
antiproliferative effect of OTX015 did not signiﬁcantly differ
among the different the histotypes, or between germinal-center
type (GCB) DLBCL (190 nmol/L; 80 nmol/L–1.5 mmol/L) and
activated B-cell–like (ABC)DLBCL (200 nmol/L; 70 nmol/L–2.28
mmol/L).
In accordance with the observed antiproliferative activity,
OTX015 treatment of DLBCL cells inhibited cell growth and
induced cell-cycle arrest with G1 accumulation and decreased S-
phase (Fig. 1B and Supplementary Fig. S1). OTX015 also induced
a time-dependent increase of b-Gal–positive cells (Fig. 1C).
OTX015 induces apoptosis in a genetically deﬁned subgroup of
DLBCL
We then assessed the induction of apoptosis after OTX015
exposure in DLBCL cells. Dose- and time-dependent apoptosis
was observed in 3of 22 (14%) cell lines treated for 72hourswith a
OTX015 in Preclinical Models of Lymphomas
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Figure 1.
OTX015 has antiproliferative activity in in vitro models of B-cell lymphomas. A, IC50 values calculated through MTT assay in 33 mature B-cell lymphoid tumor
cell lines after 72 hours of drug exposure (experiments done in triplicate). Green, PLL; red, ABC-DLBCL; blue, GCB-DLBCL; yellow, MCL; black, MM; orange, splenic
MZL. B, representative ﬂow cytometry proﬁles showing cell-cycle alterations induced by OTX015 (500 nmol/L) in the SU-DHL-6 cell line. C, representative
image showing the appearance of b-Gal–positive cells after exposure of the DoHH2 cell line to OTX015. D, percentage of apoptotic cells before and after 72 hours
of OTX015 (500 nmol/L) or DMSO (NT).
Boi et al.
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dose of 500 nmol/L (Fig. 1D and Supplementary Fig. S2). A
massive apoptotic induction was obtained in SU-DHL-2 and
TMD8,whereasOCI-Ly3 had a lower, although signiﬁcant, induc-
tion of apoptosis. All these three cell lines presented common
genetic and biologic features: derivation from ABC-DLBCL,
mutated MYD88 gene, wild-type TP53, mutations in CD79B
(SU-DHL-2, TMD8), or in CARD11 (OCI-Ly3). The presence of
mutations in genes coding for MYD88 and for components of the
BCR signaling was signiﬁcantly associated with apoptosis induc-
tion (P ¼ 0.027).
Transcriptional signature of OTX015 in DLBCL cell lines
To obtain a global view of the transcriptional changes after
OTX015 treatment, we performed GEP on two sensitive cell lines,
one derived from GCB-DLBCL (SU-DHL-6) and one from ABC-
DLBCL (SU-DHL-2), treated with DMSO or with OTX015 (500
nmol/L) for 1, 2, 4, 8, and 12 hours. OTX015 affected, in a time-
dependent manner, important biologic processes: NF-kB, Toll-
like receptor (TLR), Janus kinase (JAK)/STAT signaling pathways,
MYC- and E2F1-regulated genes, cell-cycle regulation, and chro-
matin structure (Fig. 2 and Supplementary Figs. S3 and S4;
P < 0.001
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Figure 2.
OTX015 induces MYC downregulation
in B-cell lymphomas. A, GSEA plot
illustrating the enrichment of the
GSEA M2711 MYC oncogenic signature
in SU-DHL-2 and SU-DHL-6 cells
treated with OTX015 (500 nmol/L).
FDR, false discovery rate; NES,
normalized enrichment score. B, MYC
protein levels are downregulated after
OTX015 treatment. C, MYC and MYC
targets CAD and NUC mRNA are
downregulated after OTX015
treatment for 8 hours in a dose-
dependent manner. Y axis, fold
change versus GAPDH and DMSO-
treated cells. D, MYC mRNA levels are
downregulated in a time-dependent
manner by OTX015 and restored after
removal of the compound from the
media after 2 hours of treatment. Y
axis, fold change versus GAPDH and
DMSO-treated cells.
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Supplementary Table S2). The upregulated genes were mainly
represented by transcripts coding for histones, overlapping with
thoseupregulated byHDACi,while thedownregulated transcripts
comprisedMYC and E2F1 targets or genes involved inNFKB/TLR/
JAK/STAT pathways. Supplementary Table S3 lists the top most
differentially expressed probes (adjusted P < 0.01 and absolute
fold change >1.5), with MYC as the most downregulated tran-
script. The OTX015 GEP signature appeared similar to that
reported following exposure to another BETbromodomain inhib-
itor, JQ1, in different tumor models (4, 5, 14, 15, 21) (Supple-
mentary Fig. S5).OTX015 appeared similar to JQ1 also in terms of
activity on cell viability and induction of apoptosis in SU-DHL-2
and DOHH2 DLBCL cell lines (data not shown), as also recently
reported by Chapuy and colleagues (10).
OTX015 induces MYC downregulation in DLBCL
Similar to that reported for other BET bromodomain inhibitors
(4, 5, 21), treatment with OTX015 led to an important negative
regulation of MYC and its target genes. MYC was the central hub
connecting almost all the most signiﬁcantly OTX015-regulated
genes (Supplementary Fig. S4), and MYC target genes were
signiﬁcantly enriched among OTX015-regulated transcripts (Fig.
2A). MYC changes were validated at RNA and protein level (Fig.
2B and C). The effect of OTX015 onMYC and its target genes was
both time anddose dependent (Fig. 2C andD). The effect onMYC
appeared reversible, as the mRNA levels started to be restored in a
time-dependent manner, albeit with different kinetics among the
individualDLBCL cell lines, after replacing drug-containingmedi-
um with fresh medium (Fig. 2D). The level and the kinetics of
MYC downregulation after drug exposure did not appear associ-
ated with the sensitivity to OTX015 (data not shown).
OTX015 affects the NFKB, TLR, and JAK/STAT signaling
pathways in DLBCL cells
OTX015 negatively regulated transcripts encoding members of
theNF-kB, TLR, and JAK/STAT signalingpathways, suchasMYD88,
IRAK1, TLR6, TNFRSF17, IL6, and IRF4, in both GCB- and ABC-
DLBCL cells (Fig. 3). The inhibitory effect of OTX015 on the
pathways was further conﬁrmed at protein level. Both immuno-
blotting and immunohistochemistry showed a reduction of the
transcriptionally active phospho-STAT3 in SU-DHL-2 and TMD8,
two ABC-DLBCL cell lines, as well a reduction of the nuclear
localization of p50 (NFKB1), indicating a clear inhibitory effect
of OTX015 on the canonical NF-kB pathway (Fig. 3B–D). In ABC-
DLBCL cell lines, we observed a reduced production of IL10 and
IL4 after 24 hours of OTX015 treatment (Supplementary Fig. S6)
and a dose-dependent downregulation of additional transcripts
suggestive ofNF-kB activation (BIRC3, TNFAIP3; data not shown).
On the basis of the hypothesis that MYD88 may play a central
role in the mechanism of action of OTX015, we sought to under-
stand whether BET bromodomain inhibitors had a direct effect on
the gene regulation. We ﬁrst analyzed the publicly available ChIP-
Seq data obtained for HBL1 ABC-DLBCL cells treated with the BET
bromodomain inhibitor JQ1(20). Treatmentwith JQ1(500nmol/
L) for 3 hours reduced the binding of BRD4 to the upstream
regulatory region of MYD88 (FDR < 0.001; Supplementary Fig.
S7A). We then performed a ChIP experiment in SU-DHL-2 ABC-
DLBCL cells exposed to DMSO or to OTX015 (500 nmol/L) for 3
hours. The drug appeared to reduce the binding of BRD4 to the
upstream regulatory regions of the MYD88 gene (Supplementary
Fig. S7B). These data suggest that BET bromodomain inhibitors
dislocate BRD4 from MYD88 regulatory regions.
OTX015 has biologic activity in a DLBCL in vivo model
We then assessed the ability of OTX015 to downregulate MYC,
the NF-kB, TLR, and JAK/STAT pathway also in an in vivomodel.
We treated SU-DHL-2 xenografts grown subcutaneously in NOD-
SCID mice with OTX015 (50 mg/kg, orally, twice a day; n ¼ 4
mice) or with control (vehicle orally, twice a day; n ¼ 4 mice) for
three days, starting when the tumors had reached the volume of
500mm3. No body weight losses were registered during the three
days of treatment. Real-time PCR showed that there was a sig-
niﬁcant downregulation of MYC, IL6, TLR6, TNFSRF17 and,
although not reaching the statistical signiﬁcance, of IRAK1, IRF4,
and STAT3 (Fig. 4A).
We then assessed the in vivo antilymphoma activity of OTX015.
NOD-SCID mice were treated with control vehicle (per os, twice a
day; n¼ 7mice) or with OTX015 (25mg/kg, orally, twice a day; n
¼ 8 mice), starting 5 days after the subcutaneous injection of SU-
DHL-2 cells and then each day for 25 days. No loss in bodyweight
was observed. OTX015 induced a reduced growth of the lympho-
ma xenografts at each analyzed time point (days 7, 10, 14, 17, 21,
and 25; Fig. 4B). At the end of the experiment (day 25), the
median tumor volumes for the control and for the experimental
armwere 600mm3 (95%CI, 550–684) and239mm3 (95%CI, 0–
582), respectively (P ¼ 0.001).
OTX015 shows in vitro synergismwith several anticancer agents
We evaluated the combination of OTX015 with a series of
conventional and targeted antilymphoma agents in a panel of ﬁve
DLBCL cell lines (Fig. 5). Strong synergismwas observed, in all the
cell lines, when OTX015 was combined with the mTOR inhibitor
everolimus (median CI, 0.11; range, 0.1–0.17) and, in ABC-cells,
with the BTK inhibitor ibrutinib (CI, 0.04; 0.02–0.1). Synergism
was also observed with OTX015 plus the PI3K-delta inhibitor
idelalisib (CI, 0.5; 0.04–2.4), the class I and II HDACi vorinostat
(CI, 0.5; 0.3–0.6), anti-CD20 mAb rituximab (CI, 0.5; 0.4–0.5),
the hypomethylating agent decitabine (CI, 0.6; 0.6–0.7), the
immunomodulant lenalidomide (CI, 0.7; 0.6–0.7). OTX015
combinations with the class I HDACi romidepsin (CI, 1.08; 1–
1.22) andwith the chemotherapy agents bendamustine (CI, 0.63;
0.1–3.97) and doxorubicin (CI, 0.83; 0.71–0.96) presented a
moderate additive effect. GCB- and ABC-DLBCL cells showed a
different sensitivity to the combinations: a stronger synergismwas
observed in ABC than in GCB DLBCL cells for ibrutinib (P <
0.0001), for idelalisib (P < 0.0001), lenalidomide (P ¼ 0.0001),
and rituximab (P ¼ 0.007).
Baseline gene expression proﬁle is associated with response to
OTX015
To identify genes and pathways thatmight predict sensitivity to
OTX015 in DLBCL we integrated the sensitivity data with the
baseline gene expression proﬁle in 14 cell lines with an IC50 lower
than 500 nmol/L and eight with a higher IC50.
Transcripts positively associated with OTX015 sensitivity were
signiﬁcantly enriched of genes involved in IFN, IL6 and IL10
signaling genes, TLR and JAK/STAT signaling, STAT3 targets, genes
involved in glucose metabolism, and hypoxia-regulated genes
(Fig. 6A and Supplementary Table S4A). The leading edge genes
(the top differentially ranked transcripts based on sensitivity to
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OTX015) comprised STAT1, STAT3, STAT4, STAT6, IL6, JAK1,
JAK2, TNF, IRAK1, TLR9, MYD88, TLR8, TRAF3, and AKT1.
Transcripts associated with lower sensitivity to OTX015 were
signiﬁcantly enriched of E2F target genes, genes involved in cell-
cycle regulation, DNA repair, P53 signaling, chromatin structure,
and apoptosis (Fig. 6B; Supplementary Table S4B). BCL2L1,
HDAC1, HDAC2, HDAC5, HDAC8, CHEK1, CHEK2, TP53, ATM,
BRCA1, CDKN1A, CDKN2A, BIRC5, MGMT were among the
leading edge genes.MYC orMYC targets did not appear associated
with sensitivity to OTX015.
Discussion
Wehave evaluated the activity and themechanismof actionof a
new BET bromodomain inhibitor, OTX015, in preclinical models
of mature B-cell lymphoid tumors. We have shown that: (i)
OTX015 has in vitro and in vivo antiproliferative activity; (ii)
OTX015 effect is largely cytostatic, with induction of apoptosis
in only a genetically deﬁned subset of cell lines; (iii) OTX015
inhibits MYC, NF-kB, TLR, and JAK/STAT pathways; (iv) OTX015
shows synergistic or additive effects when combined with several
Figure 3.
OTX015 downregulates NFKB/TLR/
JAK/STAT pathways in DLBCL in vitro
models. A, expression changes of TLR6,
IRAK1, MYD88, IL6, TNFRSF17, IRF4, and
STAT3 in four DLBCL cell lines exposed
to OTX015 (500 nmol/L) for 24 hours.
Y axis, fold change versus GAPDH and
DMSO-treated cells. B, protein levels of
total STAT3 and phosphorylated
STAT3 in SU-DHL-2 cell line treated with
DMSO or OTX015 (500 nmol/L) for 8 or
24 hours, GAPDH was used as a loading
control. C, immunohistochemistry
for phosphorylated STAT3 in the SU-
DHL-2 cell line treated with DMSO or
OTX015 (500 nmol/L) for 24 hours. D,
immunohistochemistry for p50 (NFKB1)
in the SU-DHL-2 cell line treated with
DMSO or OTX015 (500 nmol/L)
for 24 hours.
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antilymphoma agents; (v) speciﬁc baseline gene expression fea-
tures are associated with a different sensitivity to OTX015.
At clinically achievable concentrations (33), OTX015 had an
antiproliferative activity in the most of the lymphoma cell lines
tested, with no differences in sensitivity among the histologic
subtypes. The effect was largely cytostatic, with apoptosis limited
to a few cell lines. OTX015 appeared to induce a senescence-like
phenotype, possibly compatible with the recently described
"senescence with incomplete growth arrest," also observed after
treatment of DLBCL cells with demethylating agents (34). The
antitumor activity of OTX015was validated in an in vivomodel of
ABC-DLBCL with demonstration of a reduced tumor growth.
Similarly to other BRD inhibitors (4, 5, 10, 21, 35), OTX015
determined a downregulation ofMYC and ofMYC target genes in
DLBCL cell lines carrying a wild-type MYC and in cells in which
the oncogene is translocated or ampliﬁed. This is a remarkable
achievement sinceMYC is a difﬁcult therapeutic target and it plays
a major role in the pathogenesis and progression of lymphomas,
as exempliﬁed by the very poor outcome of DLBCL cases over-
expressing both MYC and BCL2 proteins and of "double hit"
lymphomas usually bearing concomitant translocations of MYC
and BCL2 oncogenes (36).
An important biologic effect we observed withOTX015, both in
the in vitroand in vivo setting,was the downregulationof theNF-kB,
TLR, and JAK/STAT3 signaling pathways, important in both the
pathogenesis and the chemoresistance of lymphomas, and partic-
ularly of ABC-DLBCL. This observation is in accordance with the
strong suppression of the TLR signaling-mediated lipopolysaccha-
ride-induced inﬂammatory response, reported with BET bromo-
domain inhibitors (37). A similar effect has been reported for JQ1
in different DLBCL cell lines (10). Additional observations indi-
cated that the downregulation of the TLR and JAK/STAT3 signaling
pathways is a relevant mechanism of action of OTX015 in DLBCL.
First, high expression of genes involved in interferon, TLR and JAK/
STAT signaling and STAT3 targets were highly associated with the
sensitivity to the compound. Second, OTX015-induced apoptosis
was limited to cell lines, bearing a functional TP53, derived from
ABC-DLBCLwith somaticmutations activating bothBCR signaling
and MYD88. Mutations activating the BCR and TLR/MYD88
signaling are common in ABC-DLBCL, in which they represent
driver events (38), and their prevalence is especially high in two
aggressive extranodal forms of DLBCL, primary central nervous
system lymphoma and primary testis DLBCL (39, 40). CD79A and
CD79B are upstreamof BTK. BTK binds toMYD88, especially if the
latter is encoded by the L265P somatic variant (41). OTX015
downregulated the expression of MYD88 and of additional mem-
bers of the TLR pathway, and both OTX015 and JQ1 reduced the
BRD4binding toMYD88 upstream regulatory region. These events
could inhibit both BCR and TLR signaling, particularly affecting
cells dependent on these pathways. Similarly, the BTK inhibitor
ibrutinib is more active in ABC-DLBCL cases with both CD79B/
CD79A and MYD88 mutated genes (38, 42). Importantly, the
combination of OTX015 and ibrutinib was strongly synergistic in
ABC-DLBCL cells. The downregulation of IRF4might contribute to
the synergism, as reported for the combination of ibrutinib and
lenalidomide (43). Notably, OTX015 was active also in ABC-
DLBCL cells carrying somatic mutations of CARD11, coding for
a protein downstream of BTK, and, accordingly, representing a
marker of resistance to ibrutinib (38, 42).
Besides ibrutinib, additional antilymphoma agents presented
an increased activity when combinedwithOTX015. The strongest
synergism was obtained with the combination with the mTOR
inhibitor everolimus at doses that can be reached in patients (44).
The mTOR is central to a signaling cascade leading to cell growth
and proliferation, and mTOR inhibitors are approved for treat-
ment of relapsedMCL (45). OTX015 was also synergistic with the
PI3K-delta inhibitor idelalisib, which has shown promising clin-
ical responses in B-cell lymphomas (46), and with the lenalido-
mide, as also recently reported for another BET bromodomain
inhibitor in MCL (47).
The synergism observed for OTX015 combined with clinically
achievable doses of rituximab is reinforced by recent reports with
another BET bromodomain inhibitor (13). The downregulation
ofCCDC86, coding for the nuclear factor cyclon, by both JQ1 (13)
and OTX015, might represent the mechanism of action of the
synergism. The combination appearedmore active inABC-DLBCL
cell lines,maybe due the common targeting of the IL10 and STAT3
pathway by both OTX015 and rituximab (48).
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Figure 4.
OTX015 has biologic activity in DLBCL in vivo models. A, OTX015
downregulates MYC and NFKB/TLR/JAK/STAT pathways in an ABC-DLBCL
in vivo model. Average of expression levels of MYC, TNFRSF17, IRF4, IRAK1,
STAT3, IL6, and TLR6, in SU-DHL-2 xenografts from four untreated mice
(CTR) and in four SU-DHL-2 xenografts from four mice treated with OTX015
for three days. Y axis, average expression levels normalized to GAPDH and to
one CTR sample. ! , P < 0.05. B, OTX015 reduces the growth of an ABC-DLBCL
in vivomodel. NOD-SCIDmice were treated with oral control vehicle (twice a
day; n ¼ 7 mice) or with oral OTX015 (25 mg/kg, twice a day; n ¼ 8 mice),
starting 5 days after the subcutaneous injection of SU-DHL-2 cells and then
each day for 25 days. ! , P < 0.05. Y axis, tumor volume in mm3. X axis, days of
treatment. Each column represents one individual animal.
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OTX015 presented synergism with the demethylating agent
decitabine and the HDACi vorinostat at concentrations phar-
macologically achievable in clinical use (49, 50), in accordance
with the similarities here observed at the level of gene expres-
sion signatures, and also with published data obtained with
other BET bromodomain inhibitors (11). HDACs of both
classes I and II were associated with a lower sensitivity to
OTX015 as single agent and, indeed the synergism appeared
stronger with the class I and IIa/b HDACi vorinostat than that
seen with the class I HDACi romidepsin suggesting that the
synergism might be class dependent.
The integration of baseline GEP and sensitivity in a large panel
of DLBCL cell lines allowed the identiﬁcation of functional path-
ways that might predict the response to the BET bromodomain
inhibitor. The cells with the highest sensitivity toOTX015 had not
only high expression levels of genes involved in the TLR/JAK/STAT
pathway, but also of transcripts that code for proteins implicated
in glucose metabolism and in hypoxia. Although the latter two
features can be associated with an active MYC program, it is
important to underline that we did not detect any association
between expression of MYC or MYC targets and sensitivity to
OTX015. On the basis of our data, it will be important to correlate
the demonstration of an active TLR/JAK/STAT pathway (for
example detecting pSTAT3) and/or the presence of somatic muta-
tions ofMYD88, CD79A/B, CARD11, and TP53with the response
to BET bromodomain inhibitors in the ongoing clinical trials.
A strong E2F gene expression signature was associated with
lower sensitivity to OTX015, although not with a clear resistance
to the compound as all our cell lines were muchmore sensitive to
the BET bromodomain inhibitor than other large series of cancer
cell lines comprising solid tumors models (5, 14, 15). In accor-
dance with the cell-cycle arrest observed at 24 to 48 hours, E2F1
target genes, but not E2F1 itself, are downregulated by both
OTX015 and JQ1 (10), at a later time point than the effect on
MYCor on TLR/JAK/STAT pathways. The high synergism reported
in leukemia preclinical models with the combination of the BET
bromodomain inhibitor PFI-1 with a pan-aurora kinase inhibitor
(12) suggests that the combination of BET bromodomain inhi-
bitors with drugs targeting the cell cycle might overcome the
observed lower sensitivity.
The gene expression signatures associated with a lower sensi-
tivity to OTX015 comprised transcripts (BCL2L1, BIRC5,MGMT,
CHEK1, CHEK2), which represent potential molecules to be
inhibited in combination with BET bromodomain inhibitors.
There are now different BET bromodomain inhibitors under
development with some of them, including OTX015, already in
phase I clinical studies. On the basis of our data of an OTX015
gene expression signature highly overlapping with that reported
with JQ1, and on the literature (10, 12, 16, 51) all the molecules,
so far all pan-BET bromodomain inhibitors, have similar preclin-
ical activity data andmechanismof action. Alongside the different
drug delivery modalities (for example, OTX015 and GSK525762
are given orally, TEN-010 subcutaneously), the toxicity and phar-
macokinetics data that from the ongoing clinical studies will be
most relevant for the further clinical development of this class of
compounds.
In conclusion, the BET bromodomain inhibitor OTX015
appears as a promising new antilymphoma agent with anti-
proliferative activity in the vast majority of the examined
preclinical models, capable of downregulating important sig-
naling pathways and of synergizing with other anticancer
molecules. Particular genetic lesions and gene expression sig-
natures are associated with high sensitivity to OTX015 antitu-
mor activity. Additional studies are needed to elucidate the
mechanism of action of OTX015, particularly when combined
with other targeted agents. Together with the early report of
clinical responses in both leukemia and lymphoma patients
treated with OTX015 in the absence of major toxicities (22), the
data presented here provide the basis for further clinical inves-
tigation of OTX015 in combination therapies.
Figure 5.
OTX015 combination showing
additive effect or synergism in most
instances with different additional
drugs. Y axis: CI < 0.3, strong
synergism; 0.3–0.9, synergism; 0.9–1.1
additive effect.Xaxis, drugs combined
with OTX015 in GCB (1 DOHH2; 2
Karpas422; 3 SUDHL6) and ABC-
DLBCL (4 U2932; 5 TMD8). C.I. for
OTX015/rituximab in DOHH2 is not
plotted due to a median value > 3. In
each box-plot, the line in themiddle of
the box represents themedian and the
box extends from the 25th to the 75th
percentile (interquartile range, IQ);
the whiskers extend to the upper and
lower adjacent values (i.e., !1.5 IQ).
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ABSTRACT (197 words) 
The epigenome is often deregulated in cancer and treatment with inhibitors of bromodomain and extra- terminal 
(BET) proteins, the readers of epigenetic acetylation marks, represents a novel therapeutic approach. Here, we 
have characterized the anti-tumor activity of three novel BET inhibitors in preclinical lymphoma models. 
The novel BET inhibitors BAY 1238097, BAY-7575 and BAY-5627 showed anti-proliferative activity in a large 
panel of cell lines derived from lymphoma with median IC50 comprised between 70 and 208 nM. BAY 1238097 
showed strong antitumor efficacy in vivo as single agent in two diffuse large B cell lymphoma models. Gene 
expression profiling showed BAY 1238097 targeted the NFKB/TLR/JAK/STAT signaling pathways, MYC and 
E2F1-regulated genes, cell cycle regulation and chromatin structure. The gene expression profiling signatures 
also highly overlapped with the signatures obtained with other BET Bromodomain inhibitors and partially 
overlapped with HDAC-i, mTOR-i and demethylating agents. Notably, BAY 1238097 presented in vitro 
synergism with EZH2, mTOR and BTK inhibitors.  
In conclusion, the novel BET inhibitors presented promising anti-lymphoma preclinical activity in vitro and in vivo 
mediated by the interference with biologic processes driving the lymphoma cells. Our data also point to 
combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains. 
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Introduction 
The members of the Bromodomain and extra-terminal (BET) family (BRD2, BRD3, BRD4 and BRDT) bind to 
acetylated proteins, including histones H3 and H4 (1), thereby acting as epigenetic readers especially at the so-
called super-enhancers, the clusters of enhancers incorporating high amounts of transcription factors and co-
activators and regulating the expression of key genes controlling cell identity in normal cells and of oncogenes 
in cancer cells (2,3). Targeting BET proteins has recently emerged as a novel and promising therapeutic 
approach to interfere with cancer cell transcription programs both in hematological and solid tumors (4-20). 
Regarding this, we and others have shown preclinical anti-tumor activity of BET inhibitors in B and T cell 
lymphomas (5,7-9,11,14,16,20-23). Importantly, the early clinical trials with BET inhibitors have reported clear 
signs of anti-tumor activity (24-26). Here, in lymphoma models, we characterized the anti-tumor activity of three 
novel BET inhibitors, BAY-7575 and BAY-5627 and, in particular, BAY 1238097, a molecule with preferential 
binding to BRD4 compared to BRD2 or BRD3, which, due to a pharmacological and pharmacokinetic favorable 
profile (27), entered the early clinical evaluation (NCT02369029)(28). 
 
Material and Methods 
Cell lines and molecules 
Established human cell lines derived from 27 diffuse large B-cell lymphoma (twenty GCB-DLBCL: FARAGE, 
OCI-LY-1, OCI-LY-2, OCI-LY-7, OCI-LY-8, OCI-LY-18, OCI-LY-19, RCK8, VAL, SU-DHL-4, SU-DHL-5, SU-
DHL-6, SU-DHL-8, SU-DHL-10, SU-DHL-16, KARPAS422, WSU-DLCL2, DOHH2, Pfeiffer, TOLEDO; seven 
ABC-DLBCL: RI-1 (RIVA), HBL-1, TMD8, U2932, SU-DHL-2, OCI-LY-3, OCI-LY-10), ten mantle cell lymphoma 
(MCL: GRANTA-519, JeKo-1, JVM-2, MAVER-1, MINO, REC-1, SP-49, SP-53, UPN-1 and Z-138), three 
splenic marginal zone lymphoma (SMZL: KARPAS1718, VL51, SSK41), nine anaplastic large T cell lymphoma 
(ALCL: JB6, Ki-JK, KARPAS-299, L-82, SUP-M2, SU-DHL-1, TS, FEPD, MAC-1), one pro-lymphocytic leukemia 
(MEC-1) and one primary mediastinal large cell lymphoma (KARPAS1106P) were cultured in culture media as 
previously indicated  (29). Cell lines has been authenticated for cell identity and for Interspecies contamination 
(IDEXX BioResearch, Ludwigsburg, Germany). BAY 1238097 (patent application WO2014026997, example 
127.1), BAY-7575 (patent application BHC WO2015004075, example 28) and BAY-5627 (patent application 
WO2015004075, example 25) were provided by Bayer AG (Berlin, Germany) and dissolved in dimethyl 
sulphoxide (DMSO) to obtain a stock concentration of 10 mM. Other compounds used were: ibrutinib, GSK126, 
everolimus (Selleckchem, Houston, TX, USA), and DZNep (Sigma Aldrich). 
Cell proliferation, cell death, cell cycle analysis  
The anti-proliferative activity of BAY-7575 and BAY-5627, and of BAY 1238097 was assessed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the doses corresponding to the IC50 (50%-
inhibitory concentration) and the LC50 (50%-lethal concentration) were estimated as previously described (30). 
Apoptosis and cell cycle distribution were evaluated on cells treated with DMSO or different doses of 
compounds, as previously reported (29).  
Western blotting analysis 
Protein extraction, separation and immunoblotting were performed as previously described (29). The following 
antibodies were used: anti-BRD4 (A301-985A100, Bethyl), anti-MYC (13987, Cell Signaling Technology, 
Danvers, MA, USA), anti-aGAPDH (MAB374, Millipore), anti-Histone H3 (ab1791, AbCam), anti-Histone 
H3K27me3 (9733, Cell Signaling Technology), anti-EZH2 (3147, Cell Signaling Technology), anti-AKT (9272, 
Cell Signaling Technology), anti- phospho-AKT Ser 473 (4060, Cell Signaling Technology), anti-phospho-mTOR 
Ser 2481 (2974, Cell Signaling Technology). 
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Chromatin immunoprecipitation 
Data mining of the publicly available ChIP-Seq dataset SRP043524 (31) and chromatin immunoprecipitation 
were performed as previously described (5).  Quantitative real-time polymerase chain reaction (PCR)  of ChIP-
DNA was performed using primers specific for a locus of BRD4 binding in the upstream regulatory region of 
EZH2 (chr7:148,502,464-148,583,441) as determined by analyzing the ChIP-Seq dataset SRP043524 (31); 
primers specific for human alpha-satellite were used as a negative control (sequences available upon request). 
Real-time polymerase chain reaction (PCR)  
RNA was extracted using the RNeasy kit (Qiagen AG, Hombrechtikon, CH). Real-time PCR was performed as 
previously described (29) (primer sequences available upon request). 
Gene expression profiling   
Gene expression profiling (GEP) was performed with the HumanHT-12 v4 Expression BeadChip (Illumina, San 
Diego, CA), as previously described (32). For GEP comparison after exposure to the compound or DMSO, 
probes presenting a false discovery rate (FDR), controlled by the Benjamini-Hochberg algorithm, < 0.05 and a 
log ratio > |1| were considered differentially expressed using the empirical Bayes (paired) moderated t-test as 
implemented in the LIMMA R-package (33). Gene set enrichment was defined with GSEA (34) on pre-ranked 
lists using the MSigDB 5.2 (34) and the SignatureDB collection (35) applying a threshold based on FDR < 0.1.  
For exploratory analyses performed on baseline gene expression profiles of cell lines with different degrees of 
sensitivity to compounds, probes presenting a P < 0.05 and a log ratio > |1| were defined differentially 
expressed using the empirical Bayes (paired) moderated t-test as implemented in CARMAweb 1.6 (36). Gene 
set enrichment was defined with GSEA (34) applying a threshold based on FDR < 0.1. All GEP raw data will be 
available at the National Center for Biotechnology Information Gene Expression Omnibus (http:// 
www.ncbi.nlm.nih.gov/geo) database.   
In vivo experiments  
Animal experiments were approved by the relevant regulatory agency of the federal state of Berlin (Landesamt 
für Gesundheit und Soziales Berlin). Animals were housed according to institutional guidelines with access to 
food (pelleted diet) and water ad libitum.  SCID female mice, 9-12 weeks old were inoculated subcutaneously 
into the right flank with 5x106 SU-DHL-8 cells/mouse suspended in 0.1 mL of matrigel or with OCI-LY-3 tumor 
fragments (3x3 mm). BAY 1238097 was prepared as a solution in NaCl 0.9% in water, pH 4 and administered 
orally under 10 mL/kg. Treatments with BAY 1238097 or vehicle control were initiated on day 4 post tumor 
inoculation for the SU-DHL-8 model (8 mice/group). BAY 1238097 was applied daily for 12 days at its maximal 
tolerated dose (MTD) of 15 mg/kg. Treatment of the OCI-LY-3 tumors started on day 21 post tumor inoculation, 
mice being randomized with a median tumor size per group of of-98mm3 for the BAY 1238097 treated group 
(n=7) and 93 mm3 for the vehicle control group (n=8).   BAY 1238097 was applied at the MTD of 45 mg/kg 
using an intermittent schedule, twice a week, for 4 weeks. 
Tumors were measured twice a week using a caliper and volume was calculated using the formula: tumor 
volume = [length x width x width]/2. Treated/control ratio was calculated at the end of the study as follows: T/C = 
(median tumor volume in the treated group/median tumor volume in the vehicle control group)x100. A T/C≤ 42% 
was declared active in agreement with NCI criteria. Differences in tumor volumes were calculated using the 
Wilcoxon rank-sum test (Stata/SE 12.1 for Mac, Stata Corporation, College Station, TX). The P-value (P) for 
significance was < 0.05. Mice body weight was determined on a daily basis and body weight loss ≥ 20%, 
compared to the first day of therapy, was judged excessive and the dose considered as toxic.  
  
Drug combinations and evaluation of synergism 
Drug combination evaluation was performed as previously described (5). Combinations were defined to be 
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synergistic if the Chou-Talalay Combination Index (CI) was < 0.9, additive if the CI was between 0.9 and 1.1 and 
antagonistic/no benefit, if the CI was > 1.1 (37).  
 
Results 
BAY 1238097, BAY-7575 and BAY-5627 have in vitro anti-tumor activity in lymphoma models 
We evaluated the anti-proliferative activity of three novel BET inhibitors - BAY 1238097, BAY-7575 and BAY-
5627 - in a panel of cell lines derived from activated B-cell type diffuse large B-cell lymphoma (ABC DLBCL; 
n.=7), germinal center B-cell type DLBCL (GCB DLBCL; n.=20), mantle cell lymphoma (MCL; n.=10); splenic 
marginal zone lymphoma (SMZL; n.=3), primary mediastinal large cell lymphoma (PMBCL, n.=1),  chronic 
lymphocytic leukemia (CLL, n.=1) and anaplastic large T cell lymphoma (ALCL, n.=9). As assessed by MTT 
assays performed after 72 hours of drug exposure, BAY 1238097, BAY-7575 and BAY-5627 were active in a 
dose-dependent manner in almost all the cell lines (Figure 1A) with median IC50 values of 231 nM (95%CI, 161-
280 nM), 103 nM (95% CI, 76-122 nM) and 71 nM (95% CI, 55-89 nM), respectively. The three compounds had 
higher activity in B cell than in T cell models (P<0.001), while no differences were observed among B-cell tumor 
types (DLBCL, MCL, SMZL) or DLBCL subtypes (ABC, GCB).  
BAY 1238097, BAY-7575 and BAY-5627 had highly correlated patterns of activity (R values > 0.8, P < 0.0001) 
(Figure S1). We also compared the activity of BAY 1238097, BAY-7575 and BAY-5627 with the results we had 
previously obtained using the BET inhibitor OTX015 (MK-8628) (5). The three novel compounds presented a 
similar pattern of activity with OTX015, which was higher for BAY-7575 (R=0.430; P=0.01) and BAY-5627 
(R=0.392; P=0.01) than for BAY 1238097 (R=0.197; P > 0.05), and higher for all of them when focusing on B 
cell derived lymphomas (R=0.739, P<0.0001; R=0.638, P=0.0001; R=0.424, P=0.02; R=0.739, P<0.0001). 
The anti-tumor activity of BAY 1238097, BAY-7575 and BAY-5627 was mainly cytostatic as indicated by the 
distribution of LC50 values, which were higher than 1 µM in 86% (44/51) of the cells exposed to BAY-7575 and 
BAY-5627 and in 84% (43/51) of those exposed to BAY 1238097. Figure 1B and S2A shows the validation in 
the eight cell lines with an LC50 <1 µM with all the three BET inhibitors, and in one with higher LC50 value 
(U2932). Time-dependent apoptosis was observed in the eight cell lines treated for 72 or 96 hours with a dose 
of 500 nM. The cytostatic activity was shown by treating six DLBCL cell lines (Farage, DOHH-2, Toledo, 
KARPAS-422, SU-DHL-4 and WSU-DLCL2) with BAY 1238097 (500 nM, 72 hours), which induced cell cycle 
arrest in G1 with decreased G2/M phase (Figure 1C and S2B). 
BAY 1238097 has in vivo anti-tumor activity in lymphoma models 
We then focused on BAY 1238097 which had been characterized extensively with regard to its pharmacological 
and pharmacokinetic properties, using different schedules and routes of administration in vivo, had a very 
favorable overall profile (27), thus entering the early clinical evaluation (28). We assessed its in vivo ability to 
reduce tumor growth in two DLBCL models implanted in SCID female mice. The first model was obtained by 
engraftment of a GCB-DLBCL cell line (SU-DHL-8) (Figure 2A, S3A). BAY 1238097, given at the MTD of 15 
mg/kg (p.o. using a daily schedule), significantly affected tumor growth in comparison with control group, with a 
T/C of 15 % on day 14 post tumor inoculation (P < 0.001). The second model was obtained by engraftment of 
an ABC-DLBCL cell line (OCI-LY-3) (Figure 2B, S3B). The treatment with BAY 1238097 at the MTD of 45 mg/kg 
(p.o. with a twice weekly schedule) significantly inhibited tumor growth as well, with a T/C of 23 % on day 48 
post tumor inoculation (P < 0.001). BAY 1238097 treatments were overall well tolerated with a maximal mean 
body weight loss of 6% on day 9 in the SU-DHL-8 study an 9% on day 45 in the OCI-LY-3 model. 
BAY 1238097 affects the gene expression of GCB DLBCL cells 
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To understand the mechanism of action of BAY 1238097 in DLBCL, we performed a gene expression profiling 
study on the cell line DOHH-2 exposed to DMSO or BAY 1238097 (500 nM) for 8, 12 or 24 hours (Figure 3A-B 
and Supplementary Table 1). We first looked at the genome-wide changes induced by the compound. BAY 
1238097 decreased target genes of Myc, Notch and E2F, members of the NFKB/MYD88 and mTOR/AKT 
signaling. The upregulated transcripts were mainly represented by histones. The GEP signatures highly 
overlapped with the signatures obtained with other BET inhibitors and partially overlapped with HDAC or mTOR 
inhibitors and demethylating agents. At the gene level, 143 probes (121 annotated transcripts) were 
downregulated and 71 (59 annotated transcripts) upregulated. BTK, CCDC86, CCND2, CD19, CD27, FAIM, 
FAIM3, IL7R, IRAK1, MAPK13, MYB, MYC, PDE4B, TNFRSF13B, TNFRSF17 were among the top 
downregulated genes. Beside histone-coding genes, the upregulated genes included CCL5, CDKN2C, CD69, 
JUN, and MKNK2.  
 
BAY 1238097 downregulates EZH2 expression and synergizes with EZH2 inhibitors 
Analysis of genomic alterations in the cell lines exposed to BAY 1238097 revealed that the presence of somatic 
mutations in the EZH2 gene was associated with higher sensitivity to the BET inhibitor (P=0.007), an 
association maintained when considering only the cell lines derived from GCB-DLBCL (P=0.025) (Figure 4A), in 
which mutations more frequently occur (38). An EZH2 signature obtained comparing series of follicular 
lymphomas with mutated EZH2 versus wild type cases (39) appeared enriched in the transcripts high in GCB-
DLBCL with higher sensitivity to BAY 1238097 (NES=1.6, P<0.01) (Figure 4B). Due to this association between 
EZH2 mutations and BAY 1238097 activity we evaluated whether EZH2 was regulated in a BET bromodomain 
dependent manner. We took advantage of publicly available ChIP-Seq data for the HBL1 DLBCL model treated 
with the BET inhibitor JQ1 (31). The EZH2 upstream regulatory region presented binding of BRD4 and JQ1 
treatment (500 nM, 3 hours) reduced the BET Bromodomain binding, indicating a direct effect of BET 
Bromodomain on the regulation of EZH2 expression (Figure 4C-D).  
Based on these findings we assessed the possible therapeutic benefit of the dual inhibition of both BET 
Bromodomain and EZH2. To pursue this aim, we first exposed eight GCB-DLBCL cell lines (five mutated EZH2, 
three wild-type EZH2 protein) to BAY 1238097 and to the EZH2-inhibitor DZNep for 72 hours. Benefit was 
observed in three cell lines, all with mutated EZH2 (synergism in WSU-DLCL2 and KARPAS-422, additive effect 
in the SU-DHL-6) (Figure 5A). Similar results were obtained combining BAY 1238097 with a second, more 
selective, EZH2 inhibitor, GSK126: the same three EZH2 mutated cell lines achieved a benefit from the 
combination treatment (Figure 5B).  
Based on these data we assessed changes at protein levels of EZH2, total histone H3 and H3K27me3 after 
exposure to BAY 1238097 single agent and in combination with GSK126. BET inhibitor treatment was followed 
by a downregulation of EZH2, histone H3 and H3K27me3 levels. A stronger downregulation of H3K27me3 
levels after the BAY 1238097/GSK126 combination was observed (Figure 5C). Similar results were obtained 
using DZNep (data not shown). 
 
Baseline features are associated with response to BAY 1238097 
The anti-proliferative activity of BAY 1238097 was not associated with MYC/BCL2/BCL6 single/double 
translocations, MLL2, MYD88, FOXO1 mutations, or TP53 status. To identify genes and pathways that might 
predict sensitivity to the novel BET inhibitor, we compared the baseline gene expression profiles of cell lines 
with a BAY 1238097 IC50 lower than 500 nM versus those with a higher IC50. The analysis was limited to GCB 
DLBCL due to sample size. Transcripts with higher expression in the most sensitive GCB DLBCL cells (n.=10) 
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were enriched of genes involved in JAK/STAT, IFN and BCR signaling, while the less sensitive GCB DLBCL 
(n.=4) had higher expression of genes involved in cell cycle, chromatin structure, and E2F1 targets (Figure S4 
and Supplementary Table 2).  
 
BAY 1238097 shows in vitro synergism with the mTOR inhibitor everolimus 
Based on the above-mentioned similarity between gene expression changes following exposure to BAY 
1238097 and mTOR-inhibitors, BAY 1238097 was combined with the mTOR inhibitor everolimus, leading to a 
therapeutic benefit in 7/8 DLBCL cell lines: synergism in 2/2 ABC-DLBCL (U-2932, TMD8) and in 5/6 GCB-
DLBCL (KARPAS-422, SU-DHL-6, DOHH-2, SU-DHL-8, Toledo) (Figure 3A). As shown in Figure 3B, the 
treatment of two DLBCL cell lines with only BAY 1238097 induced a downregulation of pAKT, which was 
maintained in the cell lines exposed to both compounds.  
 
BAY 1238097 shows in vitro synergism with the BTK inhibitor ibrutinib 
As mentioned above, a high expression of JAK/STAT and IFN signaling genes was positively associated with 
sensitivity to BAY 1238097, which also downregulated the NFKB/MYD88 pathway, including the BTK transcript. 
Among all cell lines exposed to the compound, the presence of the L265P-MYD88 somatic mutation was 
associated with higher sensitivity to the BET inhibitor in ABC DLBCL cell lines (P=0.05). We assessed the 
combination of BAY 1238097 with the BTK-inhibitor ibrutinib and observed synergism in 2/2 ABC-DLBCL cell 
lines harboring the L265P MYD88 mutation (OCI-LY-10, TMD8). No benefit was observed in the two ABC-
DLBCL cell lines bearing a wild-type MYD88 (SU-DHL-2, U-2932) (Figure 3C). 
 
Discussion  
We have evaluated the activity of three novel BET Bromodomain inhibitors BAY-7575 and BAY-5627, and BAY 
1238097 in pre-clinical models of mature lymphoid tumors, focusing on the latter compound which entered 
clinical evaluation, and we found that: i) all three compounds had a wide anti-proliferative activity, which was 
mostly cytostatic; ii) BAY 1238097 affected cellular pathways relevant for the lymphoma cells; iii) sensitivity to 
BAY 1238097 was associated with phenotypic and genetic features; iv) BAY 1238097 reduced EZH2 
expression and synergized with EZH2 inhibitors; v) BAY 1238097 synergized with mTOR and BTK inhibitors. 
The anti-tumor activity of BAY-7575, BAY-5627 and BAY 1238097 was higher in cell lines derived from B than T 
cell lymphoma but it did not further differ based on lymphoma histotype or the presence of genetic lesions such 
as MYC gene translocation or TP53 inactivation. The three compounds shared a very similar pattern of activity 
across all the tested lymphoma models, which also partially correlated with what was previously observed with 
other BET inhibitors such as OTX015 and JQ1 (5,8). The anti-tumor activity of BAY 1238097 was furthermore 
confirmed in two in vivo DLBCL xenograft models where a strong efficacy was demonstrated when giving the 
compound orally using either a daily or a twice weekly schedule. As for other targeted agents (5,40), the activity 
was mostly cytostatic, with very few cell lines, derived from ABC DLBCL (as seen with OTX015 (5)), from GCB 
DLBCL and from MCL, undergoing apoptosis after 72 hours of drug exposure.  
Baseline gene expression profiling is a strategy to identify mutations and features associated with response to a 
compound and to suggest possible combinatorial schemes. The cells with the highest sensitivity to BAY 
1238097 had not only high expression levels of genes involved in the JAK/STAT, IFN and BCR signaling, but 
also higher incidence of somatic mutations in EZH2 and MYD88, which could represent potential biomarkers. 
These data also suggested rational combinations to be further explored. Gain-of-function mutations of EZH2 
gene frequently occur in GCB DLBCL and follicular lymphomas (38,41). Here, both the mutation and an EZH2 
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gene expression signature derived from follicular lymphomas were associated with higher sensitivity to BAY 
1238097 in GCB-DLBCL. This prompted us to look at the effect of BAY 1238097 on EZH2 expression and to 
possible therapeutic consequences. The analysis of publicly available ChIP-Seq data (31) indicated that in 
DLBCL EZH2 is indeed expressed in a BRD4-depenedent manner, and in accordance with the data reported by 
Zhao et al. (42), JQ1 can inhibit the binding. When we treated DLBCL cells with BAY 1238097 we observed a 
downregulation of EZH2 and, more importantly, of H3K27me3, the marker of EZH2 activity. Interestingly, this 
led to a synergism when we combined pharmacological inhibition of both BET Bromodomains and EZH2, 
suggesting that this combination of epigenetic drugs is worth further preclinical and clinical investigations.  
Besides regulating EZH2 levels, BAY 1238097 decreased MYC, target genes of MYC, Notch and E2F, as well 
as members of the NFKB/MYD88 and mTOR/AKT signaling pathways, changes which are in line with what was 
seen previously with other BET inhibitors (8,11,43-45).  
Finally, based on these expression changes and on data previously reported by us and others (5,21)(31,46-48), 
we evaluated the combination of BAY 1238097 with the BTK inhibitor ibrutinib and the mTOR inhibitor 
everolimus. Synergism was observed combining BAY 1238097 and the BTK inhibitor in the ibrutinib-sensitive 
ABC-DLBCL cell lines while no benefit was observed in ibrutinib-resistant ABC-DLBCL cells, suggesting that the 
addition of the BET inhibitor cannot overcome a genetically-driven resistance. In accordance to what was seen 
with the BET inhibitor OTX015 (5), the combination of BAY 1238097 with everolimus was highly beneficial both 
in ABC and in GCB DLBCL cells. Immunoblotting data suggested that the synergism could be due to decreased 
levels of pAKT after BET inhibitor treatment, which might attenuate the negative feedback observed after 
applying mTOR inhibitors alone (49).  
In conclusion, the novel BET inhibitors BAY-7575 and BAY-5627, and BAY 1238097 showed a clear anti-
lymphoma preclinical activity mediated by interfering with biologic processes driving the lymphoma cells. Our 
data also point to combination schemes targeting EZH2, mTOR and BTK alongside BET Bromodomains. 
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Figure 1. BAY-7575, BAY-5627 and BAY 1238097 have anti-proliferative activity in vitro and in vivo in 
models of B-cell lymphomas. (A) IC50 value distribution in 51 lymphoma cell lines. In each box-plot, the line 
in the middle of the box represents the median and the box extends from the 25th to the 75th percentile 
(interquartile range, IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ); outside 
values have been omitted from the figure. Y-axis, IC50 values in nM. “DLBCL, ABC”, activated B-cell type 
diffuse large B-cell lymphoma (n.=7); “DLBCL, GCB”, germinal center B-cell type diffuse large B-cell lymphoma 
(n.=20); “MCL”, mantle cell lymphoma (n.=10); “SMZL”, splenic marginal zone lymphoma (n.=3); “PMBCL”, 
primary mediastinal large cell lymphoma (n.=1); “CLL”, chronic lymphocytic leukemia (n.=1); “ALCL”, anaplastic 
large T cell lymphoma (n.=9). Y-axis, IC50 values in nM.  (B) Apoptosis was evaluated by Annexin-V/7-AAD 
staining in several cell lines exposed to 500 nM of each compounds for 72 hours. (C) Cell cycle analysis of cells 
treated with BAY 1238097 (500 nM for 72 hours).  
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Figure 2. BAY 1238097 has in vivo anti-proliferative activity in models of diffuse large B-cell lymphoma. 
(A) SCID mice subcutaneously inoculated with the GCB DLBCL SU-DHL-8 cell line and treated with BAY 
1238097 (n.=8) or vehicle control (n.=8): tumor volumes differences between treated and control mice were 
statistically significant starting on day 10. *, P < 0.05. Y-axis: median tumor volumes. X-axis, days post 
inoculation (B). SCID mice subcutaneously inoculated with the ABC DLBCL OCI-LY-3 cell line and treated with 
BAY 1238097 (n.=7) or vehicle control (n.=8): tumor volumes differences between treated and control mice 
were statistically significant starting on day 27. *, P < 0.05. Y-axis: median tumor volumes. X-axis, days post 
inoculation. 
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Figure 3. BAY 1238097 affects the gene expression of GCB DLBCL cells. Representative GSEA plots 
illustrating the gene-set enrichment in genes upregulated (A) and downregulated (B) in DOHH-2 cell line after 
BAY 1238097 exposure. FDR, false discovery rate; NES, normalized enrichment score.  
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Figure 4. EZH2 mutational status is associated with sensitivity to BAY 1238097 and both JQ1 and BAY 
1238097 decrease BRD4 binding to EZH2 promoter region. (A) EZH2 mutation in GCB-DLBCL was 
associated with higher sensitivity to BAY 1238097. Box-plots present the distribution of IC50 values in ten EZH2 
wild-type vs. seven mutated GCB cell lines. (B) EZH2 signature from follicular lymphomas with or without EZH2 
mutation was associated with higher sensitivity in GCB-DLBCL cell lines. (C) Decreased BRD4 binding to the 
upstream regulatory regions of EZH2 in HBL1 ABC-DLBCL cells following treatment with JQ1: ChIP-Seq reads 
at the EZH2 gene locus showing BRD4 binding in HBL1 ABC-DLBCL cells exposed to DMSO (blue) or 500 nM 
JQ1 (red) for 3 hours. The red and blue tracks have been overlaid to better show the reduction in BRD4 binding 
after JQ1 exposure. The lower panel shows the EZH2 gene structure. (D) Decreased BRD4 binding to the 
upstream regulatory regions of EZH2 in DOHH-2 GCB-DLBCL cells following treatment with BAY 1238097 (500 
nM for 3 hours). Cells were fixed with formaldehyde and subjected to the Chromatin Immunoprecipitation (ChIP) 
assay. Anti-IgG served as a negative control for the ChIP assay. Quantitative real-time PCR showed the 
enrichment of BRD4 binding in the upstream regulatory regions of EZH2, which decreased following treatment 
with BAY 1238097. Amplification of the centromeric human alpha satellite sequence served as a negative 
control. For each primer set, results were normalized to total input chromatin DNA samples.  
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Figure 5. BAY 1238097 shows in vitro synergism with EZH2 inhibitors with a decrease in EZH2 protein 
levels and H3K27me3. BAY 1238097 was tested in combination with the EZH2 inhibitor DZNep (A) or with 
GSK126 (B) in EZH2 mutant and EZH2 wild-type GCB-DLBCL cell lines. In each box-plot, the line in the middle 
of the box represents the median and the box extends from the 25th to the 75th percentile (interquartile range, 
IQ); the whiskers extend to the upper and lower adjacent values (i.e., ±1.5 IQ); outside values have been 
omitted from the figure. Y-axis: combination index (CI) values (<0.3, strong synergism; 0.3-0.9, synergism; 0.9-
1.1, additive effect; > 1.1, no benefit/antagonism. (C) Four GCB-DLBCL cells lines (1 wild-type, 3 mutated 
EZH2) were treated with 500 nM BAY 1238097 or with an EZH2 inhibitor (DZNep and GSK126, both used at the 
concentration of 500 nM) as single agents and combination for 72 hours. The arrow indicates the EZH2 correct 
band. DMSO alone was added as negative control cells. Membranes were hybridized with antibodies against 
EZH2, H3K27me3, histone H3 and GAPDH.  
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Figure 6. BAY 1238097 shows in vitro synergism with the mTOR inhibitor everolimus.  (A) BAY 1238097 
was tested in combination with the mTOR inhibitor everolimus in ABC-DLBCL and GCB-DLBCL cell lines. (B) 
Two GCB-DLBCL cell lines were treated with 500 nM BAY 1238097 or with 100 nM everolimus as single agents 
and in combination for 72 hours. Untreated cells and DMSO-treated cells were added as negative controls. 
Membranes were hybridized with antibodies against phospho-mTOR, phospho-AKT, AKT, or GAPDH. Y-axis: 
combination index (CI) values (<0.3, strong synergism; 0.3-0.9, synergism; 0.9-1.1, additive effect; > 1.1, no 
benefit/antagonism). In each box-plot, the line in the middle of the box represents the median and the box 
extends from the 25th to the 75th percentile (interquartile range, IQ); the whiskers extend to the upper and lower 
adjacent values (i.e., 1.5 IQ) and outside values have been omitted from the figure.  
